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Abstract 
 
Sigma (σ) receptors are well established as a non-opioid, non-
phencyclidine, and haloperidol-sensitive receptor family with its own 
binding profile and a characteristic distribution in the central nervous 
system (CNS) as well as in endocrine, immune, and some peripheral 
tissues. Two σ receptors subtypes, termed σ1 and σ2, have been 
pharmacologically characterized, but, to date, only the σ1 has also 
been cloned. 
Activation of σ1 receptors alter several neurotransmitter systems 
and dopamine (DA) neurotrasmission has been often shown to 
constitute an important target of σ receptors in different experimental 
models; however the exact role of σ1 receptor in dopaminergic 
neurotransmission remains unclear. The DA transporter (DAT) 
modulates the spatial and temporal aspects of dopaminergic synaptic 
transmission and interprer the primary mechanism by wich 
dopaminergic neurons terminate the signal transmission. For this 
reason present studies have been focused in understanding whether, in 
cell models, the human subtype of σ1 (hσ1) receptor is able to directly 
modulate the human DA transporter (hDAT).  
In the first part of this thesis, HEK-293 and SH-SY5Y cells were 
permanently transfected with the hσ1 receptor. Subsequently, they 
were transfected with another plasmid for transiently expressing the 
hDAT. The hDAT activity was estimated using the described [3H]DA 
uptake assay and the effects of σ ligands were evaluated by measuring 
the uptaken [3H]DA after treating the cells with known σ agonists and 
antagonists. Results illustrated in this thesis demonstrate that 
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activation of overexpressed hσ1 receptors by (+)-pentazocine, the σ1 
agonist prototype, determines an increase of 40% of the extracellular 
[3H]DA uptake, in comparison to non-treated controls and the σ1 
antagonists BD-1047 and NE-100 prevent the positive effect of (+)-
pentazocine on DA reuptake 
DA is likely to be considered a neurotoxic molecule. In fact, when 
levels of intracellular DA abnormally invrease, vescicles can’t 
sequester the DA which is metabolized by MAO (A and B) and 
COMT with consequent overproduction of oxygen reactive species 
and toxic catabolites. Stress induced by these molecules leads cells to 
death. Thus, for the second part of this thesis, experiments have been 
performed in order to investigate functional alterations caused by the 
(+)-pentazocine-mediated increase of DA uptake; particularly it has 
been investigated if the increase of intracellular [DA] could affect 
cells viability. Results obtained from this study demonstrate that (+)-
pentazocine alone increases DA cell toxicity in a concentration-
dependent manner only in cells co-expressing hσ1 and hDAT and σ1 
antagonists are able to revert the (+)-pentazocine-induced increase of 
cell susceptibility to DA toxicity. 
In the last part of this thesis, the functional cross-talking between 
hσ1 receptor and hDAT has been further investigated using confocal 
microscopy. From the acquired data it could be suggested that, 
following exposure to (+)-pentazocine, the hσ1 receptors massively 
translocate towards the plasma membrane and colocalize with the 
hDATs. However, any physical interaction between the two proteins 
remains to be proved. 
In conclusion, the presented study shows for the first time that, in 
cell models, hσ1 receptors directly modulate the hDAT activity. 
 - 5 - 
Facilitation of DA uptake induced by (+)-pentazocine is reflected on 
the increased cell susceptibility to DA toxicity; these effects are 
prevented by σ1 selective antagonists. Since numerous compounds, 
including several drugs of abuse, bind to σ1 receptors and activating 
them could facilitate the damage of dopaminergic neurons, the 
reported protective effect showed by σ1 antagonists would represent 
the pharmacological basis to test these compounds in experimental 
models of dopaminergic neurodegenerative diseases (i.e. Parkinson’s 
Disease). 
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INTRODUCTION 
 
  
CHAPTER 1, 
 
 
THE SIGMA-1 RECEPTOR 
Introduction - Chapter 1 
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1.1 Historical background 
 
The concept of sigma (σ) receptors was first introduced in literature by 
Martin and collegues in 1976 (Martin et al., 1976). Basing on the 
physiological action induced by some benzomorphans-related molecules on 
morphine-dependent and non-dependent chronic spinal dogs, Martin and co-
workers were able to discern three different gropus. They hypothesized that 
the observed differences were caused by the interactions with three different 
subtypes of opioid receptors: 
1) the µ subtype, wich mediated the action of morphine and 
related compounds 
2) the κ subtype, wich mediated the action of ketocyclazocine and 
related compounds 
3) the σ subtype, wich mediated the action of racemic mixture of 
N-allynormetazocine (SKF-10,047) and related compounds  
Two subsequent findings convincingly demonstrated that σ receptors 
are not members of the opioid receptor family. First, the opioid receptors 
and the σ binding site exhibited an opposite enantioselectivity; opioid 
receptors are stereoselective for the (-)-isomers of benzomoprphans, 
whereas σ receptors are stereoselective for the (+) counterpart. Second, 
traditional opioid receptors antagonists, such as naloxone or naltrexone, 
were ineffective against both the in vivo and the in vitro effects of the (+)-
SKF-10,047 (Brady et al., 1982; Iwamoto, 1981; Katz et al., 1985; Slifer and 
Balster, 1983; Vaupel, 1983). In addition, the (-)-SKF-10,047 has been 
found to possess high affinity for µ and κ opioid receptors (Zukin et al., 
1982).  
Introduction - Chapter 1 
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Binding experiments further determined that the (+)- isomer of SKF-
10,047 is also able to displace the tritiated phenylcyclohexylpiperidine 
([3H]-PCP) in rat brains homogenates (Mendelshon et al., 1985; Zukin et al., 
1982). For this reason, σ receptors were often cited as σ/opioid/PCP 
receptors and many researchers believed that σ and PCP were the same 
binding site. The finding that the two potent σ ligands haloperidol and (±)-
pentazocine aren’t able to displace the [3H]-PCP from its binding site (Tam 
et al., 1983; Tam and Cook, 1984) convinced the scientific community that 
the (+)-SKF-10,047 is able to bind two different sites: the PCP binding site, 
subsequently identified as the N-methyl-D-aspartate (NMDA) glutamate 
receptor (Mendelshon et al., 1985; Wong et al., 1988) and a second different 
binding site, the σ receptor. Further autoradiographic studies also 
demonstrated that the PCP receptor and the σ receptors have a different 
distribution in the rat brain (Gundlach et al., 1986a and b; Manallac et al., 
1987; Sircar et al., 1986). At present, the σ receptor is considered to be a 
unique receptor family. 
 
 
1.2 Pharmacological characterization of the σ receptors: 
the σ1 and the σ2 receptors 
 
The main charachteristics of the σ receptors class include that they can 
bind with high to moderate affinity to a wide spectrum of known compounds 
of different structural class, such as benzomorphans (pentazocine, SKF-
10,047), butyrophenones (haloperidol), guanidines (DTG), piperidines ((+)-
3-PPP), morphinans (dextromethorphan), tricyclic antidepressants 
(imipramine), phenothiazines (chlorpromazine), serotonin-uptake inhibitors 
Introduction - Chapter 1 
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(sertraline), monoamine oxidase inhibitors (clorgyline), psycostimulants 
(cocaine, 3,4-Methylenedioxymethamphetamine), certain steroids 
(progesterone) (reviewed in Hayashi and Su, 2004a). 
The presence of at least two σ receptors subtypes was first suggested by 
binding experiments, using two highly selective radiolabeled probes for σ 
receptors: [3H]-DTG and [3H](+)-3-PPP. In fact, (+)-benzomorphans such as 
(+)-pentazocine and (+)-SKF-10,047 were able to significantly displace the 
two radiolabeled probes from guinea pig brain homogenates and they also 
showed a marked lower affinity when tested on PC12 membranes (Hellewell 
and Bowen, 1990). When binding the rat hepatic σ sites with [3H]-DTG, the 
receptor profile of σ ligands was found to be similar to that observed in 
PC12 cells; moreover, when the σ radioligand [3H](+)-pentazocine was 
used, the results showed the same σ ligand selectivity previously observed in 
guinea pig brain (Hellewell and Bowen, 1990; Walker et al., 1990). Though, 
basing on the differences in the binding pattern, it was possible to 
distinguish two different σ receptor subtypes, called σ1 and σ2 (Hellewell 
and Bowen 1990; Quirion et al. 1992). The σ1 receptors exhibit a major 
stereoselectivity towards the dextrorotatory isomers of the benzomorphans 
and many other opioids whereas the σ2 receptors display a reverse 
stereospecificity, since they bind with a similar affinity both the levorotatory 
and the dextrorotatory isomers of the benzomorphans (Table 1.1). For more 
than a decade the 1,3-di(2-tolyl)guanidine (DTG) remained the only slightly 
selective σ2 ligand; for this reason the [3H]-DTG was widely employed in 
the σ2 binding experiments, masking the σ1 binding with the cold (+)-
pentazocine. Anyhow, today, some σ2 preferring ligands, such as the SM-21 
(Ghelardini et al., 2000), have been synthesized and charachterized. The 
progesterone is also able to differentiate between σ1 and σ2, interacting with 
only the σ1 subtype (Kahoun and Ruoho, 1992); for this reason the 
Introduction - Chapter 1 
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progesterone is believed to be a putative endogenous ligand of σ1 
(Ganapathy et al., 1999). A third σ receptors subtype was also proposed; it 
was called σ3 (Quirion et al., 1992), but, to date, no convincing binding data 
or selective ligands are available for this putative receptor subtype.  
 
Table 1.1. Pharmacology of σ receptor ligands; following Ki values are obtained with 
different experimental approaches wich are described in respective references. 
 
Affinity  
[Ki nM] Drugs 
σ1 σ2 
Function 
on σ1 
receptors 
Other activities References 
BENZOMPORPHANS 
(+)-Pentazocine 16.7 6611 Agonist - Vilner and Bowen, 2000 
(–)-Pentazocine 807 2324 Agonist 
κ1 agonist, µ1, µ2, ligand, 
low affinity δ and κ3 opioid 
ligand  
Vilner and Bowen, 2000 
+ Chien and Pasternak 
1995b 
(+)-SKF-10,047 597  39740 Agonist NMDA receptor ligand Vilner and Bowen, 2000 + Hayashi and Su, 2004 
(-)-SKF-10,047 50399   41461 Agonist - Vilner and Bowen, 2000 
ANTIPSYCHOTICS 
Haloperidol 6.44   221 Antagonist Dopamine D2 and D3 antagonist; σ2 agonist  
Vilner and Bowen, 2000 
+ Maurice et al., 2001a° 
+ Jaen et al., 1993 
Chlorpromazine 453 1628 ? Dopamine D2 antagonist 
Matsumoto and Pouw, 
2000 + Hayashi and Su, 
2004  
ANTIDEPRESSANTS 
Clorgyline 2.9 505 Agonist? Irreversible monoamine oxidase A inhibitor 
Bermack and Debonnel, 
2005 + Itzhak et al., 
1991 
Fluoxetine 240 16100 Agonist Selective 5-HT reuptake inhibitor 
Hayashi and Su, 2008 + 
Narita et al., 1996 
Fluvoxamine 36 8439 Agonist Selective 5-HT reuptake inhibitor 
Hayashi and Su, 2008 + 
Narita et al., 1996 
Imipramine 343 2107 Agonist Monoamine reuptake inhibitor 
Hayashi and Su, 2008 + 
Narita et al., 1996 
Sertraline 57 5297 Agonist Selective 5-HT reuptake inhibitor 
Hayashi and Su, 2008 + 
Bermack and Debonnel, 
2005 + Narita et al., 
1996 
ANTITUSSIVES 
Carbetapentane 128 1953 Agonist Muscarinic antagonist, σ2 agonist 
Matsuno et al., 1996 + 
Calderon et al., 1994 + 
Maurice et al., 2001a 
Dextromethorphan 205 11060 Agonist NMDA receptor allosteric antagonist 
LePage et al., 2005 + 
Shin et al., 2005 + 
Maurice et al., 2001a 
Dimemorfan 151 4421 Agonist ? 
Shin et al., 2005 + 
Wang et al., 2003 + 
Chou et al., 1999 
PARKINSON’S AND/OR ALZHEIMER’S DISEASE 
Amantadine 7440 ? Agonist? NMDA antagonist, antiviral properties 
Peeters et al., 2004 + 
Chen and Lipton, 2006 
Donepezil 14.6  ? Agonist Cholinesterase inhibitor 
Kato et al., 1999 + 
Maurice et al., 2006a + 
Meunier et al., 2006 
Memantine 2600 ? Agonist? NMDA antagonist, 
antiviral properties 
Peeters et al., 2004 + 
Chen and Lipton, 2006 
Introduction - Chapter 1 
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DRUG OF ABUSE 
Cocaine 2000 31000 Agonist 
Monoamine transporters 
inhibitor, amongst other 
actions, psychostimulant 
Matsumoto et al., 2002 
+ Rothman and 
Bauerman, 2003 
Metamphetamine 2160 46670 ? 
Preferential DAT inhibitor, 
amongst other actions, 
psychostimulant 
Nguyen et al., 2005 + 
Fleckenstein et al., 2007 
MDMA 3057 8889 ? 
Preferential SERT 
inhibitor, among other 
actions, psychostimulant 
Brammer et al., 2006 + 
Green et al., 2003 
PUTATIVE ENDOGENOUS REGULATORS 
Neuropeptide Y 
(NPY) ~10* ? Agonist? 
Anti-amnesic, anti-
convulsivant 
Maurice et al., 2001a + 
Roman et al., 1989 + 
Ault and Werling, 1997 
DHEAS 5200 ? Agonist GABAA negative 
modulator 
Hong et al., 2004 + 
Maurice et al., 2001a 
Pregnenolone sulfate 980 ? Agonist NMDA positive/GABAA 
negative modulator 
Hong et al., 2004 + 
Maurice et al., 2001a 
Progesterone 130 ? Antagonist NMDA negative/GABAA positive modulator 
Hong et al., 2004 + 
Maurice et al., 2001a 
DMT 14750 21710 Agonist 
agonist 5-HT2A and  
5-HT2A receptors, 
psychedelic drug 
Fontanilla et al., 2009 + 
Su et al., 2009 + Smith 
et al., 1998 
D-erythro-sphingosine 140 13000 Agonist? Endogenous amine involved in lipid signalling 
Ramachandran et al., 
2009 
N,N-dimethyl-
sphingosine 120 2800 Agonist? 
Endogenous amine 
involved in lipid signalling 
Ramachandran et al., 
2009 
L-threo-sphingosine 20 8300 Agonist? Endogenous amine involved in lipid signalling 
Ramachandran et al., 
2009 
Sphinganine 70 35000 Agonist? Endogenous amine involved in lipid signalling 
Ramachandran et al., 
2009 
ANTICONVULSANTS 
Phenytoin (DPH) 
Not 
measu-
reable 
Not 
measu-
reable 
Allosteric 
modulator 
Delayed rectifier K+ 
channel blocker, T-type 
Ca2+ current inhibitor, Na+ 
current inhibitor 
Walker et al., 1990 + 
Cobos et al., 2005 and 
2006 + Nobile and 
Lagostena, 1998 + 
Todorovic and Lingle, 
1998 + Rush et al., 1997 
Ropizine 
Not 
measu-
reable 
Not 
measu-
reable 
Allosteric 
modulator ? Walker et al., 1990 
OTHER σ DRUGS 
AC-927 30 138 Antagonist σ2 antagonist Matsumoto et al., 2008 
BD-737 8.78 68.3 Agonist - 
McCracken 1999b + 
Vilner and Bowen, 2000 
+ Hellewell et al., 1994 
+ Guitart et al., 2004 
BD-1008 2 8 Antagonist σ2 agonist 
McCracken 1999b + 
Vilner and Bowen, 2000 
+ Hayashi and Su, 2004 
BD-1047 0.9 47 Antagonist α adrenoceptor ligand 
McCracken et al., 1999° 
+ Matsumoto et al., 
1995 + Maurice et al., 
2001a 
BD-1063 9 449 Antagonist - 
Matsumoto et al., 1995 
+ McCracken 1999b + 
Brammer et al., 2006 + 
Maurice et al., 2001a 
BMY-14802 66 51 Antagonist 5-HT1A agonist 
Matsumoto and Pouw, 
2000 + Guitart et al., 
2004 + Matos et al., 
1996 
DTG 77 43 ? σ2 agonist 
Kedjouar et al., 1999 + 
Maurice et al., 2001a + 
Matsumoto and Pouw, 
2000 
Dup734 10 ? Antagonist 5-HT2 antagonist Tam et al., 1992 
Eliprodil  
(SL-82.0715) 132 634 ? 
NMDA antagonist, α1 
adrenoceptor ligand 
Hashimoto and London, 
1995 
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E-5842 4 220 Antagonist 
High affinity for α2B, α1a 
and α1B adrenergic 
receptors, low to moderate 
affinity for dopamine, 5-
HT and glutamate 
receptors 
Guitart et al., 1998 + 
Guitart et al., 2004 
JO-1784 (Igmesine) 39 ? Agonist - Guitart et al., 2004 
MR-200 1.5 21.9 Agonist - 
Ronsisvalle et al., 
2001b, Kanzaki et al, 
1992 
NE-100 1.5 84.6 Antagonist - Chaki et al., 1996 
OPC-14523 
47 
(IC50 
nM) 
56 
(IC50 
nM) 
Agonist 
Agonist of pre- and post-
synaptic 5-HT1A 
receptors, SERT inhibitor 
Tottori et al., 2001 + 
Guitart et al., 2004 + 
Bermack and Debonnel, 
2007 
(+)-3-PPP 79 120 Agonist 
σ2 agonist, NMDA 
receptor ligand, 
dopaminergic agonist 
Walker et al., 1990 + 
Höfner and Wanner, 
2000 + Hayashi and Su 
2004 
(-)-3-PPP ~310 ~1200 ? - Itzhak et al., 1991 
PRE-084 44 ? Agonist - Maurice et al., 1999 
Rimcazole 
(BW-234U) 2380 1162 Antagonist DAT inhibitor 
Matsumoto and Pouw, 
2000 + Matsumoto et 
al., 2001c 
SA-4503 17.4 1784 Agonist - Matsuno and Mita, 1998 
SR-31742A 5.3 for the whole σ population - 
High affinity for C8-C7 
sterol isomerase Poncelet et al., 1993 
SM-21 >1000 67.5 ? Agonist σ2 Ghelardini et al., 2000 
?: to date not studied or unclear  
-: no other pharmacological target has been described. 
* This result has been first reported by Roman et al. in the 1989; however it hasn’t been confirmed later in other researches. 
 
Another distinguish feature between the two classes of σ receptors is 
their interaction with ropizine and phenytoin (Musacchio et al., 1989a; 
DeHaven-Hudkins et al., 1993). σ1 receptors are allosterically modulated by 
these compounds whereas σ2 receptors are not affected. Furthermore,these 
two classes of receptors are also distingushable on the basis of their 
moleculare weight. In fact the σ1 receptor was found to be a 25 kDa single 
protein which has been cloned (see section 1.3) in several animal species 
and humans (Kekuda et al., 1996; Prasad et al., 1998; Hanner et al., 1996; 
Pan et al., 1998; Seth et al., 1997, 1998); on the other hand, the σ2 receptors, 
not yet been cloned, have an apparent molecular weight of 18-21 kDa, 
detected with [3H]azido-DTG photoaffinity labelling in the presence of 
dextrallorphan to mask σ1 binding site (Hellewell and Bowen, 1990; 
Hellewell et al., 1994). 
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Currently, the classification of σ receptors comprising the σ1 and the σ2 
subtypes is widely accepted by the scientific community. 
 
Figure1.1. Chemical structure of the most important sigma ligands 
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1.3 Cloning and molecular characterization of σ1 
receptors 
 
One of the most important step in the σ receptor comprehension was 
the cloning of the σ1 receptor. In 1996, Hanner et al. (Hanner et al., 1996) 
successfully purified and cloned the σ1 binding site from guinea pig liver 
microsomes. Hanner et al. used the aminoacid (AA) sequence to degenerate 
nucleotide primers and they succesfully used these primers to amplify a RT-
PCR product, with guinea pig liver as RNA source. From then on, the σ1 
was also cloned from other different sources: from the JAR human 
choriocarcinoma cell line (Kekuda et al., 1996; Prasad et al., 1998), from the 
rat brain and from the mouse brain (Seth et al., 1998; Mei and Pasternak, 
2001; Pan et al., 1998). The σ1 cDNA cloned from guinea pig is 1857 bp 
long and it codes for a 223 amino acids protein. The estimated molecular 
mass was 25,3 kDa, then very similar to the values coming from the 
photoaffinity labeling experiments. The human σ1 cDNA is 1,653 bp long, 
with a coding sequence of 672 bp long that codes for a 223 AA protein 
(Kekuda et al., 1996). Moreover, the AA sequence of the human σ receptor 
bears 93% of homology with the guinea pig σ1 (Kekuda et al., 1996). 
Analysis of the AA sequence showed that both the human and the guinea 
pig σ1 receptors carry, at the N-terminus, the AA sequence motif 
MQWAVGRR, wich is considered an endoplasmic reticulum retention 
signal. As showed in figure (Fig.1.2), also the mouse and the rat brain σ1 AA 
sequence is highly conserved, showing high homologies both with the 
guinea pig and the human σ1 receptors. 
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Figure 1.2. Comparison of the AA sequence of σ1 receptors from different mammallian 
species. Regions with identical AA are indicated by dark shaded boxes and region with 
conservative substitution are indicated by lightly shadow boxes (image from Sigma 
Receptors Handbook, Matsumoto, Bowen and Su, 2007) 
 
The AA sequence of the cloned σ1 showed no homology to any other 
mammalian protein, but it was found to share around 30% of homology with 
ERG2, a fungal gene product that possess a sterol C8-C7 isomerase activity 
(Moebius et al., 1997). Interstingly, the most conserved domain in both the 
peroteins carries a sterol/steroid-binding domain, obligatory for a protein 
involved in sterol synthesis (Hanner et al., 1996a), but, probably, also a key 
feature for σ1 to play its endogenous role. In fact, the existence of a lipohilic 
sterol/steroidbinding site also explains the surprising ability of the cloned σ1 
to bind so many drugs from distinct pharmacological classes with high 
affinity (Hanner et al., 1996). However, the cloned σ1 receptor doesn’t 
possess any sterol isomerase activity similar to ERG2 fungal enzyme 
(Hanner et al., 1996). Moreover, the mammallian sterol isomerase has been 
cloned, it is called emopamil-binding protein and it doesn’t show any 
structural similarity to either the yeast C8-C7 sterol isomerase or 
mammallian σ1 receptors (Hanner et al, 1995; Silve et al., 1996). 
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The cloned mammalian σ1 receptors has been shown to be an integral 
membrane protein able to localize to the nuclear and the endoplasmic 
reticulum (Jbilo et al., 1997). The hydropathy analyses have led to the 
prediction of two different transmembrane topology models consisting of 
one (Hanner et al., 1996; Kekuda et al., 1996; Seth et al., 1997; Seth et al., 
1998) or two (Jbilo et al., 1997; Pan et al., 1998; Mei and Pasternak, 2001) 
transmembranes domains (Fig. 1.3). Evidence supporting the two 
transmembranes model were provided later by Aydar et al. (Aydar et al., 
2002); using a GFP probe and two fusion protein, the C-terminal GFP-σ1 
(GFP-C-σ1) and the N-terminal GFP-σ1 (GFP-N-σ1), Aydar et al. (Aydar et 
al., 2002) were able to prove that, when expressed in in Xenopus laevis 
oocytes, the σ1 receptor posseses two transmembrane segments and both the 
termini are located in the cytoplasmatic lumen (Fig. 1.3). 
 
 
Figure 1.3. Structural models proposed for the σ1 receptor, with a single putative 
transmembrane domain (A) and two putative transmembrane domains (B) (Guitart et al., 
2004) 
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Another relevant finding in σ1 receptor biology was the discovery of an 
alternatively spliced variant of the human σ1 receptor, expressed in the 
human T lymphocyte cell line Jurkatt (Ganapathy et al., 1999). This splice 
variant, that lacks 31 AA in the position 119-149, doesn’t have the ability to 
bind the classical σ1 ligands. At present, it is not known wether the σ1 splice 
variant is expressed in human tissues and wich could be his 
pathophysiological implications. 
 
 
1.4 Distribution of σ1 receptors 
 
1.4.1 Anatomical distribution of σ1 receptors 
 
σ receptors are widely distributed throughout the whole body. In order 
to understand the physiological roles of the σ receptors, many efforts were 
made in studying their anatomical localization.  
In the central nervous system (CNS), they have been extensively 
studied because of their potential role in several CNS disorders (reviewed in 
Hayashi and Su, 2004a). The initial binding studies were performed using 
the two not σ1/σ2 selective probes [3H](+)-3-PPP and [3H](+)-DTG 
(Bouchard and Quirion, 1997; Gundlach et al., 1986a; McLean and Weber, 
1998); these studies showed that the highest concentration of σ receptors in 
the brain are in the brainstem motor nuclei. In fact high densities of σ 
receptors were found in the major constituents of brainstem motor circuits, 
like the cerebellum, the red nucleus, the gray matter of the spinal cord and 
both the basal ganglia and the pars compacta of the substantia nigra 
(Bouchard and Quirion, 1997; Gundlach et al., 1986a; McLean and Weber, 
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1998). The functional studies confirmed that the σ receptors have a role in 
modulating some motor functions (Bouchard and Quirion, 1997; Gundlach 
et al., 1986a; McLean and Weber, 1998); moreover, the σ agonists are able 
to directly stimulate motor behaviors via nigrostriatal dopaminergic 
pathways (Bastianetto et al., 1995; Goldstein et al., 1989; Patrick et al., 
1993; Walker et al., 1993) With the availaibility of new σ1/σ2 more selective 
compounds, it was also possible to demonstrate that both the σ1 and σ2 
subtypes are involved in the motor function modulation (Bouchard and 
Quirion, 1997; Patrick et al., 1993; Matsumoto and Pouw, 2000) 
The σ binding sites appear to be highly concentrated also in the spinal 
cord (Kovacs and Larson, 1995, 1998; Alonso et al., 2000), mainly in the 
dorsal horn (Alonso et al., 2000), in the hippocampus and in many other 
limbic and paralimbic areas, such as the cingulate cortex and the amygdala,  
The studies focused on the anatomical distribution of σ1 receptors have 
been extensively described in the rodent brain with autoradiographic 
methods employing selective σ1 ligands (Okuyama et al., 1995; Walker et 
al., 1992; Ishiwata et al., 1998 and 2006; Kawamura et al., 2000a and b), 
with in situ hybridization (Kitaichi et al., 2000; Zamanillo et al., 2000) and 
with immunohistochemical techniques (Alonso et al., 2000). In these 
studies, σ1 appeared to be particularly concentrated in all brain areas where 
dopamine (DA) is widely released, especially in the gyrus dentatus of the 
hippocampus suggesting that they may modulate cognitive behaviors, mood 
and affective states (Bouchars and Quirion, 1997), or maybe involved in 
psychostimulant actions (reviewed in Matsumoto et al., 2003). High 
concentrations of σ1 receptors were also found in the facial nucleus, in the 
thalamic and hypothalamic nuclei, in the striatum, in the cerebellum, in the 
dorsal raphe nucleus and in the locus coeruleus (Bouchard and Quirion 
1997; Inoue et al., 2000), whereas the σ2 appeared more concentrated in the 
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brain areas involved in the control of posture and movement (Bouchard and 
Quirion 1997). 
The σ1 receptor is also widely distributed in the peripheral organs. It 
has been found in the digestive tract (Samovilova and Vinogradov 1992), in 
the kidney (Hellewell et al., 1994), in the liver (McCann and Su, 1991; 
Hellewell et al., 1994; DeHaven-Hudkins et al., 1994), in the heart (Ela et 
al., 1994; Monassier and Bousquet, 2002; DeHaven-Hudkins et al., 1994), in 
the lungs (Stone et al., 2006), in the vas deferens (DeHaven-Hudkins et al., 
1991), in the testis (Wolfe et al., 1989; DeHaven-Hudkins et al., 1994), in 
the ovaries (Wolfe et al., 1989), and also in blood mononuclear cells (Wolfe 
et al., 1888). the σ2 receptors have also been found in different peripheral 
organs; it appeared to be particularly concentrated in the liver and in the 
kidney (Hellewell et al. 1994). 
 
1.4.2 Subcellular distribution of σ1 receptors 
 
Early studies aimed in clarifying the subcellular localization of σ 
receptors were difficult and not much accurate because the ligand binding 
assays were the only strategy available to mark the σ binding sites. However 
by combining rat membrane fractionation and radioligand binding 
experiments, some groups obtained some preliminary data (Cagnotto et al., 
1994; DeHaven-Hudkins et al., 1994; Itzhak et al., 1991; Jbilo et al., 1997; 
Kekuda et al., 1996; McCann et al., 1989; McCann et al., 1994; Tanaka et 
al., 1995). Interestingly, the not σ1/σ2 selective radioactive ligands [3H](+)-
SKF-10,047, [3H](+)-3-PPP and [3H]DTG were found to bind some 
subcellular fraction, respectively with the following order of affinity: 
microsomal > mitochondrial > synaptosomal > myelin > nuclear fraction 
(Itzhak et al., 1991). On the other hand, when using the σ1 selective [3H](+)-
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pentazocine as radioactive probe, the affinity for the same subcellular 
fractions was slightly different, respectively: microsomal > nuclear fraction 
> myelin > mitochondrial > synaptosomal (Cagnotto et al., 1994; McCann et 
al., 1989). Taken toghether, these results indicated for the first time that the 
distribution of the σ1 receptors in the synaptic regions of plasma membrane 
or in the mithocondria is minimum, whereas the σ1 are predominatly 
enriched in microsomes, suggesting a localization on the endoplasmatic 
reticulum (ER). 
The avalaibility of the specific antibodies against the σ1 receptors led to 
more accurates studies. Western blotting experiments confirmed the data 
obtained with binding results not only in the rat brain neurons, but also in 
oligodendrocytes, in lymphocytes and in the NG108-15 neuroblastoma x 
glioma cell line (Hayashi et al., 2000; Dussossoy et al., 1999; Alonso et al., 
2000). In the immunocytochemical researches, performed with the 
promonocytic cell line THP, the σ1 specifically localized on the ER 
membrane and on nuclear envelopes (Dussossoy et al., 1999; Jbilo et al., 
1997). In others immunofluorescence studies, σ1 polyclonal antibodies were 
able to selectively stain the ER in the cytoplasmatic area of neuronal and 
retinal rat cells (Alonso et al., 2000; Hayashi et al., 2001, Morin-Surun et al., 
1999; Ola et al., 2001). 
However, the most accurate data come from the confocal fluorescence 
microscopy investigations. In the NG108 cell line, the endogenous 
expressed σ1 receptors were found to localize on both the ER and the nuclear 
envelope, but, at the ER level, they are highly clustered in globular 
structures enriched in cholesterol and neutral lipids, similar to the lipid rafts 
(Hayashi and Su, 2003a; Hayashi and Su, 2003b; Hayashi and Su, 2007). 
Interestingly, the fusion protein σ1-C-terminally enhanced yellow 
fluorescence protein (EYFP-C-σ1) showed the same distribution of the 
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endogenous expressed σ1 receptors, whereas the fusion protein σ1-N-
terminally enhanced yellow fluorescence protein (EYFP-N-σ1) didn’t 
behave like the endogenous receptor; in fact the EYFP-N-σ1 receptor was 
diffused in the ER tubules, but it couldn’t target the lipid raft-like structures. 
Moreover, the EYFP-N-σ1 transfected cells lines failed in the 
compartmentalization of neutral lipids in lipid rich globular structures, 
indicating a putative role of the σ1 receptors in the intracellular lipid 
homeostasis (Hayashi and Su, 2003b). 
To date, the σ1 receptors are considered by the scientific community an 
ER protein with a unique distribution pattern. 
 
 
1.5 Potential σ1 receptor endogenous ligand(s) 
 
The endogenous ligand of the σ1 receptors have not yet been 
inequivocabilly identified. 
First efforts to discover endogenous σ ligand(s) were based on the 
fractionation techniques, since the classical strategy for identifying an 
endogenous ligand is to extract it from the tissue where it acts. These studies 
provided proofs of the existence of a peptide-related substance, called 
“sigmaphin”, isolated from the guinea pig brain (Su et al., 1986; Contreras 
et al., 1987) and a porcine liver extract able to bind the σ binding sites 
(Nagornaia et al., 19888). Even if these efforts proved the existence of 
endogenous extracts able to bind to the σ receptors, none of these substances 
were ever purified or charachterized. 
Early binding experiments reported that two endogenous neuropeptides, 
neuropeptide Y (NPY) and peptide YY (PYY), were able to strongly 
displace the [3H](+)-SKF-10,047 from rat brain homogenates σ receptors (Ki 
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of 9.8 and 4.9 nM, respectively) (Roman et al., 1989). However, subsequent 
experiments couldn’t confirm this hypothesis (McCann and Su, 1991; Tam 
and Mitchell, 1991). 
The search for an endogenous ligand led to the discovery that certain 
neurosteroids possess affinity for σ1 receptors. The interaction between 
neurosteroids and σ1 receptors was first reported by Su and co-workers (Su 
et al., 1988). Among the other tested neurosteroids, the progesterone 
appeared to bind to the σ receptors with the highest affinity (Su et al., 1988). 
Furthermore, the binding experiments, using [3H]progesterone as radioactive 
probe, unveiled a drug displacement pattern consistent with σ receptors 
(McCann and Su, 1991; Yamada et al., 1994). The possibility that 
neurosteroids could be the endogenous σ1 receptors ligands is further 
supported by the discovery that the σ1 receptor possess a sterol/steroid 
binding pocket (Mei and Pasternak, 2001). However, the affinity of 
progesterone for the σ1 receptors subtype, that falls in the µM range, doesn’t 
appear high enough for an endogenous ligand and the progesterone 
concentration in free serum is insufficient to occupy the σ1 receptors in the 
brain (Schwarz et al., 1989). In addition, the other steroids such as 
dehydroepiandrosterone sulfate (DHEAS), pregnenolone sulfate, 
testosterone and deoxycorticosterone exhibit even lower affinities than 
progesterone for the σ1 receptor subtype (Su et al., 1988 and 1990; Hayashi 
and Su, 2004a). Anyhow, several publications keep confirming the ability of 
progesterone to bind the σ receptors (Hanner et al., 1996; Ganapathy et al., 
1999; Klein et al., 1994; Maurice et al., 1996; Ramamoorthy et al., 1995). 
The few available functional studies indicate that some neurosteroids act as 
agonists (e.g. pregnenolone), while others act as antagonists (e.g. 
progesterone) (Maurice et al., 2001a). 
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Recently, the endogenous N,N-dimethyltryptamine (DMT) was found 
to be able to bind and regulate the σ1 receptors (Fontanilla et al., 2009). The 
DMT is historically known to be the most active psychoactive compound in 
some sacramental teas (such as ayahuasca and yagè) used in native 
shamanic rituals in South America. However, DMT can be produced by 
enzymes in mammalian lung (Axelrod, 1961) and in rodent brain (Savaedra 
and Axelrod, 1962) and it has also been found in human urine, blood and 
cerebrospinal fluid (Franzen and Gross, 1965; Beaton and Morris, 1984). 
The affinity of DMT for the σ1 receptors falls in the µM range (Fontanilla et 
al., 2009) and it is similar to the affinity of progesterone for the same σ 
receptors subtypes. Moreover, in mouse models, µM concentrations of DMT 
induced the same hypermobility effects observed with the σ1 selective ligand 
(+)-SKF-10,047, while both the DMT and (+)-SKF-10,047 can’t cause the 
same pharmacological effects in the σ1 KO mice (Fontanilla et al., 2009). 
These results strongly support that the behavioral actions of DMT are 
mediated by the σ1 receptors.  
The endogenous sphingolipids were also recently found to compete 
with [3H](+)-pentazocine on the σ1 binding site (Ramachandran et al., 2009). 
In particular, the p-erytrhro-sphingosine, or just sphingosine, was find to 
bind to the σ1 receptors with the highest affinity, but not its major 
metabolite, the sphingosine-1-phosphate, that couldn’t bind at all both the σ 
receptors subtypes (Ramachandran et al., 2009). This finding suggests a 
putative cross-talking between the enzyme sphingosine kinase and the σ1 
receptors, mediated by the sphingosine itself (Ramachandran et al., 2009). 
Though, also the sphingosine was proposed as endogenous σ1 mediator. 
To date, it appears clearer and clearer that σ receptors possess high 
affinity for many endogenous molecules and numerous research groups 
share the opinion that these enigmatic receptors could be regulated by a 
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broad spectrum of endogenous products. Moreover, since the involvement 
of σ receptors in the modulation of several subcellular effectors has been 
also reported (Section 1.6), the hypothesis that the σ receptors could affect 
many biological functions is widely accepted. Even the term “σ endogenous 
ligand” is disappering from literature, substituted by the less specific 
definition of “σ endogenous regulator”. 
 
 
1.6 Allosteric modulation of the σ1 receptors 
 
The anticonvulsivant drug phenytoin (DPH) is known to allosterically 
modulates the binding of σ1 radioligands without affecting σ2 radioligands 
(Quirion et al., 1992). However, DPH not only discriminates between σ1 and 
σ2 ligands, but it is also able to differently modulate the activity of σ1 
ligands. In fact, DPH increased the binding of [3H]dextromethorphan, 
[3H](+)-SKF-10,047, [3H](+)-3-PPP and [3H](+)-pentazocine (Musacchio et 
al., 1987, 1988, 1989a and b; Craviso and Musacchio, 1983; Karbon et al., 
1991; Bailey and Karbon, 1993; McCann and Su, 1991; Culp et al., 1992; 
Rothman et al., 1991; Bonhaus et al., 1993; Chaki et al., 1996; DeHaven-
Hudkins et al., 1993), but not the binding of σ1 [3H]haloperidol, 
[3H]progesterone, [3H]DTG, [3H]DuP 734, [3H]RS-23597-190 and [3H]-
N,N-dipropyl-2- [4-methoxy-3- (2-phenylethoxy) phenyl]-ethylamine 
([3H]NE-100) (Karbon et al., 1991; Meyer et al., 1998; Culp et al., 1992; 
Bonhaus et al., 1994; Tanaka et al., 1995; Chaki et al., 1996). 
It was initially proposed that the differential sensitivity of σ1 
compounds to the DPH allosteric modulation should be restricted to 
compounds that bind selectively the σ1 receptor subtype (DeHaven-Hudkins 
et al., 1993). However, this hypothesis is not entirely consistent with the 
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more recent data on the σ ligands selectivity patterns. The newest researches 
demonstrated that the allosteric modulation by DPH of the affinity of σ1 
receptor ligands depends on the agonist or antagonist profile of the ligand 
(Cobos et al., 2006). 
 
 
1.7 Modulation of cellular effectors by σ1 receptors 
 
1.7.1 Is the σ1 coupled to the G-proteins? 
 
One of the earliest issues regarding the cellular effects of the σ1 
receptors was their possible coupling to G-proteins. Even if this idea has 
been investigated with many different approaches, to date, the results are 
still contradictory (Bermack and Debonnel, 2005; Guitart et al., 2004). 
With the avalaibility of the cloned σ1 receptor and a deeper knoweledge 
of its molecular conformation (fig.1.2 and 1.3), it was suddendly clear that 
the σ1 doesn’t possess at all the typical structure of a G-protein-coupled 
receptor (with seven transmembrane domains). Even so, the literature is still 
filled with controversial data. For example, it has been reported that G-
proteins mediate some electrophysiological and behavioural responses of σ1 
ligands (Soriani et al., 1998, 1999a; Bergeron et al., 1996; Ueda et al., 2001) 
whereas, in other experimental models, some σ1 agonists, such as (+)-
pentazocine, (+)-SKF-10,047, (+)-3-PPP and BD-737 were unable to 
increase GTPase activity in rat brain membranes (Hong and Werling, 2000; 
Odagaki et al., 2005). 
The existence of both metabotropic and non-metabotropic σ1 receptor 
subtypes was also proposed (Maruo et al., 2000). However, inequivocabilly 
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proofs of the existence of this hypothetic σ1 metabotropic subtype have not 
yet been carried out. 
 
1.7.2 σ1 modulation of PLC-PKC-IP3 Ca2+ release system: 
intracellular dynamics following the σ1 receptors activation 
 
It is known that the ER can works as calcium (Ca2+) deposit and, under 
certain stimuli, it can release the Ca2+ in the cytoplasm (Hayashi and Su, 
2000), or directly to mitochondria (Hayashi and Su, 2007). The ankyrins are 
a member of a family of cytoskeletal adapter proteins that interconnect 
membrane proteins with the cell cytoskeleton (Bennett and Stenbuck, 1979), 
they are present on the ER, on the plasma membrane and on the Golgi 
complex (De Matteis and Morrow, 1998; Tuvia et al., 1999) and they are 
known to affect the Ca2+ efflux interacting with inositol 1,4,5-trisphosphate 
receptors (IP3Rs) (Chien and Pasternak, 1994; De Waard et al., 1997). 
In the 2000 Hayashi and Su first described the role of σ1 receptors in 
regulating the Ca2+ efflux from the ER storages, physically interacting with 
the ankyrin-IP3Rs complex. 
The regulation of the Ca2+ signalling by σ1 receptors is a complex one 
and involves the translocation of σ1 receptors from the lipid rafts of the ER 
to the plasma membrane, to the nucleus and, partially, σ1 can also dislocate 
around the whole cell without leaving the ER. At the resting state, in the 
previously described highly clustered globular structures, the σ1 receptors 
form a complex with the ankyrin (specifically the ANK220 isomer) and the 
IP3Rs (Hayashi and Su, 2001) The σ1 receptors activation by agonists 
induces the dissociation of the σ1 receptor-ANK220 complex from the IP3Rs 
channel (Hayashi and Su, 2001), potentiating the calcium efflux induced by 
the 1,4,5-trisphosphate (IP3) in a bell-shaped curve fashion (Hayashi et al., 
Introduction - Chapter 1 
 - 34 - 
2000). This issue directly correlates the σ1 receptors to the known 
PLC/PKC/IP3 Ca2+ release mechanism. In fact, the activities of the receptors 
that activates the PLC system, enhancing the inositol IP3 cytoplasmatic 
concentration level, such as receptors for bradykinin and brain-derived 
neurotrophic factor (TrkB) (Hong et al., 2004; Peeters et al., 2004; Yagasaki 
et al. 2006), are undoubtely affected by the σ1 activation. 
In the NG-108 cell line, the enhancement of Ca2+ efflux has been 
reported not only when treating the cells with the known selective σ1 
agonists such as PRE 084 or (+)-pentazocine, but also when using some 
neurosteroids, such as pregnenolone sulfate and DHEA (Hayashi et al., 
2000, Hong et al., 2004). The destiny of the released σ1 receptor/ANK220 
complex is still unknown, but, as described later on the introduction (section 
1.7.3), it is clear that the σ1 receptors could modulate many other systems by 
protein-protein interactions. Interestingly, once activated, σ1 receptors are 
also able to reach the plasma membrane and they can even be be exocytosed 
(Hayashi and Su, 2003a). Though, so far, it’s not possible to exclude the 
hypothesis that the σ1 receptor/ANK220 complex could bind other protein 
systems, modulating their functionality.  
In the presence of a σ1 antagonist, σ1 receptors dissociates from the 
ANK220, which, in turn, remains associated to the IP3Rs (Hayashi and Su, 
2001). In this case, the ANK220 is still able to counteract the bradykinin-
induced Ca2+ efflux and the σ1 agonist-induced Ca2+ release potentiation is 
completely prevented. This latter effect has been also observed after the pre-
treatment with progesterone and with a specific σ1 receptor antisense 
oligodeoxynucleotide (Hayashi et al., 2000, Hong and Werling, 2002). 
Additionally, in vivo, the silencing of IP3Rs receptors induces a decrease of 
the σ1 receptor mRNA levels (Novakova et al., 2007), suggesting a putative 
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cross-talking between the two systems. The Hayashi and Su model is 
illustrated in figure 1.4. 
 
Figure 1.4. The σ1 receptors regulation of the ankyrin-IP3Rs complex at ER level (image 
taken from Cobos et al., 2008) 
 
Since the Ca2+ intracellular concentration ([Ca2+]i) is one of the most 
important second messengers, it is likely to hypotesize that the σ1 receptors 
are able to affect many others proteins systems through the modulation of 
the Ca2+ concentration itself. 
The physical association between the ER and mitochondria, which is 
known as the mitochondria-associated ER membrane (MAM), has been also 
described in literature (reviewed in Hayashi et al., 2009) The MAM plays 
important roles in various cellular ‘housekeeping’ functions including the 
non-vesicular transport of phospholipids (reviewed in Hayashi et al., 2009). 
The σ1 receptors were found also in the MAM; at this level, the σ1 receptors 
play a role in the regulation of the direct Ca2+ exchanges between the ER 
and the mitochondria (Hayashi and Su, 2007). The mechanism is a very 
complex one and it’s well reviewed in Hayashi et al., 2009. 
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1.7.3 Modulation of plasmalemma ion channels 
 
1.7.3.1 Calcium channels 
 
In addition to the effects discussed in the section 1.7.2, σ1 receptors are 
able to regulate the [Ca2+]i, triggering the plasmalemma voltage dependent 
Ca2+ channels. 
Church and Fletcher first reported in 1995 a σ1 interference, while 
studying the variation of the [Ca2+]i in cultured hippocampal pyramidal 
neurons preparations (Church and Fletcher, 1995). In their model, several σ1 
ligands, such as haloperidol, BD-737, carbetapentane, ifenprodil, rimcazole 
and dextromethorphan, blocked the increase of [Ca2+]i mediated by high-
voltage-activated channels (Church and Fletcher, 1995). σ1 ligands were also 
found to inhibit the depolarization-induced increasing in the [Ca2+]i in 
primary cultures of neurones and forebrain synaptosomes (Klette et al., 
1997; Brent et al., 1996 and 1997). However, in these experiments σ1 
agonists and antagonists produced the same effects wich might be also due 
to the involvement of the σ2 receptors subtype (reviewed in Monnet, 2005). 
In another series of experiments performed in rat forebrain synaptosomes, 
the (+)-pentazocine, the (-)-pentazocine, the BD-1008 and the DTG not only 
inhibited the raising of the Ca2+ levels induced by the depolarization, but 
they also reduced the basal [Ca2+]i, indicating that the σ receptors are able to 
directly affect the [Ca2+]i (Brent et al, 1996 and 1997). These latter effects 
were prevented by the pretreatment with the σ1 antagonist rimcazole. 
The involvement of σ1 in the Ca2+ plasmalemma channels regulation 
has been further confirmed. Hayashi and Su reported that, in the NG-108 
cell line, the σ1 agonist (+)-pentazocine inhibits the [Ca2+]i increase induced 
by KCl depolarization, whereas another σ1 agonist, PRE-084, induce the 
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opposite effects, potentiating the KCl [Ca2+]i increase (Hayashi and Su, 
2000). Since the pretreatment with the σ1 receptor antisense 
oligodeoxynucleotide blocked the effects of both the molecules, it has been 
ruled out that the σ1 is the subtype involved in the modulation of the 
plasmalemma Ca2+ channels (Hayashi and Su, 2000).  
 
1.7.3.2 Potassium channels 
 
In different research models, potassium (K+) channels have been 
reported to constitute one of the σ receptors target. The σ1 selective ligands 
(+)-pentazocine and igmesine (JO-1784) were firstly reported as negative 
modulators of several K+ currents in frog melanotropic cells (Soriani et al., 
1998, 1999a and b). The effects described in these latter experiments seem 
to be mediated by a Gs-protein (Soriani et al., 1998, 1999a). However, in the 
rat neurohypophysial terminals, the voltage-gated K+ channels are inhibited 
by the σ agonists (±)-pentazocine and (±)-SKF-10,047, despite intra-
terminal perfusion with GTP-free solutions, a G-protein inhibitor (GDPβS), 
a G-protein activator (GTPγS) or a non-hydrolysable ATP analogue 
(AMPPcP) (Lupardus et al., 2000). Though, Lupardus and co-workers 
excluded that the G-proteins could mediate the σ signalling (Lupardus et al., 
2000). The same research group also reported that the K+ channels 
expressed in oocytes without the σ1 receptors are unresponsive to the σ 
agonists, while, when both the channel and the σ1 were co-expressed, the K+ 
current can be inhibited while triggering the σ1 receptors (Lupardus et al., 
2000). These findings indicate that the inhibition of K+ channels by σ 
receptor agonists does not arise from direct interactions of these ligands with 
the channel itself. The involvement of the G-proteins has been also excluded 
while studying the effects of σ receptor activation on voltage-activated K+ 
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channels and action potentials in isolated rat intracardiac neurons, using the 
whole-cell patch-clamp recording techniques (Zhang and Cuevas, 2005). In 
this research, different types of voltage-activated K+ channels were inhibited 
by several σ ligands and the observed blockade was not sensitive to the 
application of GDPβS (Zhang and Cuevas, 2005). The observed inhibition of 
K+ channels is dose-dependent, and the rank order potency of (+)-
pentazocine > ibogaine > DTG suggests that the effects are mediated by the 
σ1 receptor subtype activation. 
Since the G-protein doesn’t appear to be the signalling pathway 
connecting the σ1 receptors to the K+ currents, to date the exact mechanism 
of this regulation remains still unknown; however, a physical protein-protein 
interaction between σ1 and the K+ channel has been observed to occur. 
Aydar and co-workers (Aydar et al., 2002) studied, in Xenopus oocytes, the 
heterologous expression of the σ1 receptors to explore the effects on  K+ 
channels Kv 1.4 and 1.5. While confirming that the σ1 ligands modulate the 
K+ channel functions, this study also led to the discovery that Kv 1.4 and 1.5 
channel coimmunoprecipitate with the σ1 receptor (Aydar et al., 2002). 
Therefore, it was proposed that the two protein could form a stable macro-
molecular complex with functional implications (Aydar et al., 2002). 
The σ1 modulation of K+ currents, as well as the Ca2+ currents suggests 
that σ1 receptors could form complexes with several other proteins. The 
hypothesis that these complexes could be involved in many different 
processes is in line with the observed wide variety of actions that the σ1 
ligands produce in the CNS and, partially, it might also explain some of the 
discrepancies found in the literature (reviewed in Bermack and Debonell, 
2005). 
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1.7.3.3 Sodium channels 
 
Cheng and co-workers (Cheng et al., 2008)) found out that, in rat medial 
prefrontal cortex slices, the σ1 receptor agonist DHEA sulfate inhibits 
persistent sodium (Na+) currents. The observed inhibitory effect is 
ameliorated by Gi protein inhibitors and protein kinase C (PKC) inhibitors 
and it is blocked by σ1 receptor antagonists (Chang et al., 2008). These 
results indicate the existence of a sodium current-controlling mechanism via 
the σ1 receptor-Gi protein–PKC signaling pathway in cortical neurons 
(Cheng et al., 2008).  
 
 
1.8 Functions of σ1 receptors on ER lipid rafts 
 
As previously described (section 1.4.2.), on the ER the σ1 receptors are 
highly clustered in globular structures enriched in cholesterol and neutral 
lipids, similar to the lipid rafts (Hayashi and Su, 2003a; Hayashi and Su, 
2003b; Hayashi and Su, 2007). At this level, they are proposed to regulate 
the lipid storage sites and the turnover of the lipid droplets associated with 
the ER (Hayashi and Su, 2005a). The endoplasmic reticulum lipid droplets 
are formed by coalescence of neutral lipids into discs inside the bilayer of 
the ER membranes. When they reach a critical size, they bud off to form 
cytosolic lipid droplets (Murphy and Vance, 1999), which are proposed to 
be a novel transport pathway of lipids between the endoplasmic reticulum 
and Golgi apparatus or plasma membrane (Ohashi et al., 2003) that can be 
mediated by σ1 receptors (Hayashi and Su, 2003a and 2005b). This σ1 
feature might explain how the σ1 receptors can interact wiht so many 
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nurotransmitter systems (see next section), whose receptors are located at 
the plasma membrane level. 
The over-expression of the σ1 receptors in PC12 and NG-108 cell lines 
also alters the functional lipid composition of the ER lipid rafts. First of all, 
the cholesterol contents are appreciably increased in the σ1 transfected cells, 
showing that the σ1 upregulation would potentiate the lipid rafts formation 
(Takebayashi et al., 2004a; Hayashi and Su, 2005a). Secondly, the 
overexpression of σ1 alters the proportion of some critical lipid raft-forming 
gangliosides, wich have been previously proposed to be involved in the re-
localization of many cytoplasmatic proteins (Simons and Ikonen, 1997). 
Among other lipid rafts proteins, the growth factors receptors appeares to be 
especially triggered by the σ1 receptors activation. In fact, it was reported 
that, in a classical agonist/antagonist fashion, the σ1 ligands could alter the 
action of the brain-derived neurotrophic factor (BDNF) on the glutamatergic 
neurotransmission (Yagasaki et al., 2006) and they can enhance the nerve 
growth factor-induced neurite sprouting in stable σ1 transfected PC12 cells 
(Takebayashi et al., 2002). Moreover, while using a σ1 dominant-negative 
model, the not functional σ1 receptor attenuates the differentiation of the 
transfected rat primary hippocampal cultured cells (Hayashi and Su, 2004b), 
reinforcing the role of σ1 receptors on cell differentiation. 
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1.9 Modulation of others major neurotrasmitter systems 
 
1.9.1 Modulation of the adrenergic system 
 
Early studies showed that both in rat brain synaptosomes and in 
cultured bovine chromaffin cells, a mixed spectra of σ1 agonists and 
antagonists (Haloperidol, (+)-3PPP, (+)-SKF-10,047 and DTG) are able to 
presynaptically inhibit the [3H]norepinephrine reuptake (Rogers and 
Lemaire, 1991).  
Also the NMDA-stimulated [3H]norepinephrine release is affected by 
σ1 receptors. In isolated rabbit iris-ciliary body, flunarizine and (+)-
pentazocine inhibited [3H]norepinephrine release and this action was 
sensitive to the NE-100 antagonism (Campana et al., 2002). On the other 
hand, in rat hippocampal slices, σ agonists, both σ1 and non-σ1 selective, 
potentiate NMDA-induced [3H]norepinephrine release. In this same 
experimental paradigm, the σ1 antagonist BD-1063 and the haloperidol 
prevent the effects of the agonists, without affecting the basal values of the 
NMDA-induced [3H]norepinephrine release (Monnet et al., 1992a, 1995 and 
1996). 
Neurosteroids were again showed to be involved in the σ1 receptors 
dynamics. In fact, DHEA, wich in many experiments acts as σ1 selective 
agonist, has been shown to potentiate NMDA-evoked [3H]norepinephrine 
release. This effect is reverted by the σ1 antagonists BD-1063 and 
progesterone and also by haloperidol (Monnet et al., 1995) 
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1.9.2 Modulation of cholinergic system 
 
Behavioral effects of the σ receptors, such as cognition and memory, 
connect these protein to the regulation of cholinergic processes. 
In vivo microdialysis studies, subcutaneous applications of both σ1 
receptors agonist (+)-SKF-10,047 and the non selective σ ligand DTG were 
shown to display positive effects on the release of acetylcholine from rat 
prefrontal cortex; the observed effect is reverted by NE-100 and haloperidol 
(Matsuno et al., 1992, 1993, 1995a). Moreover, in line with the classical σ1 
pharmacology, (+)-SKF-10,047 induces a greater effect than its enantiomer, 
(-)-SKF-10,047. 
Using the same experiment model, it was found that several σ ligands 
like (+)-3PPP, SA-4503, (+)-pentazocine, (+)-SKF-10,047, and DTG 
increase the spontaneaous acetylcholine release in the hippocampus 
(Kobayashi et al., 1996a and b), in the frontal cortex (Kobayashi et al., 
1996b), but not in the striatum (Kobayashi et al., 1996a). These results also 
give important informations about the CNS distrbution of σ1 receptors. In 
addition, the σ1 agonists JO-1784, (+)-SKF-10,047 and SA-4503 positively 
affect the KCl-induced [3H]acetylcholine release from rat hippocampal 
slices (Junien et al, 1991; Horan et al., 2002). This effect is antagonized by 
the presence of haloperidol and DTG alone is able to inhibit the KCl-
stimulated [3H]acetylcholine release (Junien et al., 1991). 
The ability to regulate cholinergic system, exhibited by some σ ligand, 
confirms that these receptors are an important target since the disregulation 
of the cholinergic system could have an enormous therapeutic potential in 
the area of Alzheimer’s desease and of others forms of dementia. 
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1.9.3 Modulation of serotonergic neurotransmission 
 
In the last decade, an increasing number of studies have been aimed to 
describe the involvement of σ receptors in the modulation of serotonergic 
neurotransmission. 
In rat, a two days treatment with 4-(N-benzylpiperidin-4-yl)-4-
iodobenzamide (4-IBP) and (+)-pentazocine produces a ~35% increase in 
the basal firing rate of 5-HT neurons, compared to saline-treated animals 
(Bermack and Debonnel, 2001). Since JO-1784 and PRE-084 failed to 
increase the firing activity of serotonergic neurons, this difference has been 
ascribed to the existence of two different subtypes of σ1 receptors, defined 
metabotropic and non-metabotropic (Bermack and Debonnel, 2001). 
Therafter OPC-14523, wich is known to bind both the σ1 and 5HT1A 
receptors (Oshiro et al., 2000; Tottori et al., 2001), was shown to increase 
the firing activity of serotonergic neurons (Bermack et al., 2004). Since NE-
100 prevents the serotoninergic OPC-14523 stimulation, it has been 
postulated that this aefect is probably mediated by σ1 receptors (Bermack et 
al., 2004). 
Moreover, neurosteroids were proposed to modulate the serotoninergic 
system via σ1 receptor activation. In fact, in female rats dorsal raphe 
nucleus, subchronic administration of allopregnelone and DHEA increases 
the firing activity of the serotoninergic neurons (Robichaud and Debonnel, 
2004 and 2006), whereas the putative σ1 antagonist progesterone alone has 
no effect (Robichaud and Debonnel, 2004). 
In summary, the activation of σ1 receptors seems to enhance the 5-HT 
neurones firing activity. These findings suggest that σ1 ligands and some 
neurosteroids might represent interesting adjuvants in the treatment of mood 
disorders. 
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1.9.4 Modulation of GABAergic system 
 
To date, few studies have described the effects of σ1 ligands on 
GABAergic neurotransmission. They all seem to indicate an inhibiting role 
of σ1 receptors. DTG has been reported to suppress the firing rate of 
GABAergic interneurons in anaesthetized rats (Zhang et al., 1993a). (+)-
SKF-10,047, serotonin and trazodone inhibit the KCl-evoked GABA release 
in rat mossy fibre cerebellar synaptosomes, but only the effects of (+)-SKF-
10,047 and trazodone are prevented by pretreatment with BD-1047 and 3-
PPP (Garrone et al., 2000). Nanomolar concentrations of neurosteroids have 
been also found to interfere with GABA neurotransmission via σ1 receptors. 
In fact, in cultured hippocampal pyramidal neurons, the pregnenolone 
sulfate inhibits GABAergic synaptic transmission by a presynaptic effect 
(Mtchedlishvili and Kapur, 2003) and this effect is counteracted by BD-
1063 and haloperidol. 
Even if these preliminary informations were reported in literature, more 
studies are necessary to confirm a putative role of σ1 in GABAergic 
neurotransmission modulation. 
 
1.9.5 Modulation of glutamatergic system 
 
The connection between σ1 receptors and glutamatergic system has 
been often reported. Among all glutamate-gated ion channels (NMDA, 
kainate and AMPA receptors), σ1 regulation of the NMDA receptor subtype 
has been deeper investigated. Moreover, adopting in vivo paradigms, some σ 
ligands have been shown to produce the same effects of the NMDA receptor 
agonists, such as mood, motricity and memory alterations (Maurice and 
Lockhart, 1997). 
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In electrophysiological models, the application of σ ligands enhances 
the responsiveness of pyramidal neurons in hippocampal CA1 and CA3 
regions to microiontophoretic applications of NMDA (Bergeron et al., 
1997). Since the NMDA potentiation effects of JO-1784 and DTG are 
prevented by pre-treatment with pertussis toxin, but not the effects of (+)-
pentazocine, again, the two different patterns of data support the possibility 
of the co-existence of two different types of σ1 receptors, metabotropic and 
non-metabotropic (Monnet et al., 1994). 
How the NMDA receptor-mediated activity is modified by σ ligands is 
yet not known. While a σ binding site on the NMDA receptor/channel has 
been postulated, autoradiographic and radioligand binding studies suggest 
that a colocalization between NMDA and σ sites is likely to exclude 
(Largent et al., 1986, Monaghan et al., 1989). 
In the 90’s, several researchers believed that neurosteroids were the 
endogenous ligands of σ1 receptors; for this reason neurosteroid-induced 
potentiation of the NMDA-evoked responses has been extensively studied. 
In rat CA3 pyramidal neurons, low doses of DHEA potentiate the NMDA 
response selectively and in a dose-dependent manner. The effect of DHEA 
is reversed by the selective σ1 antagonist NE-100 and by haloperidol 
(Bergeron et al, 1996;. Debonnel et al., 1996). Progesterone have no effect 
by itself but, at low doses, it reverses the potentiation of NMDA response 
induced by DHEA as well as those induced by other nonsteroidal σ ligands: 
(+)-pentazocine, JO-1784 and DTG (Bergeron et al, 1996). The σ 
potentiation of NMDA response in the CA3 region of rat dorsal 
hippocampus is significantly greater in ovariectomized rats, a classical 
progesterone-lacking model, than in males and in non-ovariectomized 
females (Debonnel et al., 1996; Bergeron et al., 1996). In addition, in 
pregnant rats, where progesterone production is greater enhanced, the 
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potentiation of neuronal response to NMDA requires 10-fold higher doses of 
DTG, (+)-pentazocine and DHEA than in female control rats (Bergeron et 
al., 1999). These results indicate that endogenous progesterone, acting as a 
σ1 antagonist, might induce a tonic decrease in NMDA receptor function. 
More recent studies have shown that the neurosteroid DHEA also enhances 
glutamatergic neurotransmission in hippocampus via σ1 receptors. In fact, 
chronic administration of DHEAs facilitates the induction of long-term 
potentiation and this effect is reversed by σ1 antagonists NE-100 and 
haloperidol (Chen et al., 2006). 
The glutamate receptor-induced increase of [Ca2+]i is also modulated by 
σ1 ligands. In early studies, some σ ligands like JO-1784, (+)-pentazocine, 
(+)-SKF-10,047, carbetapentane, dextromethorphan, (+)-cyclazocine, DTG 
and haloperidol were reported to reduce NMDA-stimulated increase of the 
[Ca2+]i (Hayashi et al., 1995; Klette et al., 1997). On the contrary, more 
recent studies have documented that σ1 ligands are able to enhance NMDA-
evoked increase of [Ca2+]i. For example, the potentiation of glutamate 
response in pyramidal neurons is increased by σ1 agonists JO-1784, (+)-
pentazocine and (+)-SKF-10,047. This σ1 effect is reversed by both the σ1 
antagonist NE-100 and the PKC inhibitor Gö-6976, suggesting that the 
modulation of NMDA responses involves somehow the PLC-PKC 
signalling cascade (Monnet et al., 2003).  
σ ligands could also regulate the glutamate release. In fact, in rat 
cultured cortical neurons, not only the glutamate release evoked by BDNF 
stimulation of the PLCγ is enhanced in an agonist/antagonist fashion by the 
σ agonists imipramine and fluvoxamine, but the over-expression of σ1 
receptors itself is sufficient to enhance the induction of the PLCγ pathway 
by BDNF and, hence, the glutamate release (Yagasaki et al., 2006). 
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Up to now, it is commonly accepted that σ1 receptors enhance NMDA-
mediated effects. Since the glutamatergic pathways are widely distributed in 
the CNS, the interactions of σ ligands with the glutamate systems might be 
crucial in several mental pathologies, including depression and psychosis. 
 
1.9.6 Modulation of the dopaminergic neurotransmission 
 
DA neurotrasmission has been often shown to constitute an important 
target of σ receptors in different experimental models. Since the reported 
results are frequently contraditory, the exact role of σ1 receptor in 
dopaminergic neurotransmission remains unclear. 
Early electrophysiological studies have reported that intravenous (i.v.) 
administration of σ agonists (+)-3-PPP, (+)-pentazocine and DTG decreases 
the firing rate of rats DA neurons (Steinfels et al., 1989). Interestingly, the σ 
antagonist BMY-14802 alone increases the firing rate in the same brain 
areas (Steinfels et al., 1989). In a similar model, it has been shown that i.v. 
administration of (+)-pentazocine is more effective in increasing the 
mesolimbic DA cell firing rate than the nigrostriatal one (Zhang et al., 
1992); however, DTG and JO-1784 did not alter DA neuronal activity at 
nontoxic doses (Zhang et al., 1992). In this same study, the σ antagonist 
BMY-14802 was able to cause a dose-dependent increase of DA cell firing 
rate in both the brain regions (Zhang et al., 1992). (+)-3-PPP is able to 
inhibit both nigrostriatal and mesolimbic DA cell firing rates, but these 
effects are reversed by (-)-eticlopride and (+)-butaclamol, suggesting that 3-
PPP-induced inhibition could be ascribed at the DA agonist properties of the 
drug (Zhang et al., 1992). More recently, Minabe and co-workers (Minabe et 
al., 1999) reported that acute administration of the σ1 agonist SA-4503 
produces a significant decrease in the number of spontaneously active 
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neurons of the substantia nigra pars compacta (SNPC), whereas, in the 
ventral tegmental area (VTA), the same compound induces the opposite 
effect, enhancing the firing rate of the DA neurons. Further data have 
confirmed the involvement of σ1 receptors, since the σ1 selective antagonist 
NE-100 is able to reverse both these effects (Minabe et al., 1999). In 
contrast, other studies reported that one-hour pretreatment with the σ 
agonists (+)-pentazocine, DTG or JO 1784 (Zhang et al., 1993b) and with 
the σ1 antagonist E-5842 (Sánchez-Arroyos and Guitart, 1999) do not alter 
the number of spontaneously active DA neurons, both in SNPC and in VTA 
(Zhang et al., 1993b; Sánchez-Arroyos and Guitart, 1999). 
Interestingly, a model of chronic administration led to a different 
pattern of data. Repeated treatments with DTG and with σ1 agonists (+)-
pentazocine (Zhang et al., 1993b) and SA-4503 (Minabe et al., 1999) 
produces a significant increase in the number of spontaneously active VTA 
DA neurons (Zhang et al., 1993b; Minabe et al., 1999), whereas, in the same 
area, the σ1 antagonist E-5842 induces the opposite effect, reducing the 
firing rate of DA neurons (Sánchez-Arroyos and Guitart, 1999). In addition, 
in the SNPC, repeated administration of JO-1784 (Zhang et al., 1993b) and 
SA-4503 (Minabe et al., 1999) decrease the number of the spontaneously 
active DA neurons and the E-5842 is devoid of activity (Sánchez-Arroyos 
and Guitart, 1999).  
In summary, the in vivo electrophysiological studies have shown that 
DA neurones responses to σ ligands might be dissimilar among different 
brain areas and they can also be affected by the extent of the treatment. 
Since the observed fluctuations in the firing rate of the DA neurons 
should be mediated by the enhancement of extracellular [DA], several 
investigations have been carried out to determine if σ receptors could 
directly regulate the intersynaptic concentrations of the major dopaminergic 
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neurotransmitter. From these studies, it has been brought to the light that the 
σ ligands deeply modify the extracellular [DA]. 
First solid evidences were reported by Gudelsky in 1995 (Gudelsky, 
1995). In fact, he observed that, following systemic administration of (+)-
pentazocine and (+)-SKF-10,047 (but not its (–)-enantiomer), striatum and 
medial prefrontal cortex extracellular [DA] increase of about 50% of the 
basal values in the first sixty minutes, followed by a rapid decrease (Fig.1.5 
A) (Gudelsky, 1995).  
A B
 
Figure 1.5. Effect on the extracellular [DA]. A) (+)-pentazocine concentration 
dependent increase of the extracellular [DA] (Gudelsky, 1995) B) Different effects of 
other ligands: dopamine receptors antagonist (-)-butaclamol, σ1 antagonist Dup734, σ 
agonist DTG and σ1 agonist (+)-3-PPP (Gudelsky, 1995). 
 
These effects are shared also by the σ1 antagonist Dup734 and by the 
DA receptor antagonist (-)-butaclamol (Fig.1.5 B), but (-)-butaclamol 
pharmacological profile appears quite different from the one of the σ 
ligands, as the DA receptors antagonist produces a major extracellular [DA] 
increase, followed by a much slower decrease. This could indicate that the σ 
ligands and the (-)-butaclamol act at a different level in the extracellular 
[DA] regulation; in fact, since the (-)-butaclamol directly antagonizes the 
DA receptors, the observed increase in the DA release colud be 
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physiologically induced for counteracting the blockade of the dopaminergic 
transmission. However, in the same experiment, the extracellular [DA] was 
unaffected by the systemic administration of DTG and it was suppressed by 
the σ1 agonist (+)-3-PPP (Gudelsky, 1995; Kanzaki et al., 1992); the (+)-3-
PPP effect was reversed by the preadministration of the σ1 antagonist BMY-
14802, whereas this last ligand alone did not affect the extracellular levels of 
DA (Kanzaki et al., 1992). Further studies clarified that the extent of the 
administered dose could greatly affect the profile of action of the σ ligands. 
In fact, in rats, the intra-striatal administration of lower doses of (+)-
pentazocine, DTG and a σ selective ligand MR200 induce a decrease of the 
extracellular [DA] (Fig.1.6 A and B) (Gudelsky 1999; Moison et al., 2003), 
but, when administered at higher doses, these ligands induce a biphasic 
effect, deeper discussed in the next section (see section 1.9.7) and consisting 
of a rapid increase of the extracellular [DA], followed by a prolonged and 
marked decrease (Fig.1.6 A and B) (Gudelsky 1999; Moison et al., 2003). 
Because the excitatory responses among the pharmacological effects 
induced by σ ligands occur only when these drugs are administered at higher 
concentrations, it has been speculated that the observed biphasic effect is 
due to the aspecific involvement of other receptors that regulate the DA 
release (Gudelsky 1999; Moison et al., 2003). Thus, the negative regulation 
of extracellular [DA] appears to be a more specific effect of the σ ligands 
than the increase of the DA levels (Gudelsky 1999; Moison et al., 2003). 
Other studies have confirmed that the σ1 receptors are able to inhibit 
DA release. The σ1 agonists (+)-pentazocine and BD-737 inhibited the KCl-
stimulated [3H]DA release of about the 40% of the basal values both in 
slices of rat nucleus accumbens and in SH-SY5Y (Ault and Werling, 1999 
and 2000). The σ1 antagonists Dup734 and BIMU-8 were able to block these 
effects (Ault and Werling, 1999 and 2000).  
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In line with all the above described results indicating that σ1 receptors 
may have an inhibitory role in regulation of extracellular [DA], more recent 
studies also indicate that repeated administration of the σ1 selective agonist 
PRE-084 causes important adaptive changes in the striatal dopaminergic 
transmission (Peeters et al., 2004). In fact, the chronic administration of 
PRE084 results in an increase of DA-induced GTPγS binding and this effect 
is reversed where both the PRE-084 and the σ1 antagonist BD-1047 are 
chronically co-administrated (Peeters et al., 2004). Thus, probably, the 
observed increase of DA receptors could be a neuronal physiological 
adaptation induced by the lack of free DA in the synaptic cleft (Peeters et 
al., 2004). 
It is well documented that σ1 receptors are able to modulate NMDA 
receptor subtype responses (see section 1.9.5). Among the major NMDA-
mediated functions, σ1 receptors have been shown to be effective in 
regulating NMDA-stimulated DA release. 
Using in vivo microdialysis techniques, it has been shown that systemic 
administration of MS-377, a σ1 antagonist, has no effect alone, but it reduces 
the increase of extracellular [DA] induced by PCP (Takahashi et al., 2001). 
The effects of MS-377 on NMDA-induced current were also determined in 
acutely dissociated DA neurons of VTA area, using patch clamp whole cell 
recording (Yamazaki et al., 2002). In this model, the σ1 antagonists MS-377, 
haloperidol, NE-100 and BD-1063 were able to attenuate the NMDA-
evoked currents (Yamazaki et al., 2002). 
The NMDA-stimulated [3H]DA release has been also investigated. In 
experiments on rat striatum slices, the σ agonists (+)-pentazocine, (+)-SKF-
10,047, BD-737 and pregnenolone sulfate inhibited NMDA-stimulated 
[3H]DA release. Interestingly, in the same studies, the putative σ1 antagonist 
progesterone behaved like the agonists (Gonzalez-Alvear and Werling, 
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1994, 1997; Nuwayhid and Werling, 2003a and b). Moreover, in these 
studies the inhibition of NMDA-stimulated [3H]DA release, observed with 
the σ1 ligands, including the progesterone, was reversed by the σ1 
antagonists DuP 734 and BD-1008 (Gonzalez-Alvear and Werling, 1994, 
1995, 1997; Nuwayhid and Werling, 2003a and b). Experimental evidence 
indicate the PLC-PKC signalling system as preferring mechanism by wich 
the σ1 receptors mediate their modulating effects on the glutamatergic 
NMDA receptors; in fact, pre-treatments with the PKCβ selective inhibitor 
LY379196 and the PLC inhibitor U-73,122 (Nuwayhid and Werling, 2003a 
and b), completely abolish the inhibition of NMDA-evoked [3H]DA release 
induced by σ receptor ligands. 
The modulation of NMDA-stimulated [3H]DA release has been also 
studied in nucleus accumbens and in cortical slices. In both preparations, σ1 
agonists (+)-pentazocine and BD-737 inhibit [3H]DA release (Ault et al., 
1998; Ault and Werling 1998). The observed inhibitory effect of σ1 agonists 
was reversed by the non selective antagonist BD-1008, DTG and also by the 
σ1 antagonist DuP 734 (Ault et al., 1998; Ault and Werling 1998), but not by 
the σ2 antagonist BIMU-8 (Ault et al., 1998; Ault and Werling 1998), 
suggesting that, in these experiments, σ1 receptors may modulate NMDA 
receptors. 
As it concerns σ2 receptors, also this receptor subtype has been 
demonstrated to modulate the extracellular levels of DA in amphetamine-
stimulated [3H]DA release experiments. In fact, in this model, the 
enhancement of amphetamine-mediated responses was reversed by the non-
selective σ antagonist BD-1008 and by the selective σ2 antagonists BIMU-8 
and Lu28-179 (Izenwasser et al., 1998; Weatherspoon and Werling, 1999) 
but not by the selective σ1 antagonist DuP 734 (Izenwasser et al., 1998; 
Weatherspoon and Werling, 1999). 
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In summary, altough in the studied described above, contradictory 
results have been often reported, σ1 receptors seem to exert an inhbitory role 
in the regulation of extracellular [DA]. 
The effect of σ1 ligands on the levels of DA metabolites in the cortex 
and striatum have been also investigated.  
Studies with in vivo brain microdialysis techniques found that some σ1 
agonists, such as (±)-pentazocine and (+)-SKF-10,047, increase extracellular 
dihydroxy phenylacetic acid (DOPAC) levels in the striatum but not in the 
frontal cortex (Matsuno et al., 1995b) and panamesine, a putative σ1 
antagonist, increases extracellular DOPAC levels in the prefrontal cortex 
(Skuza et al., 1998); σ1 antagonists MR-200 and BMY-14802 do not modify 
extracellular DOPAC levels in the striatum (Moison et al., 2003; Kanzaki et 
al., 1992). Using the same experiment paradigm, also DTG was shown to 
increase extracellular DOPAC levels after intra-nigral administration 
(Bastianetto et al., 1995), however, in following researches, this result hasn’t 
been further confirmed (Moison et al., 2003).  
The σ1 ligands modulation of the levels of extracellular homovanillic 
acid (HVA), another DA metabolite, has also been evaluated. σ1 antagonist 
BMY-14802 doesn’t affect HVA levels in the striatum (Kanzaki et al., 
1992), but other σ ligands, such as DTG and panamesine, increased 
extracellular HVA levels in the striatum and medial prefrontal cortex, 
respectively (Skuza et al., 1998; Bastianetto et al., 1995). Thus, it appears 
that some σ1 ligands may modulate the DA metabolism.  
In post-mortem experiments, both the two σ1 agonist prototypes (+)-
pentazocine and (+)-SKF-10,047 definetly increased tissue levels of 
DOPAC and HVA in the striatum (Iyengar et al., 1990); however, in the 
same experimental conditions, the putative σ1 agonist SA-4503 increases 
DOPAC levels only in the frontal cortex, but not in the striatum (Kobayashi 
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et al., 1997) and the putative σ1 antagonist panamesine increased DOPAC 
and HVA levels in both the brain cortex and striatum (Skuza et al., 1998). 
These results show that σ1 ligands are able to increase the DOPAC and HVA 
levels in brain. However, both σ1 agonist and antagonists have been shown 
to produce this effect. 
 
1.9.7 Biphasic effects of of σ1 agonists in regulating of 
extracellular DA concentrations 
 
In several experimental paradigms, such as behavioural, biochemical 
and electrophysiological models, σ1 ligands induce a biphasic bell-shaped 
effect.  
As previously described, in rat, intrastriatal infusion of the σ1 selective 
agonists (+)-pentazocine (Fig.1.6 A) and MR-200 (Fig.1.6 B) by a 
microdialysis probe results in a biphasic effect on extracellular DA 
concentration, consisting in a rapid increase, during the first thirty minutes, 
followed by a more prolonged and marked decrease (Fig.1.6 A and B) 
(Gudelsky 1999; Moison et al., 2003). 
 
A B
 
Figure 1.6. Effect on the extracellular [DA]. A) The bell-shaped response is dependent 
from the administered (+)-pentazocine concentration (Gudelsky, 1995); in this case, also 
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the less effective isomer (-)-pentazocine induces the bell-shaped response and this is 
probably due to the very high concentration used in the experiment (Gudelsky, 1999). B) 
The bell-shaped response is dependent from the MR-200 concentrations (Moison et al., 
2003): the pharmacological effects begin at 10µM, but the biphasic trend only begins at 
100µM (Moison et al., 2003). 
 
The biphasic effect is evident only when high concentrations of σ1 
ligand are administered. As shown in figure 1.6, (+)-pentazocine induces the 
bell-shaped response only when administered at concentrations over 1mM 
(Fig.1.6 A) and MR-200 induces the same response only at concentrations 
over 100µM (Fig.1.6 B). At lower doses, both the σ1 agonists definitely 
appear to induce mainly extracellular [DA] decrease (Fig.1.6 A and B) 
(Gudelsky 1999; Moison et al., 2003). In addition, the infusion of the 
NMDA antagonist 3-(2-carboxypiperazine-4-yl)propyl-1-phosphonic acid 
(CPP) (100 µM) significantly attenuates the initial increase but not the 
subsequent decrease of DA release, produced by the intrastriatal infusion of 
(+)-pentazocine (Fig.1.7) (Gudelsky 1999). These findings indicate that the 
increasing effect of the extracellular [DA] could be mediated by the NMDA 
receptor itself, directly or following the activation by other systems. 
However, since the subsequent decrease of the extracellular [DA] isn’t 
affected by CPP, this latter effect should be ascribed only to σ1 receptors 
(Gudelsky 1999). 
 
Figure 1.7. The NMDA antagonist CPP alone 
doesn’t induce any physiological change and it 
prevents the rapid (+)-pentazocine-stimulated 
increase of the extracellular [DA]. However, 
the CPP isn’t able to reverse the following 
prolonged decrease of the extracellular [DA] 
(Gudelsky 1999). 
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In the NG-108 cell line transfected with σ1 mouse receptor, the σ1 
agonists (+)-pentazocine, PRE-084 and and pregnenolone sulfate, without 
effect by themselves, potentiate the bradykinin-induced increase of cytosolic 
free Ca2+ concentration in a bell-shaped manner. This effect of σ1 ligands is 
also blocked by an antisense oligodeoxynucleotide against the cloned σ1 
receptors (Hayashi et al., 2000). In isolated cardiac myocytes from adult 
rats, the exposure to 10 nM of haloperidol or (+)-pentazocine induces an 
increase in the amplitude of contraction, reaching 188% and 138% 
(respectively) of control level. A lower concentration of haloperidol or (+)-
pentazocine (1 nM) does not induce the same increase in contraction 
amplitude observed with higher concentration, but rather reduces the 
amplitude to 70-80% of control (Novakova et al., 1995). Another dual effect 
of σ ligands has been reported in vivo electrophysiological studies 
investigating the σ-selective modulation of NMDA-induced neuronal 
activation in rat CA3 dorsal hippocampus region. At lower doses, σ ligands 
DTG, JO-1784 and (+)-pentazocine dose-dependently enhance NMDA-
induced activation of CA3 pyramidal neurons (Monnet et al, 1992b). 
However, at higher doses, the effects of selective σ1 agonists, such as JO-
1784 and (+)-pentazocine, progressively decrease until vanishing and they 
are even able to act as antagonists, preventing the potentiation induced by 
low doses of other σ agonists (Bergeron et al., 1995; Bergeron and 
Debonnel, 1997). 
To explain the dual effect of the σ1 ligands, many hypotheses have been 
proposed, such as the existence of two σ1 receptors subtypes (Bergeron and 
Debonnel, 1997; Novakova et al., 1995; Bermack and Debonnel, 2005) or 
conformations (Novakova et al., 1995). In my opinion σ ligands simply lose 
their σ selectivity when administered at higher concentrations and they bind 
also other receptors classes, activating several disparate responses. 
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However, the biphasic trend of σ1 ligands effects is an important factor to 
take into account while attemping to explain the controversial data about the 
σ1 receptors (Bermack and Debonnel, 2005). 
 
 
1.10 Therapeutical potential of σ1 receptors 
 
Given the widespread distribution of σ1 receptors in the CNS and their 
different modulatory roles at cellular, biochemical and neurotransmission 
levels, the σ1 ligands appear to be useful tools in different therapeutic fields, 
wich are briefly described in this chapter. 
 
1.10.1 Role of σ1 receptors in learning and memory 
 
Based on studies demonstrating that σ1 receptor agonists potentiate 
NMDA-induced neuronal firing in the CA3 region of the hippocampus 
(Monnet et al., 1990) and that σ1 agonists increase extracellular 
acetylcholine levels in the rat hippocampus and cortex, measured in vivo by 
intracerebral microdialysis (Matsuno et al., 1993b), σ1 receptors have been 
extensively studied within the context of learning and memory.  
It is known that deficits in cortical cholinergic activity have been 
observed in some cognitive diseases, such as Alzheimer’s desease and 
pathological ageing. The learning impairment induced by the muscarinic 
antagonist scopolamine is reversed by several σ1 agonists, suc as (+)-
pentazocine, JO-1874, SA-4503 and two neurosteroids, pregnenolone sulfate 
and DHEA (Maurice et al., 1997a; Maurice et al., 2001a; Monnet and 
Maurice, 2006) In addition, attenuation of the scopolamine-induced 
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amnesia, observed with σ1 agonists, is selectively reversed by known σ1 
antagonists, including haloperidol, NE-100, the neurosteroid progesterone 
and also by the downregulation of σ1 receptor expression by specific 
antisense oligodeoxynucleotides (Maurice et al., 1997; Maurice et al., 
2001c; Monnet and Maurice, 2006). The cholinesterase inhibitor donepezil, 
that is used in treating Alzheimer's disease, is also a potent σ1 receptor 
ligand with an affinity of 14.6 nM (Kato et al.,1999). Precise 
pharmacological examinations of the interaction of donepezil with σ1 
receptors indicate not only that, on these receptors, donepezil could act as 
agonist, but also that the activation of the σ1 receptors themselves could be 
involved in the donepezil anti-amnesic therapeutic properties (Maurice et 
al., 2006a; Meunier et al., 2006a and b). In fact, in rats, donepezil is able to 
protect against dizocilpine-, amyloid β25–35 related peptide-, or carbon 
monoxide-induced mnemonic impairment, but these effects are abolished by 
pretreatment with the σ1 selective antagonist BD-1047 or antisense 
oligodeoxynucleotides (Maurice et al., 2006a). Others cholinesterase 
inhibitors, such as rivastigmine and tacrine, also attenuate dizocilpine-
induced learning impairments (Maurice et al., 2006a); however 
pharmacological effects of these latter compounds aren’t antagonized by 
BD-1047 (Maurice et al., 2006a). 
Dizocilpine is a non-competitive NMDA receptor antagonist. Since 
activation of NMDA receptors is a crucial step in the estabilshment of long-
term potentiation, chronic administration of dizocilpine represent a useful 
tool to study the memory and learning impairments both in rats and in mice 
(Murray et al., 1995). In this model, learning deficits are attenuated by the σ 
ligands (+)-SKF-10,047, (+)-pentazocine, JO-1784, DTG, PRE 084 and 
SA4503 and also the putative endogenous σ1 agonists DHEAs and 
pregnenolone sulfate (Maurice et al., 1999, 2001a, 2001b, 2006a, 2006b; 
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Monnet and Maurice, 2006). The anti-amnesic properties of these σ ligands 
are reverted by the known σ1 antagonists haloperidol, BMY-14802, NE-100 
and BD-1047, by the putative endogenous σ1 antagonists progesterone and 
by the administration of antisense oligodeoxynucleotides against σ1 receptor 
(Maurice et al., 1999b, 2001a, 2001b, 2006a, 2006b; Monnet and Maurice, 
2006). The ANAVEX-41, a new potent σ1-muscarinic mixed agonist, has 
been shown to be an effective anti-amnesic agent against dizocilpine-
induced learning impairments with its effect being blocked by the σ1 
receptor antagonist BD-1047 (Espallergues et al., 2007). 
σ1 agonists were also reported to soften the learning impairment 
induced by the nicotinic antagonist mecamylamine, or by cortical 
cholinergic dysfunction caused by ibotenic acid injection in the basal 
forebrain (Maurice et al., 1997a, 2001a; Monnet and Maurice, 2006).  
Repeated exposures to carbon monoxide (CO) gas induce a long-lasting 
but delayed amnesia which is measurable about one week after exposure. In 
this model, the hippocampal cholinergic system appears markedly affected 
by the hypoxic toxicity caused by CO (Maurice et al., 1997a). σ1 ligands 
have neuroprotective properties also in the CO-induced amnesia models, 
since, the σ ligands (+)-SKF-10,047, PRE-084, JO-1784 and DTG reversed 
CO-induced amnesia, and their effects were prevented by the σ1 antagonists 
NE-100 and BD-1047 (Maurice et al., 1999; Meunier et al., 2006a). 
Therefore, in conclusion, while selective σ1 agonists failed to improve 
the mnemonic processes in healthy control animals, they seem to markedly 
improve the learning and memory impairments in animal models of amnesia 
and significantly attenuata the mnemonic deficits. 
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1.10.2 Alzheimer’s desease and σ1 receptors 
 
Among the memory and learning disorders, Alzheimer’s disease (AD) 
is the most common form of late-life dementia. Also in AD models of 
amnesia, σ1 activation seems to ameliorate the mnemonic deficit symptoms. 
Nontransgenic models of AD have been characterized in rats infused with 
the amyloid β1–40 protein or in mice injected centrally with amyloid β25–35 
peptide (Yamada and Nabeshima, 2000). In experiments performed using 
the amyloid β25-35-induced AD model, the σ1 receptor agonists (+)-
pentazocine, PRE 084, SA4503, (+)-SKF-10,047, the antitussive drug 
dextromethorphan and the putative σ1 agonists DHEAs and pregnenolone 
sulfate attenuated, in a dose-dependent and bell-shaped manner, the memory 
deficits observed in mice seven days after β25–35 peptide injection. These 
effects of σ1 agonists were reverted by haloperidol, BD 1047 and the 
putative σ1 antagonist progesterone (Maurice et al., 1998, Meunier et al., 
2006c; Wang et al., 2003). In the same experimental model, the 
cholinesterase inhibitor donepezil (Meunier et al., 2006c) and the σ1-
muscarinic mixed ligand ANAVEX-41 (Villard et al., 2009) were shown to 
be able to attenuate learning and memory deficits and hippocampal neuronal 
death caused by β25–35 peptide administrations. These findings are consistent 
with recent results indicating that, in cultured rat cortical neurons, the 
amyloid β25–35-induced neuronal death is blocked by PRE-084 and the 
neuroprotective effects of this compound is, in turn, blocked by the σ1 
receptor antagonist, NE-100 (Marrazzo et al., 2005). 
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1.10.3 Schizophrenia and σ1 receptors 
 
Schizophrenia is a psychiatric pathology that describes a 
neuropsychiatric and mental disorder characterized by abnormalities in the 
perception or expression of reality. 
The DA hypothesis of schizophrenia was first proposed in 1960s and it 
implicates the enhancing of mesolimbic DA functions. In particular it 
proposes that an excessive activation of D2 receptors could be the cause of 
the positive symptoms of schizophrenia (Depatie and Lal, 2001). This 
hypothesi, largely resulted from the finding drugs which blocks DA 
function, like the phenothiazines, could reduce psychotic symptoms 
(Depatie and Lal, 2001). It is also supported by the observation that 
amphetamine, cocaine, methylphenidate and related psychostimulants, all of 
which enhance DA neurotransmission by presynaptic mechanisms, and 
other dopaminergic agonists, including apomorphine, can mimic acute 
positive symptoms of schizophrenia in normal subjects (Depatie and Lal, 
2001). 
This explanation is now believed to be overly simplicistic, even 
because newer antipsychotic medications (called atypical antipsychotic) can 
be equally effective as older medications (called typical antipsychotic), but 
they also affect serotonin functions and may have slightly less of a DA 
blocking effect (Jones et al., 2002). In addition, lower levels of glutamate 
receptors found in postmortem brains of people previously diagnosed with 
schizophrenia suggest that the neurotransmitter glutamate and the reduced 
function of the NMDA receptor could be involved in schizophrenia 
pathogenesis (Konradi and Heckers, 2003) The glutamatergic hypothesis is 
further supported by the finding that PCP not only emulates positive 
symptoms but also mimics the long-lasting psychological and social 
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dysfunctions similarly to the negative symptoms of the disease, and can also 
induce schizophrenia-like psychosis in humans. 
Since σ, DA and glutamate receptors share intricate relationships (see 
section 1.9), σ receptors are thought to be involved in the schizophrenia 
pathophysiolgy; consistent evidences arose from the finding that several σ 
agonists, such as (+)-SKF-10,047 and (+)-pentazocine exhibit 
psychotomimetic effects (Tam and Cook, 1984; Walker et al., 1990; 
Matsumoto and Pouw, 2000) and that many antipsychotic drugs, such as 
chlorpromazine, haloperidol and nemonapride and the psychotomimetics 
drugs used in schizophrenia models, such as amphetamine, 
methamphetamine, PCP and cocaine bind also to the σ receptors (reviewed 
in Hayashi and Su, 2004) 
In behavioral models of schizophrenia in which the dopaminergic 
function is affected, σ1 antagonists have been shown to ameliorate some 
symptoms. In the behavioral sensitization induced by repeated 
administrations of psychostimulants, a broad spectra of σ1 antagonists 
inhibit the sensitization to methamphetamine (Akiyama et al., 1994; 
Takahashi et al., 2000, Ujike et al., 1992a) and cocaine (Ujike et al., 1996; 
witkin et al., 1993). Nonselective σ1 antagonists, such as rimcazole, E-5842 
and panamesine inhibit the amphetamine-induced locomotor activity 
(Guitart et al., 1998; Poncelet et al., 1993; Rückert and Schmidt., 1993; 
Skuza and Rogoz, 2006), but the symptoms of apomorphine-induced 
climbing are antagonized only by E-5842 and panamesine, but not by 
rimcazole (Guitart et al., 1998; Skuza and Rogoz, 2006; Takahashi et al., 
1999; Taylor et al., 1993). Moreover, the σ1 antagonist BD-1047 failed to 
antagonize the acute symptoms in the two mentioned models (Skuza et al., 
2006). Again, the reported pharmacological actions of σ ligands show 
several contradictions and these results are also in contrast with the studies 
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showing that the σ agonists, nor the antagonists, depress the dopaminergic 
neurotransmission (see section 1.9.6). Since many other targets are known to 
be involved in schizophrenia physiopathology, the reported differences in 
the effects elicited by σ ligands might be ascribed to the involvement of 
other neurotransmitter systems. 
In addition to dopaminergic dysfunctions, alterations of glutamatergic 
neurotransmission are also involved in schizophrenia. In vivo model in wich 
the glutamatergic system is affected, σ1 ligands modify some animal 
behaviors. PCP-induced head weaving is insensitive to selective D2 
antagonists but it’s attenuated by the antagonists NE-100, haloperidol, BMY 
14802, Dup 734 and MS-377 (Hayashi and Su 2005; Takahashi et al., 1999). 
The BD 1047, rimcazole and panamesine also attenuate PCP-induced head 
twitching (Skuza et al., 2006). In monoamine-depleted mice, σ1 receptor 
agonists such as (+)-pentazocine, (+)-SKF-10,047 and 3-(+)-PPP enhance 
the dizocilpine-induced psychotomimetic effects and this enhancement is 
blocked by σ1 antagonist NE-100 (Okuyama et al., 1996). For these reasons, 
σ1 blockade has been proposed for treating the negative symptoms of 
schizophrenia. However, among negative symptoms of schizophrenia, 
cognitive deficits are considered the most severe features of the illness and it 
has been extensively reported that σ1 agonists are able to improve PCP-
induced cognitive deficits, with this effect being reversed by σ antagonists 
(reviewed in Hayashi and Su, 2004, 2005). In summary, these results 
suggest that σ1 agonists could be useful for treating cognitive deficits of 
schizophrenia but, at the same time, σ1 antagonists would counteract 
negative symptoms. Therefore, a purported schizophrenia therapy based 
exclusively on σ1 appears to be not useful. 
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1.10.4 Role of σ1 receptors in depression 
 
Depression, also known as major depressive disorder is a mental 
disorder characterized by low mood accompanied by low self-esteem, and 
loss of interest or pleasure in normally enjoyable activities. The major 
depressive disorder is characterized by disfunctions in brain areas where the 
monoaminergic neurotransmitters are widely released, especially in the 
frontal cortex and the hippocampus (Delgado and Moreno, 2000). 
Preclinical studies have shown that targeting the σ1 receptors alone is 
sufficient (but it is not requisite) to produce antidepressant-like effects. The 
antidepressant effects of σ ligands have been tested in behavioral models. In 
the tail suspension test, the selective σ1 agonists SA-4503 and (+)-
pentazocine decrease the immobility time and this effect is antagonized by 
NE-100 (Ukai et al., 1998). Several σ1 agonists, such as SA-4503, (+)-
pentazocine, JO-1784, UMB23 and donepezil have been shown to decrease 
immobility in the forced swimming test and this effect is blocked by known 
σ1 antagonists (Maurice et al., 1999, and 2006a; Skuza et al., 2002a; Urani et 
al., 2001 and 2002; Wang et al., 2007). Recently, also the selective σ1 
receptor agonist PRE-084 has been reported to exhibit an antidepressant-like 
effect in the forced swim test (Skuza and Rogoz, 2009). This effect is 
counteracted by BD 1047 but not by SM-21, σ1 and σ2 receptor antagonists, 
respectively (Skuza and Rogoz, 2009). Furthermore, the σ1-stimulated 
decrease of immobility is more pronounced in C57BL/6J mice than in 
Albino Swiss mice and this result is consistent with the finding that the brain 
level of the endogenous σ1 antagonist progesterone in C57BL/6J mice is 
two-fold lower than that of Albino Swiss mice (Phan et al., 2002). 
According to this latter finding, it has been also shown that in the forced 
swim test the antidepressant-like effects of σ1 agonists JO-1784 and PRE-
084, in adrenalectomized mice (a model of progesterone-lacking mice) are 
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enhanced compared to the non-adrenalectomized control mice and these 
effects are blocked by BD-1047 (Urani et al., 2001). Moreover, the 
neurosteroids that are known to act as σ1 receptors agonists, such as DHEAS 
and pregnenolone sulfate, are able decrease immobility in the forced 
swimming test (Maurice et al., 2001a and 2006a; Skuza and Rogoz, 2002; 
Urani et al., 2001 and 2002; Wang et al., 2007). Thus, again, neurosteroids 
are shown to be related to σ1 functions.  
Interesting is the finding that an extract of Hypericum Perforatum, wich 
is used as antidepressant, seems to exert its pharmacological actions also 
through σ1 receptors (Mennini and Gobbi, 2004). 
σ1 agonists are also able to potentiate the firing of serotonergic neurons 
of dorsal raphe nucleus after just two days of treatment, whereas the effects 
of serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors 
take several weeks to emerge. Thus, it seems that the antidepressant activity 
promoted by σ1 agonists could emerge faster compared to the existing 
medications (Bermack and Debonnel, 2001). The OPC-14523 is a 
compound that shows a mixed pharmacological profile, since it has been 
reported to act as a SSRI and σ1 agonist at the same time (Tottori et al., 
2001; Hayashi and Su, 2004a). In the forced swimming test, this compound 
produces a marked antidepressant-like activity after a single oral 
administration and this effect is blocked by both the σ1 and 5-HT1A 
antagonists (Tottori et al., 2001; Hayashi and Su, 2004a). In line with this 
finding, coadministration of the σ1 agonist (+)-pentazocine and the SSRI 
venlafaxine results in a synergistic antidepressant-like effect, also when 
administered at subeffective doses (Dhir and Kulkarni, 2007). Interestingly, 
this activity is suppressed by several σ1 antagonists, including progesterone 
(Dhir and Kulkarni, 2007). Thus triggering both σ1 and the serotonin 
Introduction - Chapter 1 
 - 66 - 
transporter (SERT) at the same time may represent a valid strategy to treat 
the major depressive disorders.  
Several evidences suggest that σ1 receptors play a role in the active 
mechanisms of selective SSRIs. In addition, it has been reported that some 
SSRIs possess moderate to high affinities for σ1 receptors in mice brain 
(Hashimoto, 2009). Among them, the order of affinity for σ1 receptors is as 
follows: fluvoxamine ~ imipramine > sertraline > fluoxetine > paroxetine 
(Takebayashi et al., 2002; Hashimoto, 2009). In a cell culture system, it has 
been demonstrated that the σ1 agonist (+)-pentazocine and the 
antidepressants fluvoxamine and imipramine, but not sertraline or 
paroxetine, significantly potentiate nerve-growth factor (NGF)-induced 
neurite outgrowth in PC12 cells and that the effect of fluvoxamine on NGF-
induced neurite outgrowth is significantly antagonized by pretreatment with 
the selective σ1 antagonist NE-100 (Takebayashi et al., 2002; Hashimoto, 
2009). Much interestingly, the enhancement of NGF neurite sprouting by 
these drugs is induced also by the overexpression of σ1 receptors 
(Takebayashi et al., 2004a).  
In humans, fluvoxamine binds to the σ1 receptors at therapeutic 
concentrations (Ishikawa et al., 2007) and the σ1 agonist JO-1784 exhibits a 
stronger antidepressant activity than the known fluoxetine, when 
administered at the dose of 20 mg/day (Bermack and Debonel, 2005). 
However, when used at 100 mg/day, the antidepressant effect of JO-1784 is 
the same of the placebo (Bermack and Debonel, 2005) and this data is in 
line with the bell-shaped dose-response curve observed following the σ1 
receptors activation in several behavioral, electrophysiological and 
biochemical models (see section 1.9.7). 
In conclusion, σ1 agonists exhibit a good antidepressant activity in 
several behavioral models. The contemporary blockade of SERT and 
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activation of σ1 receptor is a promising strategy and, for this reason, the 
design of the mixed affinity ligands represent a good prospect in terms of 
efficacy. 
 
1.10.5 Role of σ1 receptors in anxiety 
 
Anxiety is a psychological and physiological state characterized by 
cognitive, somatic, emotional, and behavioral components. This disorder is 
characterized by excessive anxiety and worry about everyday life events 
with no obvious reasons for worry. People with symptoms of generalized 
anxiety disorder tend to expect disaster and can't stop worrying about health, 
money, family, work, or school. 
Recently, the role of σ receptors, particularly the σ1 receptor subtype 
has been identified as a target for the pathophysiology of anxiety. The 
effects of σ1 ligands have been assayed in several behavioral tests, such as in 
the conditioned fear stress model, in the sexual dysfunction induced by 
stress, in the marble-burying behavior and in the colonic motor disturbances 
induced by fear. 
In the conditioned fear stress model, mice exhibit a marked suppression 
of motility when placed in an environment in which they had previously 
received an electric footshock. In this model, (+)-SKF-10,047, JO-1784, the 
neurosteroids pregnenolone sulfate and DHEAS and also the antitussive 
dextromethorphan attenuate, in a bell-shaped dose-response manner, the 
motor suppression induced by electric footshock (Kamei et al., 1996 and 
1997; Noda et al., 2000; Urani et al., 2004). The involvement of σ1 receptors 
has been confirmed by the known σ1 antagonist NE-100 and progesterone 
wich block the effects elicited by the agonists (Noda et al., 2000; Urani et 
al., 2004). Interestingly, in this same model, (+)-pentazocine is devoid of 
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any effect (Kamei et al., 1996 and 1997). It has been shown that in plasma 
and brain of stressed mice the concentration of endogenous σ1 active 
steroids is altered (Noda et al., 2000; Urani et al., 2004). For this reason, 
neurosteroids are believed to modulate the fear stress responses via σ1 
receptors (Noda et al., 2000; Urani et al., 2004). Supporting this hypothesis 
is the finding that the attenuation of the motor suppression induced by σ1 
agonists JO-1784, (+)-SKF-10,047 and DHEAS is higher in a model of 
progesterone-lacking mice, such are rats after chronic 
intracerebroventricular infusion of amyloid β1–40 peptide (Urani et al., 2004). 
In the model of sexual dysfunction induced by stress, the DHEA is able 
to attenuate the stress-induced effect and this activity is counteracted by NE-
100 (Mizuno et al., 2006). 
In mice the marble burying behavior, that is used as a model for both 
anxiety and obsessive compulsive disorder, is reduced by fluvoxamine. The 
effect of this antidepressant is prevented by the σ1 selective antagonists BD-
1063 and BD-1047, but not by the σ2 antagonist SM-21, suggesting the 
involvement of the subtype 1 alone in the effect elicited by this 
antidepressant (Egashira et al., 2007). 
The σ1 agonist JO-1784 is able to reduce the colonic motor disturbances 
induced by fear stress in rats, a model that mimicks the gastrointestinal tract 
disorders frequently present in anxiety. This effect is reversed by the σ1 
antagonist BMY-14802 (Gue et al., 1992). 
Although σ1 receptor modulators appear as suitable therapeutic options 
for treating anxiety, this topic still needs further preclinical and clinical 
exploration (Kulkarni and Dhir, 2009). 
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1.10.6 σ1 receptors and analgesia 
 
In the CNS, the σ1 receptors are widely distributed in the areas known 
to be involved in pain control, such as the superficial layers of the spinal 
cord dorsal horn, the periaqueductal gray matter, the locus ceruleus and 
rostroventral medulla (Alonso et al., 2000; Kitaichi et al., 2000). Modulation 
of analgesia by σ1 receptors has been studied both in opioids-induced 
models and in absence of opioid agonists. 
 
1.10.6.1 Modulation of opioid analgesia 
 
The involvement of σ1 receptors in the opioid-induced analgesia has 
been first reported on rat tail-flick experiments (Chien and Pasternak, 1993). 
In this model, the systemic administration of σ1 ligands such as (+)-
pentazocine and DTG results in a considerable inhibition of the 
antinoception induced by morphine (Chien and Pasternak, 1993, 1994 and 
1995a; Mei and Pasternak, 2002). In line with this finding, the σ1 
antagonists, such as haloperidol and (+)-MR-200, not only reversed the 
effect of the agonists, but also increase opioid-induced analgesia; this may 
indicate that σ1 receptors could also work as a tonically active anti-opioid 
system (Chien and Pasternak, 1993, 1994 and 1995a; Marrazzo et al., 2006; 
Ronsisvalle et al., 2001a). However, the σ1 ligands (+)-SKF-10,047 and NE-
100 and specific σ1 antisense oligodeoxynucleotides weren’t able to 
modulate the κ1 stimulated analgesia in the acetic acid-induced writhing test 
(Hiramatsu et al., 2002 and 2004), suggesting that modulation of analgesia 
by σ1 receptors does not affect the κ opioid receptors antinoception activity. 
The activity of σ1 receptors was found to differ, depending on the 
considered nervous system area. In the tail-flick model, intrathecal 
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administrations of the σ1 receptor agonist (+)-pentazocine doesn’t attenuate 
the intrathecal analgesic effect of morphine, indicating that the modulation 
of opioid analgesia by σ1 receptors should not occur at spinal level (Mei and 
Pasternak, 2002). On the other hand, when given supraspinally 
(intracerebroventricular administration), (+)-pentazocine diminishes the 
analgesic effect of of κ and µ opioid receptors agonists nalorphine and 
nalbuphine (Mei and Pasternak, 2002). Moreover, the finding that the 
intracerebroventricular administration of σ1 specific antisense 
oligodeoxynucleotides enhances the opioids-induced anti-noception, further 
confirms the supraspinal location of the σ1 receptor-mediated modulation of 
analgesia (King et al., 1997; Mei and Pasternak, 2002; Pan et al., 1998). 
More detailed results have been reported after microinjecting morphine, in 
conjunction with (+)-pentazocine, haloperidol, or both, in three different 
brainstem nuclei, the periaqueductal gray, the rostroventral medulla and the 
locus coeruleus (Mei and Pasternak, 2007). In these experiments, both the 
locus coeruleus and rostroventral medulla were sensitive to (+)-pentazocine, 
but not the periaqueductal gray. The involvment of the rostroventral medulla 
is particularly interesting as, in this study, it was the only region showing a 
tonic σ1 activity and it could also modulate the morphine analgesia 
administrated in periaqueductal gray (Mei and Pasternak, 2007). 
 
1.10.6.2 Analgesic effect of the σ1 ligands 
 
The modulation of analgesia by σ1 receptors has been also investigated 
in absence of opioids. 
Even if, in both the tail-flick model and the acetic acid-induced 
writhing test, several σ1 ligands and antisense treatments were shown to be 
ineffective in producing any analgesic response when administered alone 
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(Cendan et al., 2005a; Chien et al., 1993, 1994, 1995a; Marrazzo et al., 
2006; Mei and Pasternak, 2002; Pan et al., 1998; Hiramatsu et al., 2002 and 
2004), other investigations have reported that σ1 receptors are able to 
modulate nociception in different behavioral tests, in the absence of opioids. 
In the nociceptive flexor response test, the σ1 agonists (+)pentazocine, SA-
4503, DHEAs and pregnolone sulfate were able to elicite dose-dependent 
flexor responses, blocked by σ1 receptor antagonists NE-100, BD1063 and 
progesterone. In the formalin test, the formalin-induced nociception is 
attenuated not only by systemic administration of the σ antagonist 
haloperidol, with an order of potency which is correlated with affinity for σ1 
receptors (Cendan et al., 2005a), but the same result was observed also in σ1 
receptor knockout mice (Cendan et al., 2005b). In line with these latter 
findings, recent studies showed that intrathecal treatment with the σ1 
receptor antagonist, BD-1047, in mice reduces formalin-induced pain and 
concomitantly attenuates the phosphorylation of N-methyl-D-aspartate 
(NMDA) receptor subunit 1 induced by formalin (Kim et al., 2006). In 
addition, intrathecal injections of the σ1 receptor agonists, PRE-084 and 
carbetapentane, increase in mice the PKC- and PKA-dependent 
phosphorylation of the NR1 subunit of the NMDA receptor. This increase is 
blocked by the σ1 receptor antagonist BD-1047 (Kim et al.,2008; Roh et al., 
2008). In sciatic-neuropathic rats, a model of neuropathic pain, the σ1 
agonist DHEA induces a rapid pronociceptive action and the σ1 antagonist 
BD-1047 is able to block the transient pronociceptive effect provoked by 
DHEA (Kibaly et al., 2008). In addition, it has been shown that the σ1 
antagonist BD-1047 also possesses an antinociceptive activity in the 
capsaicin-induced headache model (Kwon et al., 2009). 
In summary, it appears that σ1 receptors antagonists alone might induce 
analgesia and could be suitable for treating the acute and the neuropathic 
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pain. In addition, while counteracting the σ1 tonic inhibition of the opioid 
system, σ1 receptor antagonists may potentiate the opioid response allowing 
to reduce the pharmacological active dose of opioid drugs. However, the 
exact molecular mechanisms of the action of σ1 receptors in the modulation 
of pain still have to be established and needs further investigations. 
 
 
1.11 σ1 receptors and drug abuse 
 
Since σ1 receptors are able to bind several drug of abuse, it has been 
proposed that they may directly modulate the effects of these drug. 
Moreover, since it has been demonstrated that the σ1 receptors are directly 
involved neuronal plasticity, it is likely that these receptors are somehow 
involved in drug dependence (Maurice et al., 2002; Matsumoto et al., 2003; 
Guitart et al., 2004; Maurice & Romieu, 2004). The role of σ1 receptors in 
the action of cocaine has been extensively investigated. In addition, σ1 
receptors appear to be involved also in the methamphetamine, 3,4-
methylenedioxymethamphetamine, (MDMA) and ethanol effects. 
 
1.11.1 Cocaine and σ1 receptors 
 
As described in 2.6.2, cocaine acts mainly as DA uptake inhibitor; 
however, in order to produce its psychostimulant effects, other mechanisms 
may also be involved (Mateo et al., 2004).  
Cocaine binds to both its main target, the dopamine transporter (DAT), 
and the σ1 receptors with Ki which falls in the µM range (Rothman et al., 
2003). It binds, preferentially, to the σ1 subtype rather than to the σ2 
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(Matsumoto et al., 2002). Thus, following the administration of a 
pharmacological active dose of cocaine, the physiological concentrations 
reached by this compound are higher enough to bind both DAT and σ1 
receptors. For this reason, the role of σ1 receptors and ligands in the 
modulation of the effect of cocaine has been extensively studied both in 
acute and chronic models. 
 
1.11.1.1 σ1 receptors modulation of the acute effects of cocaine 
 
Among the acute side effects elicited by cocaine, hyperlocomotion 
represents one of the earliest and most evident symptoms. For this reason, 
locomotor effects of cocaine are often used as tool for studying the 
antipsychostimulant properties of novel compounds. Several σ1 antagonist, 
such as haloperidol, BD-1008, BD-1047, BD-1063, BMY-14802, 
panamesine and rimcazole as the administration of σ1 receptor antisense 
oligodeoxynucleotides have been reported to attenuate the acute 
hyperlocomotion activity induced by cocaine in rodents (Matsumoto et al., 
2001a and 2003). 
Convulsions and lethality are the typical side effects of cocaine 
overdose. The cocaine-induced convulsions, resulting from exposure to 
higher doses of cocaine, represent a good model to measure the cocaine-
induced toxicity and the protective effects of the antipsychostimulants. The 
σ1 antagonists BMY-14802, BD-1008, BD-1063, BD-1047 and rimcazole, 
as well as antisense oligodeoxynucleotides silencing σ1 receptors 
significantly prevent cocaine-induced convulsions (Ushijima et al., 1998; 
Matsumoto et al., 2001a, 2001b, 2001c, 2002, 2003 and 2004; Maurice et 
al., 2002; Katz et al., 2003; Daniels et al., 2006). Interistingly, the ability of 
these compounds to prevent cocaine-induced convulsions is more related 
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with their affinities for σ receptors rather than for affinity towards DAT 
(Matsumoto et al., 2001c). In addition, it has been shown that some σ2 
receptors preferential ligands are able to prevent the cocaine-induced 
convulsions; this finding suggests that both the σ receptors subtypes may be 
able to modulate the acute effects of the cocaine (reviewed in Matsumoto et 
al., 2003). As it concerns the role of σ1 receptors on lethality induced by 
cocaine, σ1 receptors antagonists revealed a protective activity, preventing 
death in animals not only when they are administered before cocaine, but 
also after (Matsumoto et al., 2001a, 2001b, 2002 and 2004; McCracken et 
al., 1999a; Daniels et al., 2006). These findings indicate that the σ1 
antagonists could have important clinical applications since they may even 
used as lifesaving drugs. 
Further data confirming the involvement of σ receptors in the action of 
cocaine are related to the administration of DTG and of selective σ1 agonists 
BD-1031, BD-1052 and SA-4503 which aggravate, in mice, the locomotor 
stimulatory actions and the toxic effects (measured as convulsions and 
lethality rate) of cocaine (Matsumoto et al., 2001a and b, 2002; McCracken 
et al.,1999a; Skuza, 1999). 
 
1.11.1.2 σ1 receptors modulate the chronic effects of cocaine 
 
Repeated administration of cocaine to laboratory animals results in 
behavioural sensitization as the animals develop an enhanced response to a 
given dose of cocaine. The estabilishment of the cocaine-induced locomotor 
sensitization, wich is considered a measurable index of nervous system 
plasticity resulting from repeated exposure to cocaine (Matsumoto et al., 
2003) is attenuated by the coadministration of several σ1 antagonists, such as 
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BMY-14802, NPC-16377, rimcazole and SR-31742 (Ujike et al., 1996; 
Witkin et al., 1993).  
The conditioned place preference (CPP) is a useful paradigm employed 
to evaluate the rewarding properties of drugs of abuse after their repeated 
administration. σ1 receptors seem to play a role in establishment and the 
expression of the CPP induced by subchronic administration of cocaine. In 
fact, the cocaine-induced CPP acquisition is potentiated by the σ1 receptor 
agonists DHEAs, pregnenolone sulfate JO-1784 or PRE-084 (Romieu et al., 
2002, Romieu et al., 2004) and the effects of the agonists are blocked by the 
σ1 antagonists progesterone and BD-1047 (Romieu et al., 2002; Romieu et 
al., 2004). In addition, repeated administrations of selective σ1 receptor 
antagonists BD 1047 and NE-100 as well as the treatment of animals with a 
specific σ1 antisense oligodeoxynucleotide are effective in reducing not only 
the estabilishment, but also the expression of cocaine-induced CPP (Romieu 
et al., 2000).  
The self-administration paradigm, as well as the CPP represent useful 
tools to evaluate craving and relapse related to cocaine addiction. In fact, an 
extinct cocaine addictive behavior can be reactivated by a discriminative 
stimulus associated with cocaine administration or by a priming injection of 
cocaine. The σ1 antagonist BD-1047 and a σ1 antisense 
oligodeoxynucleotide are able to attenuate the relapse behavior in both the 
described models (Martin-Fardon et al., 2007, Romieu et al., 2004). 
Moreover, the σ1 agonists DHEA (Romieu et al., 2004), PRE 084, JO-1784 
(Romieu et al., 2002) are capable to reactivate the CPP after extinction in 
rats previously conditioned to cocaine, in a BD-1047 sensitive manner 
(Romieu et al., 2004). These results suggest that σ1 antagonists could be 
employed as terapy to prevent craving and relapse of cocaine addiction. 
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In summary, these studies show that cocaine might produce its 
behavioral and biochemical effects, at least in part, through its interaction 
with σ1 receptors. Thus, σ1 antagonists should be considered for developing 
potential therapies to treat different aspects of cocaine abuse, such as acute 
effects, long term effects and relapses. 
 
1.11.2 Methamphetamine, MDMA and σ1 receptors 
 
Methamphetamine, like cocaine, binds the σ1 receptors in the 
micromolar range; it binds also the σ2 receptors with a 20-fold lower affinity 
than the σ1 subtype (Nguyen et al., 2005). As previously shown in section 
1.10.3, several σ1 antagonists, such as BMY-14802, E-5842, DTG, SR-
31742A, MS-377, BD-1063 or BD-1047, and σ1 antisense 
oligodeoxynucleotides, attenuate in vivo several effects of 
methamphetamine, such as the enhancement of locomotor activity or the 
development of methamphetamine-induced behavioural sensitisation (Ujike 
et al. 1992b; Taylor et al. 1993; Ruckert and Schmidt, 1993; Poncelet et al., 
1993; Guitart et al., 1998; Takahashi et al., 2000; Nguyen et al., 2005). 
It has been reported that σ1 receptors could modulate also the effects of 
MDMA, a methamphetamine-related psychostimulant. In fact, the σ1 
antagonist BD-1063 attenuates the MDMA-induced locomotor activity 
(Brammer et al., 2006); moreover, BMY-14802 and MS-377, other two 
known σ1 antagonists, inhibit also the behavioral sensitization induced by 
the repeated administration of MDMA (Ujike et al., 1992a; Akiyama et al., 
1994; Takahashi et al., 2000). 
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1.11.3 Ethanol and σ1 receptors 
 
The involvement of σ1 receptors in the effect of ethanol has been 
examined in vivo behavioral paradigms. In rodents, the σ1 receptor 
antagonist BD-1047 has been shown to counteract the ethanol-induced 
locomotor stimulation, CPP and taste aversion and also to attenuate some 
symptoms of the abstinence syndrome after chronic ethanol consumption 
(Maurice et al., 2003; Meunier et al., 2006b). In line with these findings, the 
σ1 receptor agonist PRE-084 enhances the ethanol-induced CPP in a dose-
dependent manner (Maurice et al., 2003). However, the σ1 agonist JO-1784 
behaves as the antagonist BD-1047 and attenuates some symptoms of the 
ethanol abstinence syndrome (Meunier et al., 2006b).  
These observations suggest that σ1 receptor could represent a novel 
target for alleviating ethanol addiction and abstinence syndrome after 
withdrawal. 
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2.1 Historical background 
 
Neurons rely upon chemical neurotransmitters for rapid (order of 
milliseconds) and precise communication with each other and with target 
organs. Neurotransmitters released into the synaptic cleft activate specific 
receptors on the postsynaptic neuron, which in turn causes opening of ion 
channels and activation of signal transduction cascades in the post-synaptic 
cell resulting in transmission of the signal.  
The dopamine (DA) neurotransmitter was originally assumed to be a 
mere intermediate in the biosynthesis of norepinephrine (NE), until 
Carlsson and coworkers performed experiments on reserpinized animals 
and revealed a previously unrecognized role for DA in the central nervous 
system (CNS) (Carlsson et al., 1957). The neurotoxin reserpine alters the 
pH gradient required for monoamine uptake into the synaptic vesicle and 
the animals treated with reserpine become immobile, contributing to what 
is known as reserpine syndrome. Loss of NE was assumed to be the cause 
of this syndrome because treatment of reserpinized animals with the NE 
precursor 3,4-Dihydroxyphenylalanine (DOPA) reversed the reserpine 
syndrome (Carlsson et al., 1957). However, analysis of tissue from 
reserpinized and DOPA treated rabbits revealed that while animals 
regained mobility, there was only modest recovery of NE levels in the brain 
(Carlsson et al., 1957). This intriguing discovery soon led to the finding 
that the DA, not the NE is correlated with recovery from reserpine 
syndrome (Carlsson and Waldeck, 1958). For the first time, the role of DA 
as a potential neuromodulator of movement defects was recognized and 
described. 
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The lifetime of the neurotransmitter released into the synaptic cleft is 
predominantly regulated by specific proteins that mediate their reuptake 
into the presynaptic cell, the neurotransmitter transporters. Julius Axelrod 
was the first to introduce the concept of reuptake by demonstrating that 
synaptically released noradrenaline is taken up by specific transporters in 
sympathetic nerve terminals (Hertting and Axelrod, 1961). Subsequently, 
reuptake mechanisms have been discovered for serotonin, DA, γ-amino 
butyric acid (GABA), glycine and a number of other neuromodulators. To 
date, neurotransmitter transporters have been described to play a very 
important role in regulating temporal and spatial aspects of 
neurotransmission.  
 
 
2.2 Functions of DAT 
 
2.2.1 Physiological activity of DAT 
 
The DA transporter (DAT) is a membrane protein whose physiological 
function is to clear released DA from the synaptic cleft, effectively 
reducing the concentration of DA at both pre- and post-synaptic DA 
receptors (Nelson, 1998). Therefore, DAT modulates the spatial and 
temporal aspects of dopaminergic synaptic transmission and, while it 
regulates the key step for terminating DA action it is considered an integral 
part of the DA system (Mortensen and Amara, 2003; Torres and Amara, 
2007).  
The DA is uptaken against its concentration gradient. As discussed in 
section 2.3.2, the driving force for this process is granted by the Na+ and 
Cl- ions symport. Electrophysiological studies have revealed that DAT also 
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exhibits channel-like properties (Kahlig et al., 2005; Carvelli et al., 2004). 
These studies demonstrate that in addition to a carrier, DAT also acts as a 
channel and directly modulates membrane potential and neuronal function 
(Blakely and DeFelice, 2007). 
The dopaminergic system is involved in learning, reward-seeking 
behavior, movement, and emotion (Sotnikova et al., 2006). Due to the 
crucial role of DAT in terminating the dopaminergic neurotransmission, 
dysfunctions of DAT contribute to the development of several neurological 
and psychiatric disorders (Torres, 2006), such as attention-deficit 
hyperactivity disorder (ADHD) and Parkinson’s disease (PD). 
 
2.2.2 DAT mediated DA efflux 
 
In addition to the physiological uptake activity, DAT has been shown 
to be capable of mediating DA efflux (Khoshbouei et al., 2005). Efflux of 
DA through DAT has been shown primarily using AMPH stimulation 
(Khoshbouei et al., 2003). Initial studies examining reverse transport for 
DAT revealed that PKC activation increased DA release from striatal slices 
with this effect being blocked by DAT inhibitors (Kantor and Gnegy, 1998; 
Cowell et al., 2000). A link to PKC and potential AMPH induced efflux 
came from studies using the mutagenesis techniques. In these researches, 
the five N-terminal serine residues in hDAT, which are considered to be 
sites of PKC phosphorylation, have been substituted with alanines. While 
alanine substitution of these residues did not effect DA uptake or surface 
expression, AMPH mediated efflux was completely abolished (Khoshbouei 
et al., 2004). Substitution of these alanine residues with aspartic acid 
residues, which mimics phosphorylation at these sites, restored AMPH 
mediated efflux (Khoshbouei et al., 2004). This work suggests that NH2-
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terminal phosphorylation directly by PKC or via another kinase, not only 
affects transporter surface expression, but also enables the transporter to 
efflux DA. 
 
 
2.3 Structural basis of physiological functions 
 
2.3.1 Molecular characterization 
 
DAT is a member of the family of Na+, Cl- -dependent substrate-
specific neuronal membrane transporters. This neurotransmitter sodium 
symporter family (NSSf) includes also transporters for NE, serotonine, 
GABA, AA such as glycine, taurine, proline, betaine, creatine and some 
bacterial homologues (Amara and Khuar, 1993; Giros and Caron, 1993; 
Uhl and Kitayama, 1993; Blakely et al., 1994; Reith et al., 1997).  
The cloning of the DA transporter came in 1991 when several groups 
using information from other recently cloned biogenic amine transporters, 
expressed cDNA capable of mediating DA uptake into non-DA cells (Giros 
et al., 1991; Usdin et al., 1991). To date it is known that DAT gene belongs 
to the solute carrier 6 genes (SLC6A3) family, the same family of other 
monoamine transporter, such as SERT and NET. The initial determination 
of the membrane topology of DAT was based upon hydrophobic sequence 
analysis and sequence similarities with the GABA transporter. These 
methods predicted twelve transmembrane domains (TMD) with a large 
extracellular loop between the third and fourth TMDs (Kilty et al., 1991). 
Further characterization of this protein used proteases, which digest 
proteins into smaller fragments, and glycosylation, which occurs only on 
extracellular loops, largely verified the initial predictions of membrane 
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topology (Vaughan and Kuhar, 1996). Thus, to date, it’s accepted that the 
topological arrangement of DAT consists of 12 membrane-spanning α-
helices with intracellular amino and carboxyl-terminal domains (Fig.2.1). 
There are three putative N-linked glycosylation sites on the large 
extracellular loop between TM3 and TM4. DAT also contains a number of 
potential phosphorylation sites on the intracellular domains, which suggests 
that kinases may mediate regulation of the transport process. 
 
Figure 2.1. Topology of the Human Dopamine Transporter (hDAT). Illustration of the 
two-dimensional topology of the hDAT showing intracellular N and C termini and the 
amino acid sequence. There are 12 transmembrane domains with alternating intra- and 
extra-cellular loops. N-linked glycosyl groups are shown at the consensus asparagine 
glycosylation sites, Asn 181, Asn 188, and Asn 205, in the second extracellular loop. In 
addition, cysteines 180 and 189 in the second extracellular loop are disulfide bonded 
(adapted from Giros & Caron, 1993). 
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2.3.2 Structural basis of DA uptake 
 
As other members of NSSf, the DAT enables the transport of substrate 
together with Na+ and Cl- as cosubstrates (Gu et al., 1994; McElvain and 
Schenk, 1992). When DA binds to the transporter in combination with Na+ 
and Cl-, the transporter becomes active and can transport DA inside the 
cell. During a transport cycle, two Na+, one Cl- and one charged molecule 
of DA are translocated resulting in the net movement of two positive 
charges per molecule of DA (Gu et al., 1994; McElvain and Schenk, 1992). 
Another plasma membrane protein, an Na+-, K+-ATPase cootransporter, 
maintains an inwardly directed transmembrane Na+ gradient by pumping 
Na+ ions out of, and K+ into, the cell. This transmembrane gradient is 
important, because it represents the driving force of the uptake process 
(Rudnick, 2002; Chen and Reith, 2003), however the exact mechanism of 
the transporter involved in this coupled transport process remain unclear. A 
great advance in understanding the NSSf has been the crystalization of a 
member of this family, the bacterial leucine transporter (LeuTAa), from 
Aquifex aeolicus (Yamashita et al., 2005). Despite a low similaritiy 
between the eukaryotic and prokaryotic members of the NSSf, the LeuTAa 
crystal structure provides the most relevant informations available for this 
family because few key regions are highly conserved throughout all of 
these symporters (Beuming et al., 2006; Zhou et al., 2007; Huang and 
Zhan, 2007; Rudnick, 2007). The LeuTAa consists of 12 transmembrane 
domains (TM#), where domains TM1 to TM5 superimpose to TM6 to 
TM10 by 176.5° (Fig.2.2). TM1 and TM6 are in direct contact with the 
binding site of leucine (the substrate) and the sodium ions (Fig.2.2).  
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Figure 2.2. Topology of the LeuTAa 
 
If the molecular structure of LeuTAa and other Na+/Cl–-dependent 
transporters correlate, TM1 and TM6 would play a vital role in the 
substrate binding of DAT, SERT, and NET. 
 
2.3.3 Glycosilation of DAT 
 
The glycosylation is a post-translational enzymatic process that links 
glycans to proteins only in specifics glycosylation sites. The N-linked 
glycosylation occurs when glycans are attached to a nitrogen of asparagine 
or arginine side chains and it represent a crucial step for the folding of 
some eukaryotic proteins. 
Human DAT (hDAT) is a heavily glycosylated (glycosylation 
accounts for ~ 30% of the molecular weight of DAT) protein in vivo. The 
large extracellular loop between TMD3 and TMD4 carries three asparagine 
residues at position 181, 188, and 205 which are considered three putative 
N-linked glycosylation sites (Giros et al., 1994). In order to understand 
whether or how glycosylation affects DAT function, several mutated 
transporters have been generated. In a study, Torres et al (Torres et al., 
2003) describe four glycosylation mutants of human DAT: N181Q, 
N188Q, N205Q, and the triple mutant. The single aminoacid mutants 
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display normal DA uptake and surface expression, indicating that single 
glycosylation sites are not essential for these processes. The triple mutant 
has a normal Km for DA uptake but suffers from a 2-fold reduction in 
Vmax along with a distribution more toward the cell interior as compared 
with wild type. Similar results were obtained by Li et al. (Li et al., 2004) 
since they reported that the non-glycosylated DAT does not transport DA 
as efficiently as wild-type DAT and prevention of N-glycosylation also 
enhances the potency of cocaine-like drugs in inhibiting DA uptake into 
intact cells, without changing their affinity for DAT when measured in 
membrane preparations prepared from these cells. Thus, non-glycosylated 
hDAT mutants both possess an appreciably reduced catalytic activity and 
an altered inhibitor sensitivity compared with wild type. 
 
2.3.4 Phosphorylation of DAT 
 
Phosphorylation is the addition of a phosphate (PO4) group to a 
protein. The addition of a PO4 molecule to a sries of AA residues can turn a 
hydrophobic portion of a protein into a polar and extremely hydrophilic 
portion of molecule, introducing deep conformational changes in the 
structure of the protein. This process is mainly regulated by two enzymes, 
the kinases that introduce and the phosphatases that cleave the PO4 group 
and it represent a very important regulatory mechanism that occurs in both 
prokaryotic and eukaryotic organisms. 
The elucidation of the primary amino acid sequence of DAT reveals 
the presence of several potential phosphorylation sites for protein kinases 
(Giros et al. 1991; Shimada et al. 1991; Usdin et al. 1991). The predicted 
intracellular domains of the human DAT contain 15 serine, 9 threonine, and 
5 tyrosine residues, many of which are found in consensus sequences for 
Introduction - Chapter 2 
 - 111 - 
protein kinase C (PKC), cAMP-dependent protein kinase (PKA), cGMP-
dependent protein kinase (PKG), and calcium calmodulin-dependent 
protein kinase (CaMK). Some of these sites are highly conserved 
throughout the neurotransmitter transporter family, including a PKC/PKG 
consensus sequence in intracellular loop 2 and several sites in the N- and 
C-terminal tails close to TMs 1 and 12 (Vaughan 2004). 
Metabolic phosphorylation of DAT with 32PO4 has been demonstrated 
in the human, rat, and mouse isoforms of DAT (reviewed in Vaughan 
2006); moreover, it has been shown that, also in absence of exogenous 
treatment, both overexpressed and native DATs diplay a constituive 
phosphorylation and deposphorylation. Thus, DAT can be considered a 
phosphoprotein. 
As discussed in 2.5, PMA and OA treatments stimulate DAT 
phosphorylation and also lead to reductions in DA transport activity 
(Zahniser and Doolen 2001; Vaughan 2004). For this reason, it was early 
hypothesized that phosphorylation could be a signal for transporter 
internalization (Gainetdinov et al., 2004). However, the deletion of the 
hDAT and rDAT N-terminal serine clusters, that abolishes transporter 
phosphorylation, does not affect PKC-induced downregulation or 
internalization, demonstrating that transporter downregulation can occur in 
the absence of stimulated phosphorylation (Granas et al. 2003; Cervinski et 
al. 2005). These finding clearly demonstrate that DAT phosphorylation is 
not an internalization signal and that induction of PKC-dependent 
downregulation might therefore occur via phosphorylation of endocytic 
components or other DAT-associated proteins. 
As better illustrated in 2.2.2, to date the only process identified that 
requires DAT phosphorylation is substrate-induced efflux of DA (Granas et 
al. 2003; Khoshbouei et al. 2004). 
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2.4 Localization of DAT 
 
2.4.1 Anathomical distribution of DAT 
 
The anatomical and subcellular distribution of DAT can be detected 
using various techniques, such as in situ hybridization, [3H]WIN-35,065-2 
binding and uptake of the tritiated DA ([3H]DA). Among these three 
techniques, the use of antibodies anti-DAT led to the most accurate 
analysis of its distribution. 
The DAT is mainly present at the SNC level, but it has been also 
found in the perifery. At SNC level, DAT localizes exclusively on DA 
neurons, such as the neurons of the two major midbrain dopaminergic 
projection pathways: 
4) the mesocorticolimbic DA neurons with cell bodies 
(somatodendritic regions/compartments) in the ventral 
tegmental area (VTA) and projecting to the medial prefrontal 
cortex and nucleus accumbens (NAc, or ventral striatum) 
5) the nigrostriatal DA neurons with cell bodies in the substantia 
nigra pars compacta (SNc) and projecting to the dorsal 
striatum (dSTR) 
 
DAT levels were found to vary in these different cortical area, 
confirming for the first time that native DAT levels differ across brain 
regions (Ciliax et al., 1999).  
High-resolution electron microscopy has been used to visualize gold 
labeled antibodies directed against the rat DA transporter (rDAT); these 
studies demonstrate that rDAT is mainly located at the plasma membrane 
in various compartments of DA neurons. In the cell body, DAT is found at 
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the plasma membrane in tubulovesicular structures. DAT was also found 
associated with the plasma membranes in intermediate and distal dendrites 
in the VTA (Hersch et al., 1997; Nirenberg et al., 1997). DAT 
immunoreactivity was also noted in dendritic compartments in the VTA, 
with the majority of immunogold signal emanating from plasma membrane 
inserted DAT (Nirenberg et al., 1997). 
 
Figure 2.3. A) DAT immunostaining in 
the pars compacta of the substantia nigra 
(Hersch et al., 1997); B) High resolution 
imaging of a DA synapse displaying the 
“peri-synaptic” localization of rDAT 
(arrows) (Hersch et al., 1997). 
 
 
 
Using both and NH2-terminal 
and second extracellular loop antibodies, it has been also confirmed the 
predicted topology of the transporter, verifying that the NH2-terminus and 
the second extracellular loop were found on opposing faces of the plasma 
membrane (Hersch et al., 1997). Also in these studies was noted a co-
localization of DAT with presynaptic DA D2 receptor (Hersch et al., 1997). 
This colocalization might be interesting since, at this level, the D2 receptors 
work as DA autoreceptors bearing a negative feedback regulation of the 
extracellular DA. In fact it is known that, once activated, the presynaptic D2 
receptors inhibit the DA synthesis and release and increase the reuptake of 
the intersynaptic DA. 
DAT is not expressed only in the SNC; in rats it has been found in 
lymphocytes and in spleen, kidney and thyme cells (Mignini et al., 2006). 
A
B
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2.4.2 Subcellular localization of DAT 
 
DAT is a membrane protein and, like others membrane proteins, it is 
synthesized in the ER Since DAT is proposed to be N-glycosylated in the 
extracellular loops (see section 2.3.1), the transporter must pass through the 
Golgi to acquire this post-translational modification. From the Golgi 
apparatus, DAT then traffics to the plasma membrane (reviewed in 
Zahniser and Sorkin, 2009).  
Mutagenesis studies have shown that several regions of DAT are 
somehow involved in the veiculation of the newly-synthesized transporters 
(reviewed in Zahniser and Sorkin, 2009). Site-point mutagenesis of the 
carboxyl-terminal tail or truncation of this region results in inefficient 
plasma membrane expression of DAT (Torres et al., 2001; Bjerggaard et 
al., 2004). In addition, an almost complete retention of the transporter in 
the ER also results from a single mutation of the conserved Gly585 to 
alanine (Miranda et al., 2004). This dysregulation is probably due to deep 
changes in the intramolecular interactions necessary for the proper folding 
of DAT. 
Anyway, the exact mechanisms that control movement of newly-
synthesized DAT from Golgi to specific cell surface locations within the 
axons and distal dendrites are not known (reviewed Zahniser and Sorkin, 
2009). 
It is possible that DAT is inserted into the plasma membrane in the 
soma and then moves laterally along the plane of the membrane to its 
functional sites where it is retained by specific interactions with the 
resident proteins.  
Alternatively, DAT could be moved from the soma to distal locations 
by anterograde vesicles in microtubule-dependent manner and then be 
inserted into the plasma membrane locally at the axonal varicosities and 
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distal dendrites. It has been demonstrated that a 
dimerization/oligomerization of DAT takes place in the ER (Sorkina et al., 
2003). This oligomerization has been proposed to be necessary for the 
correct anterograde transport of DAT (Sorkina et al., 2003; Torres et al., 
2003). 
 
 
2.5 DAT regulation 
 
Neurotransmitter transporter often interprer the primary mechanism by 
wich neurons terminate the signal transmission. For this reason, fine and 
functional regulation pathways are capital step for modulating the 
neurotransmission. 
DAT, like other neurotransmitter transporters, is subjected to 
constitutive and regulated endocytosis. Following the endocytotic process, 
the internalized DAT can be recycled back to the plasma membrane. This 
dynamic regulation of the transporters expression on cell surface is known 
as trafficking. 
Trafficking of DAT is regulated by several different effectors: 
- PKC 
- inhibition of phosphatases 
- mitogen-activated protein kinase phosphatase (MKP3) 
- endogenous and exogenous ligands 
- other proteins interacting with DAT 
 
It is well estabilished and described that rapid loss of the surface DAT 
occurs within minutes after the activation of the PKC by phorbol esters, 
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such as PMA. This issue was first reported in xenopus oocytes and in Sf9 
insect cells expressing the cloned hDAT Zhu et al., 1997; Pristupa et al., 
1998). In addition, [3H]DA uptake experiments on dissociated embryonic 
mesencephalic neurons also showed that, following pretreatment with PMA 
the Vmax of DA transport is strongly inhbited. 
The PKC family comprises different classes of isoforms: 
- classic isoforms, Ca2+- and diacylglycerol (DAG)-dependent (α, β1, 
β2, γ); 
- non-classic isoforms, Ca2+-indipendent, but DAG-dependent (δ, ε, θ, 
ή); 
- atypic isoforms Ca2+ and DAG-indipendent (λ, ζ). 
 
Among all PKC isoforms, both β subtypes mainly appear to be 
responsible for regulation of DAT trafficking (reviewed in Vaughan 2006). 
However, the exact molecular mechanisms by wich PKC down-regulates 
DAT remains unclear. 
As previously described (see section 2.3.4), deletion of DAT 
phosphorylation sites doesn’t affect the PKC-induced clathrin-dynamin 
mediated internalization of the transporter, indicating that others 
mechanisms are likely to be involved. 
Even if it is known that a pool of plasma membrane DAT is also 
associated with cholesterol-rich rafts, regulating its transport activity 
(Foster et al., 2008), cholesterol-disrupting drugs do not affect PKC-
dependent DAT endocytosis, suggesting that DAT internalization is not 
mediated by lipid rafts (Sorkina et al., 2005).  
Recent mutagenesis studies suggest that the ubiquitination of DAT 
could be strictly connected to the observed PKC-stimulated endocytosis. In 
fact, specific site mutation of three lysine clustered in the DAT 
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aminoterminus, Lys19, Lys27, and Lys35 result in diminished 
internalization of DAT in response to PKC activation (Miranda et al., 
2007). Screenings for identifying the proteins involved in PKC-dependent 
DAT trafficking toward the cytoplasm were made using siRNA techniques. 
These studies identified the NEDD4-2, a protein containing an E3 ubiquitin 
ligase domain, as an essential component of PKC-dependent DAT 
endocytosis (Sorkina et al., 2006). siRNA-induced knock-down of 
NEDD4-2 also results in inhibition of DAT ubiquitination, thus implicating 
NEDD4-2 as an E3 ligase for DAT (Sorkina et al., 2006). These data, 
together with DAT mutagenesis, indicate that ubiquitination of the DAT 
amino-terminus is crucial for PKC-dependent DAT endocytosis and that 
the NEDD4-2 itself may be one of the major PKC molecular effectors. 
 
 
 
Figure 2.4. PKC dependent mechanism related to DAT internalization is the 
ubiquitination of the transporter. Ubiquitinated DAT is recruited into clathrin-coated 
pits (CCP) and then internalized via clathrin coated vesicles (CCV) to early recycling 
endosomes (EE/RE) wich prepare the DAT for being recycled back to the surface 
(adapted from Zhaniser and Sorkin, 2009). 
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The role of phosphatases in regulation of DAT phosphorylation levels 
has been established using the okadaic acid (OA) a broad-spectrum protein 
phosphatase inhibitor. Treatment of rat striatal tissue or heterologously 
expressing cells with OA produces robust increases in the DAT 
phosphorylation and it also decreases DAT cell surface expression and 
activity within 5–10min (Huff et al. 1997; Vaughan et al. 1997; Cowell et 
al. 2000; Granas et al. 2003; Lin et al. 2003; Cervinski et al. 2005). The 
phosphorylation increase, observed in absence of exogenous kinase 
activators, reflects the rate of basal phosphorylation indicating that, in 
resting neurons, significant tonic phosphatase activity maintains DAT in a 
state of relative dephosphorylation. This robust dephosphorylation pressure 
may lead to the identification of endogenous signals regulating DA uptake 
activity. 
A recent genetic complementation screening, performed in Xenopus 
oocytes, identified a mitogen-activated protein (MAP) kinase phosphatase, 
MKP3, as a molecule that inhibits PKC internalization of DAT (Mortensen 
et al., 2008). In this study, transient expression of MPK3 in MDCK cells 
stably expressing DAT inhibited PKC-stimulated endocytosis of DAT and 
enhanced DAT activity. MPK3 does not interfere with PKC-induced 
ubiquitylation of DAT; the molecular mechanism underlying the MPK3 
effects acts at a more downstream step, to stabilize DAT on cell surface by 
blocking dynamin-dependent internalization and slowing the DAT 
degradation processes (Mortensen et al., 2008). 
Exogenous and endogenous substrates also strongly modulate DAT 
functions. Ethanol, arachidonic acid and nitric oxide has been shown to 
interfere with DAT activity (Cass et al., 1991; L’hirondel et al., 1995; 
Mayfield et al., 2001b; Kiss et al., 1999).  
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Ethanol potentiates DA uptake in Xenopus oocytes, SK-N-SH and 
HEK-293 cells (Riherd et al., 2008). Since ethanol's action on DAT 
function and regulation is consistent across both neuronal and non-neuronal 
models, a direct action of ethanol on transporter trafficking in mammalian 
systems has been proposed (Riherd et al., 2008). In C6 rat glioma cells, 
arachidonic acid induces a double effect; while a brief incubation leads to 
an increase of the DA uptake, a longer exposition completely abolishes the 
DAT activity (Zhang and Reith, 1996). In the same cell line, NO reduces 
the number of the DAT on the plasma membrane, but, simultaneously, it 
increases the SERT activity (Miller and Hoffman, 1994). This finding 
suggests that NO may regulate these two neuronal transporters with 
different molecular mechanisms. 
Protein-protein interactions were also shown to regulate DAT 
trafficking. In cells, once internalized within vescicles, DAT can 
alternatively be degraded by lysosomes or anchors to the microtubular net 
before recycle back to the plasma membrane. A neuronal protein called α-
synuclein (α-Syn) is able to directly interact with recycled DAT and 
anchors it to the microtubules surface (reviewed in Sidhu et al., 2004). α-
Syn is a small neuronal protein (140AA) implicated in many cellular 
processes; at presynaptic sites α-Syn is implicated in synaptic vesicle 
formation, axonal transport, and DA synthesis and metabolism. In a normal 
situation, α-Syn exists as a soluble or lipid-bound structure. From co-
immunoprecipitation studies, α-Syn was found to interact directly with the 
DAT, forming a protein-protein heteromeric complex in transfected cells, 
primary cultures of mesencephalic neurons and rat SNC (Wersinger and 
Sidhu, 2003; Wersinger et al., 2003; Lee et al., 2001). These interactions 
occurs between the non-amyloid component domain (residues 58–107) of 
α-Syn and the last 22 amino acids of the carboxy-terminal tail of DAT 
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(Wersinger et al., 2003). α-Syn attenuates DAT function, trafficks DAT 
away from the plasma membrane and, participating in the formation of a 
protein-protein complex with DAT, anchors the monoamine transporter to 
microtubules membrane. Thus a probable α-Syn function is the 
maintenance of DA homeostasis through a modulation of DAT activity, by 
regulating its level at the cell surface (Wersinger and Sidhu, 2005). 
To better understand the role of the α-Syn in the regulation of the DAT 
trafficking, the microtubular network has been destabilized treating the 
cells with colchicine, vinblastine, or nocodazole (Wersinger and Sidhu, 
2005). Destabilization of the microtubular network disrupts the ability of α-
Syn to modulate DAT function, resulting in an increased level of 
trafficking to the plasma membrane, which is accompanied by an increased 
rate of DA uptake, DA-induced oxidative stress, and accelerated cell death. 
Since DAT is the only means by which dopaminergic neurons can re-
uptake synaptically released DA (Gainetdinov and Caron, 2003). The 
increased presence of DAT at the plasma membrane clearly results in an 
increased rate of re-uptake, causing excessive accumulation of high 
intracellular levels of ROS and reactive nitrogen species; this latter effect 
contributes to cytotoxic events which culminate in neuronal death 
(Wersinger and Sidhu, 2005) and it can partially explain why mutations of 
α-Syn (se section 2.7) have been implicated in the genesis of Parkinson’s 
disease (PD).  
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2.6 DAT pharmacology 
 
2.6.1 Dopamine reuptake inhibitor 
 
A dopamine reuptake inhibitor is a drug which is able to negatively 
affect the reuptake of DA by blocking DAT’s action. In turn, this inhibition 
leads to increase extracellular concentrations of DA and therefore to 
potentiate the dopaminergic neurotransmission. 
Inhibitors of DAT may be used in the clinical treatment of several 
pathologies, such as attention-deficit hyperactivity disorder (Solanto, 
1998), narcolepsy (Fry, 1998), major depressive disorder (if resistant to 
typical treatments) (Nutt, 2008) and PD (see section 2.7). In addition, DAT 
inhibitors may be employed as anorectics for treating severe obesity 
(reviewed in Wang et al., 2002), they are studied as anticraving agents 
against drug addiction (reviewed in Haile et al., 2009) and they are often 
used as tool to indagine the site of action of cocaine, amphetamine and 
MDMA on DAT (Meiergerd and Schenk, 1994; reviewed in Carroll et al., 
1992). 
Among the DAT inhibitors, nomifensine, mazindole, GBR 12909, 
metilphenidate, benztropine and Win 35,065-2 have been shown to inhibit 
the DA reuptake at very low concentration (Table 2.1). 
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Table 2.1. Pharmacology data of DAT receptor ligands; Ki were obtained by 
competitive binding experiments using [3H]Win-35,428 as tritiated probe 
 
Ligand Chemical structure Ki (nM) DAT source References 
GBR-12909 
 
30 ± 2.3 
Striatal rat 
synaptosom
es 
Zhu et al., 
2009 
Mazindole 
 
12 ± 2 
CHO cells 
transfected 
with wild 
type hDAT 
Uakiro et al., 
2007 
Nomifensine 
 
Not 
measurable* - - 
Benztropine 
 
85 ± 9 
CHO cells 
transfected 
with wild 
type hDAT 
Uakiro et al., 
2007 
Cocaine 
 
197 ± 22 
CHO cells 
transfected 
with wild 
type hDAT 
Uakiro et al., 
2007 
MDMA 
 
>10000 
CHO cells 
transfected 
with wild 
type hDAT 
Fantegrossi et 
al., 2009 
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AMPH 
 
478 ± 52 
CHO cells 
transfected 
with wild 
type hDAT 
Uakiro et al., 
2007 
Win-35,428 
 
2.81 ± 0.14 
Sinaptosomi 
striatali di 
ratto 
Zhu et al., 
2009 
Metilphenidate 
 
72 ± 5 
CHO cells 
transfected 
with wild 
type hDAT 
Uakiro et al., 
2007 
* This value is impossible to evaluate with satndards binding techniques, because nomifensine binds to the DAT on a different site 
than the ligand [3H]Win-35 (Meiergerd and Schenk, 1994). 
 
 
2.6.2 DAT and psychostimulants 
 
Addiction to psychostimulants drugs is a significant medical, social 
and economic problem facing society. Traditionally, addiction to these 
drugs was treated as a psychological disorder; however, after the 
elucidation of the dangerous physiological effects of these drugs, their 
abuse has been classified as a physiological disorder. Therefore, today drug 
addiction is defined as a brain disorder characterized by compulsive drug-
seeking behavior and uncontrollable drug intake (Koob, 2000). Although 
progress has been made in developing new psychosocial treatments for 
psychostimulants dependence, currently no medications approved for the 
treatment of cocaine dependence are available. 
It has been shown that psychostimulant drugs interact with regions of 
the brain where dopaminergic terminals are abundant, specifically the 
mesolimbic dopaminergic system (Kreek, 2001). The two most widely 
abused psychostimulant drugs are cocaine and amphetamines (AMPHs). 
Cocaine is the most powerful stimulant of natural origin (Fisher et al., 
1987). It is extracted from the leaves of Erythroxylon Coca (Kreek et al., 
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2005). It is still used by South Americans to relieve fatigue (Schultes, 
1987). Pure cocaine (as hydrochloride) was used as a local anesthetic for 
surgeries in the 1880s and the main stimulant drug used in tonics and 
elixirs for various illnesses in the early 1900s (Koller-Becker, 1962). To 
date cocaine doesn’t have any approved therapeutical indication, but it is 
widespread abused all around the planet as recreational drug. In last 
decade, the number of cocaine users has dramatically increased and to date 
cocaine abuse represent a serious health problem in many areas of the 
world. Only in the US, in 2001, there were an estimated 27.8 million who 
had used cocaine at least once in their lifetime (Gorelick et al., 2004; 
ONDCP, 2003) and in 2007 the estimated number of current cocaine users 
was 2.1 million (NIDA, research report series. Cocaine: abuse and 
addiction. 2009).  
Amphetamine is a synthetic drug related to the plant derivative 
ephedrine and it was first synthesized in in 1887 (Edeleanu, 1887). 
Amphetamine is the first member of a group of compounds that have 
similar structures and biological properties and are collectively called 
“amphetamines”. The group also includes methamphetamine, synthesized 
six years later and MDMA, patented in 1914 (Berman et al., 2008). 
AMPHs are known to produce insomnia and euphoria, enhance focus and 
decrease fatigue and appetite.  
During time, amphetamine and methamphetamine were used for the 
treatment of narcolepsy, mild depression, postencephalitic parkinsonism, 
chronic alcoholism, cerebral arteriosclerosis and hay fever and they were 
also sold as decongestionant. During World War II amphetamine and 
methamphetamine were extensively used to combat fatigue and increase 
alertness in soldiers. To date, the only approved marketing indications for 
these two drugs are treatment of ADHD, obesity and narcolepsy (Berman 
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et al., 2008), but their use is tightly controlled, mainly because of their 
potential for abuse that can lead to severe psychological and physiological 
dependence (Berman et al., 2008). On the other hand, MDMA possess a 
too high abuse potential and it’s not accepted for medical uses (Berman et 
al., 2008). According to the 2005 National Survey on Drug Use and Health 
(NSDUH), in US an estimated 10.4 million people age 12 or older (4.3 
percent of the population) have been tried with AMPHs at some time of 
their lives and, in the same year, the estimated number of current AMPHs 
users was 512,000 (Research Report Series. Methamphetamine: abuse and 
addiction). 
Both cocaine and AMPHs act increasing the extracellular DA 
concentrations, which is thought to mediate the rewarding and reinforcing 
properties of these drugs (reviewed in Torres et al., 2003); however the 
molecular mechanism of action of these two drugs is quite different. 
Cocaine binds to the 5-HT transporter (SERT) (Woolverton ans 
Johnson, 1992), norepinephrine transporter (NET) (Blakely et al., 1994) 
and DAT (Church et al., 1987; Di Chiara & Imperato, 1988; Hurd & 
Ungerstedt, 1989; Maisonneuve et al., 1990; Nielsen et al., 1983; Pani et 
al., 1990); thus cocaine inhibits presynaptic reuptake of 5-HT, 
norepinephrine and DA, elevating the concentration of these three 
neurotransmitters in the synaptic cleft. Although cocaine affects all the 
three monoamine transporters, the reinforcing and stimulating effects of 
cocaine seem to depend primarily on its interaction with DAT (Ritz et al., 
1987; Koob and Bloom, 1988; Kuhar et al., 1991). 
AMPHs have three effects at the monoaminergic synapse 
1) blockade of DA uptake; 
2) promotion of release of DA into the synaptic cleft; 
3) inhibition of monoamine oxidase (MAO); 
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Concerning the first issue, it is well described that AMPHs are able to 
directly inhibit the DAT uptake activity (Schmitz et al., 2001). 
For what it concerns the promotion of the DA release, AMPHs induce 
this effect through two mechanisms. On the one hand they activate the 
reversal DAT activity, wich is described in section 2.2.2. On the other 
hand, AMPHs can increase the DA release through the depletion of DA 
vescicles. It has been demonstrated the existence of two classes of DA 
vesicles that are differentially depleted by AMPH (Anderson et al., 1998): 
at low concentrations, AMPH preferentially depletes the large vesicles, 
while at higher concentrations, AMPH depletes small vesicles more than 
large vesicles. It is known that, in the SNC, dopaminergic 
neurotransmission is regulated by DAT, but also by another membrane-
bound transporter: the vesicular monoamine transporter-2 (VMAT2). Once 
the DA is transported inside the cell, VMAT2 permits DA uptake into 
synaptic vesicles or other intracellular organelles (Wang et al., 1997). 
Numerous evidences support the hypothesis that AMPH could be taken up 
into vesicles by VMAT2 and displace the vescicular DA (reviewed in Sora 
et al., 2009). However, it has also been well estabilished that AMPHs 
compete with reserpine binding to VMAT2 (Peter et al., 1994); since 
reserpine acts by blocking the vesicular monoamine transporter VMAT2, it 
is still not straightforward to prove that AMPHs are actually VMAT2 
transported substrates (reviewed in Sora et al., 2009). 
As third and last point, it has been proved that AMPH inhibits the 
oxidation of aliphatic amines ex vivo, in tissues obtained from several 
sources including heart, liver and brain (Blaschko et al., 1940; Mann et al., 
1937); specifically, AMPH acts as a competitive inhibitor for type A MAO 
(Mantle et al., 1976; Miller and Hoffman., 1980). In conclusion, the role of 
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MAO inhibition in the expression of the pharmacological effects of AMPH 
does not seem as robust as the effect of AMPH on amine transporters. 
 
 
2.7 Molecular pathogenesis of Parkinson’s disease 
 
Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative 
disorder clinically characterized by motor symptoms such as tremor at rest, 
rigidity, slowness of movement (bradykinesia) and postural instability 
(Jankovic, 2008).  
In 1817 James Parkinson first described the motor symptoms of the 
clinical syndrome (called “shaking palsy” by the author) that was later to 
bear his name (Parkinson, reprinted 2002). More than 100 years passed 
(1919) after the original description by Parkinson before it was recognised 
that patients with PD progressively lose dopaminergic neurons in the 
substantia nigra pars compacta (SNpc). These neurons reside in the 
midbrain and project axons to the forebrain where they release DA into the 
striatum. Striatal DA release is critical for the coordination and initiation of 
movement. The loss of this DA input is primarily responsible for the 
manifestation of motor symptoms in PD. Another pathological hallmark of 
PD is the presence of intracytoplasmic abnormal aggregates of protein in 
dopaminergic neurons, called Lewy bodies (LB); first described in 1912 by 
Friedrich Lewy following post-mortem analysis of brains, LB are found 
primarily in the SNpc and another midbrain nucleus, the locus coeruleus 
(LC) in PD patients and are still considered one of the standard criterion for 
PD diagnosis (Gibb and Lees, 1988). In 1960 it was discovered that DA 
concentrations are markedly decreased in the striatum of patients with PD; 
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this finding soon led to the first trials of levodopa in PD patients 
(Birkmayer and Hornykiewicz, 1961). 
To date, increased oxidative stress, mitochondrial dysfunction, genetic 
mutations, abnormal handling of misfolded proteins by the ubiquitin–
proteasome and the autophagy–lysosomal systems, inflammation and other 
pathogenic mechanisms have been identified as contributing factors in the 
death of dopaminergic and non-dopaminergic cells in the brains of patients 
with PD. Some of them are briefly described in following sections. 
 
2.7.1 Dopamine metabolism and oxidative stress 
 
DA is synthesized in the cytoplasm from the amino acid tyrosine. 
Tyrosine is converted to L-DOPA by the cytoplasmic enzyme tyrosine 
hydroxylase (TH); this step represents the rate-limiting step of 
catecholamine synthesis (Fig.2.5) (Kumer and Vrana, 1996). L-DOPA is 
decarboxylated to DA by L-amino-acid decarboxylase (AADC) (Fig.2.5) 
(Kumer and Vrana, 1996). Newly synthesized DA is taken up into synaptic 
vesicles by the vesicular VMAT2 in a ATP-dependent process. 
Norepinephrine and epinephrine are subsequently synthesized from DA; 
thus biogen amines share the same biosynthesis pathway and primary 
pecursor. The multiple and complex mechanisms regulating TH activity 
and its expression are not the subjects of this PhD dissertation; however it 
worth remarking that TH activity is regulated through feedback inhibition 
by catecholamines (Zigmond et al., 1989) and that the activation of the DA 
D2 autoreceptor further inhibits DA synthesis.  
Vesicular DA is released into the synapse from the neuronal terminal 
by exocytosis following stimulation and recycled back into the terminal by 
DAT. Once reuptaken from the synaptic cleft, DA can either be stored into 
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synaptic vesicles to be reused, or metabolized by mitochondrial MAOB 
(Fig.2.5) (Berry et al., 1994) to form hydrogen peroxide (H2O2) and 3,4-
dihydroxyphenylaldehyde, which is rapidly oxidized by aldehyde 
dehydrogenase to 3,4-dihydroxyphenylacetic acid (DOPAC). 
Approximately 40% of DOPAC is eliminated without further metabolism 
and 60% is converted to homovanillic acid (HVA) by catechol-O-
methyltransferase (COMT) (Fig.2.5) (reviewed in Eisenhofer et al., 2004) 
 
 
Figure 2.5. Metabolism of DA. 
 
Cytosolic DA has the propensity to generate cytotoxic reactive oxygen 
species (ROS) and neurotoxic quinones (DAQs), spontaneously or by 
enzymatic metabolism (Graham, 1978; Hastings et al., 1996; Montine et 
al., 1997). 
Introduction - Chapter 2 
 - 130 - 
Oxidation of DA generates superoxide (O2-) and hydrogen peroxide 
(H2O2), which can form an hydroxyl radical (OH•) in the iron-catalyzed 
Fenton reaction (Halliwell and Gutteridge, 1984). If these ROS are not 
inactivated by natural antioxidants (glutathione peroxidases, superoxide 
dismutases, catalase, reduced glutathione (GSH), ubiquinol, uric acid, 
essential minerals and vitamines), their high chemical reactivity can 
damage all types of cellular macromolecules susceptible to oxidation 
(German, 1999). Interestingly, GSH levels within dopaminergic neurons 
are depleted in PD patients, suggesting that, in these cells, the ability to 
manage ROS is compromised or overwhelmed by an abnormal ROS 
production (Jenner, 2003). 
Inside cells, several enzymes can catalyze DAQs synthesis. These 
species react with cysteinyl residues of proteins to form 5-cysteyl-catechols 
adducts (LaVoie and Hastings., 1999). Since sulfhydryl groups of cysteine 
are often located in the active site of proteins, the normal cellular functions 
of the affected proteins can be inhibited by the covalent interaction with 
DAQs, with toxic consequences (LaVoie and Hastings., 1999). 
In addition, also the DA metabolite DOPAC reacts with cystein 
residues of proteins to form covalent adducts (Fornstedt et al., 1986). 
As reported, DA is likely to be considered a neurotoxic molecule. In 
normal conditions, VMAT2 sequesters about 90% of the catecholamines, 
leaving only a 10% to escape and being metabolized (reviewed in 
Eisenhofer et al., 2004). This rapid sequestration activity is thought to 
protect the cells from an excessive intracellular accumulation of DA and 
subsequent degradation to neurotoxic species. When a dysfunction causes 
the level of intracellular DA to abnormally increase, vescicles can’t 
sequester the DA which is metabolized by MAO (A and B) and COMT 
with consequent overproduction of oxygen reactive species and toxic 
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catabolites (Hastings, 1995, Hastings et al., 1996). Stress induced by these 
molecules leads cells to death. 
Thus, DA concentrations in the cytoplasms appear to be strictly 
connect to DA neurotoxicity and, even if it is well estabilished that PD is a 
multifactorial disease, an increasing number of evidences suggests that DA 
metabolites-induced oxidative stress is a common mechanism by wich 
dysfunctions in synthesis, storage, release, reuptake and metabolism of DA 
lead to the dopaminergic neurons degeneration observed in PD (Jenner, 
2003). 
 
2.7.2 Genetic factors contributing to Parkinson’s disease 
 
It is known that a variety of genetic and environmental factors 
contribute to the degeneration of nigral DA neurons observed in PD. For 
what it concerns the genetic component, so far mutations of five genes have 
been linked clearly to familial forms of PD: leucin-rich repeat kinase 2 
(LRRK2), serine/threonine-protein kinase (PINK1), DJ-1 (PARK7), α-
synuclein (α-Syn) and parkin (PARK2). 
LRRK2, or dardarin, is a protein member of the leucine-rich repeat 
kinase family. The cellular and molecular mechanisms of LRRK2 toxicity 
remain unclear, but it has been described that mutations in LRRK2 gene are 
associated with an autosomal-dominant Parkinsonism, with clinical and 
molecular features of PD, including deposits of aggregated protein (Smith 
et al., 2005), known as Parkinson's disease type 8.  
PINK1 is a mitochondrial enzyme wich is thought to protect cells from 
stress-induced mitochondrial dysfunction. In fact, in vitro overexpression 
of wild type PINK1 reduces the basal neuronal pro-apoptotic activity 
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preventing mitochondrial cytochrome c release and this function is 
abrogated in familial PD-linked PINK1 mutants (Petit et al., 2005). 
DJ-1 is an highly conserved 189 amino acid protein wich is 
ubiquitously and widely expressed in most mammalian tissues, including 
brain and belongs to the DJ-1/ThiJ/PfpI superfamily. Deletion and point 
(L166P) mutations of DJ-1 have DJ-1 locus have been associated with a 
rare form of autosomal recessive early-onset parkinsonism, known as type 
7 (Bonifati et al., 2003; Taira et al., 2004). DJ-1 eliminates hydrogen 
peroxide in vitro by oxidizing itself exhibiting intrinsic ROS scavenger 
properties and its expression is induced by oxidative stress (Taira et al., 
2004). The protective role of DJ-1 is confirmed by the finding that 
mutations of DJ-1 lead to cell death in vitro (Taira et al., 2004).  
α-Syn is a protein underlying multiple cellular functions being 
involved in modulation of DAT recycling (see section 2.5) and regulation 
of neuronal Golgi apparatus and vesicle trafficking (Cooper et al., 2006) 
and it is also able to interact with microtubules (Alim et al., 2004) and 
membrane lipids (Uversky, 2007). Three missense mutations in α-Syn gene 
(A53T, A30P and E46K) (Kruger et al., 1998; Polymeropoulos et al., 1997; 
Zarranz et al., 2004) as well as α-Syn gene locus triplication (Singleton et 
al., 2003) are associated with autosomal dominant PD. The involvement of 
α-Syn in PD pathogenesis is further confirmed by the finding that fibrillar 
aggregations of α-Syn are the major structural component of Lewy bodies 
(Spillantini et al., 1998).  
Mutated α-Syn and abnormal α-Syn expression alter multiple 
molecular functions of the cell to produce the neurotoxic effects. Both 
A30P and A53T mutants increase vulnerability of cells towards various 
toxic insults and enhance DAT-mediated DA toxicity (Lehmensiek et al., 
2006). Mice expressing human A53T α-Syn develop mitochondrial 
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pathologies and dysfunctions (Stichel et al., 2007). In addition, 
overexpression of α-Syn leads to accumulation of the protein wich cause a 
cytotoxic dysregulation of the vesicular trafficking from endoplasmic 
reticulum to Golgi apparatus (Cooper et al., 2006).  
Due to the crucial roles of α-Syn in PD pathogenesis, to date the term 
“synucleinopathy” is often use in licterature as PD synonimous (Mosharov 
et al., 2009). 
Parkin is s a component of a multiprotein E3 ubiquitin ligase complex 
which in turn is part of the ubiquitin-proteasome system that mediates the 
targeting of substrate proteins for proteasomal degradation (Shimura et al., 
2000). Mutation of Parkin gene sequence have been identified in patients 
with a familial form of PD, known as autosomal recessive juvenile 
Parkinson disease (Polymeropoulos et al.,1997; Shimura et al., 2000). 
A first obvious predicted mechanism for recessive Parkin mutations in 
PD is the accumulation of toxic proteins that would normally be degraded 
by Parkin. Although many substrates of E3 ubiquitin ligase have been 
identified (CDCrel-1, synphilin 1, α-Sp22, and α-Syn), none of them were 
found to accumulate in the brains of Parkin-deficient mice (Goldberg et al., 
2003; Palacino et al., 2004). However, it is possible that another 
unidentified Parkin substrate can accumulate to toxic levels upon Parkin 
inactivation.  
It is known that Parkin impairs the α-Syn/DAT coupling by interacting 
with the carboxyl-terminus of the DAT and blocks the α-Syn modulation of 
DAT trafficking (Moszczynska et al., 2007). In certain conditions, i.e. 
overexpression, α-Syn can even enhance both DAT cell surface expression 
and DAT-mediated DA uptake leading to an increase of the DA induced 
oxidative toxicity. This effect is counteracted by wild type Parkin that acts 
as a neuroprotective molecular mechanism, but it is still unclear if Parkin 
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mediates these effects by blocking the DAT internalization or the DAT 
exocytosis pathways (Moszczynska et al., 2007). In addition, 
overexpression of Parkin alone also directly protects human DA 
neuroblastoma cell lines SH-SY5Y and SK-N-SH from apoptosis induced 
by DA or 6-OHDA and also decreases the level of ROS and protein 
carbonyls in the cell. (Moszczynska et al., 2007; Jiang et al., 2004). 
Consistent with this, PD-linked mutations of Parkin significantly abrogated 
the observed protective effect of wild-type Parkin, as well as its ability to 
suppress ROS and protein carbonylation (Jiang et al., 2004). For these 
reasons, to date, Parkin is considered a neuroprotective protein that is 
crucial for neuronal survival (Feany and Pallanck, 2003). 
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3.1 Aim of the study 
 
Stimulation of σ1 receptors has a biphasic effect on intersynaptic 
[dopamine] (DA) In vivo, σ1 agonists rapidly produce a significant (40-50% of 
basal levels) increase in extracellular [DA] observed within 30 minutes of 
administration. This increase is followed by a more prolonged (150 minutes) 
and marked decrease (-70% of basal levels) of the extracellular DA levels (see 
section 1.9.7). 
It has been shown that DA release is inhibited by σ1 agonists in many 
experimental paradigms (see section 1.9.7). For this reason, inhibition of DA 
release has been proposed to contribute σ1-mediated fluctuations of 
extracellular [DA]. However, the hypothesis that σ1 receptors could act 
through the modulation of DA uptake has never been investigated. 
In dopaminergic neurons, uptake of intersynaptic DA is mediated by DA 
transporter (DAT) and this uptake represents the most relevant molecular 
mechanism extinguishing dopaminergic signal.  
Due to the key role of DAT in regulating extracellular DA levels, the first 
part of this research has been performed to understand if σ1 receptors may 
modulate DAT uptake mechanisms in cells models and, to investigate it, eight 
different clones have been set up. 
A) HEK-293 and SH-SY5Y native cells; 
B) HEK-293 and SH-SY5Y cells stably transfected with human σ1 
(hσ1) receptors; 
C) HEK-293 and SH-SY5Y native cells, transiently transfected with 
human DAT (hDAT); 
D) HEK-293 and SH-SY5Y cells stably transfected with human hσ1 
(A), transiently transfected with human DAT (hDAT). 
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Cells A) were adopted to estimate basal values. B) clones have been used 
to check the stable transfection of hσ1 and to produce the double transfected 
D) clones. Ultimately, C) and D) were employed in uptake assays as model of 
hDAT in presence or absence of hσ1 overexpression. 48h after transfection 
with hDAT, uptake activity has been evaluated adopting the [3H]DA uptake 
assay, a technique that is well charachterized in literature (Cervinski et al., 
2005). Once obtained basal uptake values, a molecular screening was 
performed to elucidate relationship between σ1 agonists and antagonists and 
the amount of uptaken DA. 
 
 
3.2 Methods 
 
3.2.1 Cell cultures 
 
For this work two different cell lines have been employed: 
1) HEK-293 is a cell line derived from human embryonic kidney 
cells. This cell line has been obtained from healthy aborted fetus 
and immortalized using sheared adenovirus 5 DNA (Graham et 
al., 1977). HEK-293 are very easy to grow and transfected and 
are widely employed in cell biology.  
2) SH-SY5Y is a thrice-cloned neuroblastoma sub-line of a bone 
marrow biopsy-derived line SK-N-SH (Biedler et al., 1978). SH-
SY5Y neuroblast-like subclone preserves norepinephrine (NE) 
neurons characteristics since it possess endogenous NE uptake 
activity and dopamine-β-hydroxylase activity. However, this line 
loses its neuronal characteristics with increasing passage 
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numbers and it is not recommended to continue culture beyond 
20 passages. SH-SY5Y cell line is difficult to transfect and it is 
very sensitive to growth conditions, but it is considered a good 
non-primary model of neurones. 
 
HEK-293 were grown in 75 ml sterile tissue-treated cell culture flasks 
(Sarsted), in a CO2 water-jacketed incubator at 37°C with 5% CO2 content. 
The medium used for HEK cells was the Minimum Essential Eagle (MEM, 
Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza), 100 µg/ml 
penicillin-streptomycin (Gibco), 2 mM L-glutamine (Lonza) and 1% Non 
Essential Amino Acids (NEAA, Gibco). Cells were splitted to 1:8 rate once 
they reached about 80% of confluence. 
SH-SY5Y were grown in 75 ml sterile tissue-treated cell culture flasks 
(Sarsted), in a CO2 water-jacketed incubator at 37°C with 5% CO2 content. 
The medium used for SH-SY5Y cells was 41,5% Nutrient Mixture F-12 
(Ham's F-12 Lonza) and 41,5% MEM (Gibco), supplemented with 15% fetal 
bovine serum (FBS, Lonza), 100 µg/ml penicillin-streptomycin (Gibco), 2 
mM L-glutamine (Lonza) and 1% Non Essential Amino Acids (NEAA, 
Gibco). Cells were splitted to 1:6 rate once they reached about 80% of 
confluence. 
 
3.2.2 Plasmids characterization 
 
Three plasmids have been employed in this study. 
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3.2.2.1 pCMV6 Entry-hSigma-1 
 
This plasmid was bought from OriGene Technologies Inc. and encodes 
for the complete hσ1 open reading frame (ORF) (672 bp, reference sequence: 
NM_005866.2) fused with the expression Myc/Flag tag peptides at the C-
terminal extremity.  
After bacteria transformation and plasmid purification (see section 3.2.3), 
the integrity of plasmid DNA was checked running the product of a double 
restriction enzyme digestion on agarose gel (1% p/v).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. (A) schematic map of pCMV6Entry- hσ1; (B) digestion of the purified plasmid 
with restriction enzymes KpnI and XhoI produces a predicted fragment of about 700bp. 
 
3.2.2.2 pEGFP-C1-hDAT 
 
This plasmid was a kind gift of Professor Susan Amara, Thomas Detre 
Professor and Chair of Neurobiology at University of Pittsburgh School of 
Medicine. pEGFP-C1-hDAT encodes for the complete hDAT ORF (1863 bp, 
pCMV6 Entry - hSigma-1
5549 bp
hSigma-1
Myc-Flag + STOP
CMV Promoter
KpnI (1003)
XhoI (1713)
~700 bp 
A) B) 
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reference sequence: NG_015885.1) fused with the enhanced green 
fluorescence protein (EGFP) at N-terminus.  
After bacteria transformation and plasmid purification (see section 3.2.3), 
the integrity of plasmid DNA was checked running the product of a double 
restriction enzyme digestion on agarose gel (1% p/v). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. (A) schematic map of pEGFP-C1-hDAT; (B) digestion of the purified plasmid 
with restriction enzymes KpnI and XhoI produces a predicted fragment of about 1900bp. 
 
3.2.2.3 pcDNA3.1(-)-hDAT 
 
This plasmid was subcloned from pEGFP-C1-hDAT. Briefly, the tract of 
DNA including hDAT sequence was excised through digestion with KpnI and 
XhoI restriction enzymes. Simultaneously, the same restriction enzymes were 
used to cut the destination vector (pcDNA3.1(-)). Digestion products were 
then separeted on agarose gel (1% p/v) and purified with a commercial kit 
~1900 bp 
A) B) 
pEGFP-C1 - hDAT
6597 bp
EGFP
hDAT NG 015885.1
CM V Promoter
XhoI (4696)
KpnI (1)
~1900 bp 
Aim of the study, methods and results – Chapter 3 
 
 - 153 - 
(Promega Wizard® SV Gel and PCR Clean-Up System). Once extracted, 
purified and quantified, a 3:1 ratio of insert and destination vector were mixed 
toghether with T4 DNA ligase (Invitrogen) and the product of ligase reaction 
was directly transformed into a E.Coli strain (see section 3.2.3 for 
transformation procedure). 
After bacteria transformation and plasmid purification (see section 3.2.3), 
the integrity of plasmid DNA was checked running the product of a double 
restriction enzyme digestion on agarose gel (1% p/v).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. (A) schematic map of pcDNA3.1(-)-hDAT; (B) digestion of the purified 
plasmid with restriction enzymes KpnI and XhoI produces a predicted fragment of about 
1900bp. 
 
 
pcDNA3.1(-) - hDAT
7258 bp
hDAT NG 015885 .1
XhoI (1)
KpnI (1903)
~1900 bp 
A) B) 
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3.2.3 Bacteria transformation, growth and plasmid purification 
 
Invitrogen One Shot TOP10® library efficiency chemically competent 
E.Coli were transformed according to manufacter protocols. Briefly, 1µg of 
plasmid DNA was pipetted directly into the vial of competent cells and the 
mixture was incubated 30 minutes on ice. After this phase, the vial was 
incubated for 30 sec in a prewarmed water bath at 42°C and placed in ice for 
3 minutes. 250 µl of pre-warmed S.O.C were then added to the bacteria and 
the mixture was left 1 hour at 225 rpm in a shaking incubator at 37°C. 20 µl to 
100 µl of the transformation vial content were then spread on Luria-Bertani 
(LB) agar plates containing 50µg/ml of the required selection antibiotic and 
dishes were inverted and incubated at 37°C overnight. The day after, newborn 
monoclonal colonies were selected to grow 16 hours in 5 ml of liquid LB 
media; plasmids were then extracted and analyzed by enzymatic restriction 
digestion and sequencing. 
Selected colonies were grown in 5 ml and 100 ml, respectively for mini 
and midi preparations. Plasmids were purified using anion-exchange tips 
provided in a commercial kit (QIAGEN Plasmid Midi Kit) and the extracted 
DNA was quantified by reading the absorbance at 260, 280 e 320 nm. 
 
3.2.4 Transfection and selection of the enginereed eukaryotic 
clones 
 
Both HEK-293 and SH-SY5Y were transfected using the ExGen500 
cationic polymer gene delivery reagent (Fermentas). Specifically, 3.3µl of 
ExGen500 were used to complex 1 µg of plasmid DNA for transfecting 80000 
cells. 
Transiently transfected cells were used 48h after transfection. 
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Stable transfected cells were selected by supplementing the complete 
medium with G418 at the final concentration of 500 µg/ml. Transfected cells 
were then maintained in this conditions and they were used at least 3 weeks 
after selection with G418. 
 
3.2.5 β-galactosidase enzyme assay system 
 
β-galactosidase enzyme assay system was used to evaluate β-
galactosidase activity in lysates prepared from cells transfected with pSV-β-
Gal vector. To estimate β-galactosidase activity, a commercial kit has been 
employed (Beta-Glo® Assay System–Promega). 48 h after transfection with 
pSV-β-Gal, about 150000 cells were lysed by freeze thawing in 200 µl of lysis 
buffer and 50 µl of this lysate were mixed with 50 µl of Beta-Glo® substrate. 
Samples were then incubated for 2 h, allowing the substrate (D-luciferin-o-β-
galactopyranoside) to be cleaved to release luciferin. Luciferin serves as a 
substrate for luciferase that is also present in the reagent. As result of the 
luciferase activity, oxyluciferin is formed with subsequent light emission, 
wich is detected and quantified in a PerkinElmer Victor2 
luminometer/spectrophotometr. The level of pSV-β-Gal plasmid expression is 
directly related to luminescence, expressed in arbitrary luminescence units. 
 
3.2.6 Protein extraction and quantitation 
 
Proteins were extracted using a commercial kit (NE-PER™ Extraction 
reagent; Pierce). Briefly cells were pelleted and resuspended in 100 µL of 
CER I buffer After 10 min incubation on ice, 5.5 µL of CER II buffer was 
added and the mixture was vortexed, incubated on ice for 1 min and then 
resuspended. The cytoplasmic fraction was separated by centrifugation at 
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16000 g for 5 min. Proteins were then quantified using the method of Lowry 
(Lowry et al., 1951). 
 
3.2.7 Western blot experiments 
 
Proteins of the cytoplasmic extract (50 µg) were denatured at 95°C for 3 
min before being loaded and separated by 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). 
We used a MagicMark™ XP Western Standard as molecular weight 
standard. Proteins were then transferred to Protran™ nitrocellulose 
membranes which were blocked with 5% nonfat milk in TBS (10 mM Tris-
HCl, pH 8, containing 150 mM NaCl) plus 0.1% Tween 20 for 2 h at room 
temperature (RT). After washing three times the membrane with TBS, blots 
were probed for 1 h at RT in TBS containing monoclonal ANTI-FLAG™ M5 
antibody (Sigma-Aldrich) at final concentration of 10 µg/ml. The membranes 
were incubated with peroxidase-conjugated secondary antibodies at a dilution 
of 1:10000. Blots were developed with SuperSignal West Pico 
chemiluminescent substrate according to the manufacturer’s protocol 
(Pierce™). Chemiluminescence was acquired using a luminescent image 
analyzer LAS-3000 (Fuji-film™). The membranes were incubated with 
peroxidase-conjugated secondary antibodies at a dilution of 1:2000. Blots 
were finally developed with SuperSignal West Pico chemiluminescent 
substrate according to the manufacturer’s protocol (Pierce™). 
Chemiluminescence was acquired using a luminescent image analyzer LAS-
3000 (Fuji-Film™). 
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3.2.8 DA uptake experiments 
 
[3H]DA assays were performed in 24-wells plates (Corning) precoated 
with poly-L-lysine. Four days before the experiments, 70000 cells were 
seeded in each well of the plate. 24h later, cells were transfected with 
pcDNA3.1(-)-hDAT and then left 48 h in the incubator at 37 °C. The day of 
the experiment, cells were washed once with 1 ml of PBS and incubated for 2 
hours in serum free media. Cells were then washed twice with PBS and 
triplicate wells were pretreated at 37 °C with 300µl of filtered Krebs-Ringer 
HEPES (KRH) buffer (25 mM HEPES, 125mM NaCl, 4.8mM KCl, 1.2mM 
KH2PO4, 1.3mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, pH 7.4) containing 
vehicle, σ ligands, or phosphorylation modulators. σ ligands and PKC 
modulators were added respectively. 1 h and 30 min prior to start the assay for 
DA transport. Compounds were dissolved at high concentration (10-2M) in 
DMSO followed by dilution in KRH buffer to a final DMSO concentration 
range varying from 1% to 0.0000001% v/v. At the end of the pretreatment 
interval, cells were placed on ice and uptake was initiated by adding 3.03 µl of 
a 100X DA stock solution to bring the final concentration of [3H]DA 
(PerkinElmer, 35Ci/mmol) to 10 nM and that of total DA to 3 µM. Control 
wells didn’t receive any treatment and nonspecific uptake was determined in 
the presence of nomifensine 10 µM. Uptake assays were carried out at 37 °C 
for 10 min and terminated by rapidly washing the wells three times with 1 ml 
of ice-cold KRH. Cells were solubilized with 500 µl of a 2% SDS solution 
and lysates were then measured for incorporated radioactivity by liquid 
scintillation after 2 h of incubation in scintillation cocktail.  
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3.2.9 Analysis of data 
 
Data were analyzed with GraphPad Prism® software (version 4.0; 
GraphPad Software Inc., San Diego, CA, USA). 
[3H]DA uptake data were normalized by setting DPM values of controls 
as 100% and of background as 0%. Controls were transfected with 
pcDNA3.1(-)-hDAT and didn’t receive any treatment before being assayed 
for [3H]DA uptake activity. Background data were obtained by measuring 
[3H]DA uptake in cells not transfected cells with the hDAT plasmid and 
treating transfected cells with nomifensine (DAT selective inhibitor) for 30 
minutes at final concentration of 10 µM (see section 3.3.3). 
All data are presented as mean ± standard error of the mean (SEM) for 
the indicated number of experiments. Statistical significance was determined 
by Newman-Keuls test after analysis of variance (ANOVA) using GraphPad 
Prism Prism® software (version 4.0; GraphPad Software Inc., San Diego, CA, 
USA). Newman-Keuls test post ANOVA was used to compare all data versus 
controls and among multiple groups. P-values < 0.05 were considered to be 
significant.  
 
3.2.10 Immunofluorescence and confocal microscopy 
 
70000 cells/well were seeded in a 6-wells plate containing a sterilized 
poly-L-lysine precoated microscope glass coverslip (Carlo Erba). After 48 h 
cells were transfected with pEGFP-C1-hDAT. 48 h after transfection cells 
were incubated incubated for 1 h in serum free medium in presence, or in 
absence of (+)-pentazocine at final concentration of 1 µM and then fixed with 
0.5 ml of a 3% solution paraformaldehyde (PFA) in PBS at 25 °C for 15 
minutes. Fixed cells were then washed three times with a PBS-BSA 3% 
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solution and permeabilized in 70% ice-cold ethanol for 3 minutes. After 
washing three times with PBS-BSA 3%, samples were incubated 2h at RT in 
PBS-BSA 3% containing monoclonal mouse ANTI-FLAG™ M2 antibody 
(Sigma-Aldrich) at final concentration of 1 µg/ml. Cells were washed three 
times with PBS-BSA 3% and incubated for 1h at RT with PBS-BSA 3% 
containing 4',6-diamidino-2-phenylindole (DAPI) at final concentration of 
300 nM to stain nuclei and CF™555 goat anti-mouse anti-mouse secondary 
antibody (Biotium) at final concentration of 7 µg/ml. Cells were washed three 
times with with PBS-BSA 3% and coverslip were mounted onto a preclean 
slide (Carlo Erba) using ProLong® Gold Antifade Reagent (Invitrogen) as 
mounting media. Mounted slides were left overnight at RT in the dark and 
then analyzed by confocal microscopy using a Nikon C1si equipped with 
Nikon eclypse TE300 confocal laser-scanning microscope. 
DAPI, EGFP and CF™555 secondary antibody were excited respectively 
at 405 nm, 488 nm and 543 nm and multiple images were were detected 
respectively at 450 nm, 515 nm and 605 nm. 
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3.3 Controls employed to validate experimental groups 
 
Several controls were performed to validate the experimental procedure 
adopted to investigate cell [3H]DA uptake and cell viability. 
 
3.3.1 Validation of transfection techniques using β-galactosidase 
enzyme assay system 
 
Efficiency of transfection conditions was checked by the β-galactosidase 
enzyme assay system (See section 3.2.5). 
A) 
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Figure 3.4. β-galactosidase activity in native cells (Not transfected), in cells transfected 
with pSV-β-Gal vector alone and in cells stably overexpressing hσ1 transfected with the 
pSV-β-Gal vector. A) results on HEK-293 cell line; B) results on SH-SY5Y cell line. 
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Results of β-galactosidase assays are reported in figure 3.4. In both HEK-
293 and SH-SY5Y cell lines, transiently transfected with pSV-β-Gal, 
produced luminescence is 3 times higher than in not transfected controls. This 
result indicates that β-galactosidase is overexpressed only in cells that 
received the pSV-β-Gal plasmid. Moreover, these data indicate that following 
transient transfection with pSV-β-Gal vector, expression of β-galactosidase in 
cells stably transfected with hσ1 receptor does not change in comparison to 
cells transfected with pSV-β-Gal vector alone. Thus, the expression of β-
galactosidase is not influenced by the presence of pCMV6 Entry-hσ1 vector. 
Transfection conditions optimized with pSV-β-Gal were then used in 
experiments done on cells transfected with pcDNA3.1(-)-hDAT plasmid. 
 
3.3.2 Western blot of stably expressed hσ1–FLAG fusion protein 
 
Overexpression of fusion protein hσ1–FLAG was confirmed with western 
blot experiments. Cells overexpressing hσ1 were then selected and used in 
experiments. 
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Figure 3.5. Western blot of HEK-293 and SH-SY5Y stably expressing hσ1-FLAG fusion 
protein compared to not transfected (NT) cells.  
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3.3.3 Topology and expression analysis of EGFP-hDAT and hσ1 
in HEK-293 by confocal microscopy  
 
In the experiments, nuclei were stained with DAPI, which emission falls 
in blue wavelength range. 
Not transfected control are not showed because in these cells any green-
shifted fluorescence was detectable. 
Since EGFP-hDAT fusion protein is able to produce fluorescence alone 
while excited at 488 nm, its detection doesn’t need conjugation with any 
secondary fluorescent antibody (Fig.3.6).  
 
 
 
Figure 3.6. Confocal images of HEK-293 transiently transfected with pEGFP-C1–hDAT; 
A) image of EGFP-hDAT alone; B) merged image of nucleus marker (blue) and EGFP-
hDAT (green); note that EGFP-hDAT fluorescence appears predominantly near the cell 
surface. 
 
These experiments confirm that HEK-293 cells transiently transfected 
with the pEGFP-C1–hDAT plasmid express the fluorescent fusion protein. 
Noteworthy, EGFP-hDAT appears mainly located on the plasma membrane 
level suggesting that the expressed protein is a functional membrane 
transporter. 
A) 
B) 
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As it concerns the detection of hσ1-FLAG, this fusion protein requires 
conjugation with a fluorescent probe in order to be detected by confocal 
microscopy. A red-shifted secondary antibody was choosen as it doesn’t 
interfere with blue DAPI and green EGFP fluorofores. 
 
 
 
Figure 3.7. Confocal images of HEK-293 stably transfected with pCMV6 Entry–hSigma1. 
A) separated images of nuclei stained with DAPI (blue) and hσ1-FLAG receptors labeled 
with a fluorescent probe (red); B) merged image of nucleus and hσ1-FLAG receptor 
markers; note that hσ1-FLAG receptors fluorescence appears predominantly in the 
cytoplasm. 
 
These experiments confirm the stable expression of hσ1-FLAG fusion 
protein. According to previously described subcellular localization of rat σ1 
receptors (see section 1.4.2), overexpressed hσ1 receptors are mainly localized 
in the cytoplasm and less around the cell membrane. 
Cootransfection of both EGFP-hDAT and hσ1-FLAG fusion proteins was 
also confirmed by confocal microscopy techniques. As showed in figure 3.8, 
both the proteins are expressed in double transfected clones. 
 
A) 
B) 
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Figure 3.8. Confocal images of HEK-293 cootransfected with pCMV6 Entry–hSigma, and 
-C1–hDAT; A) separated images of nuclei stained with DAPI (blue), hσ1-FLAG receptors 
labeled with a fluorescent probe (red) and EGFP-hDAT (green); B) merged image of 
nucleus and hσ1-FLAG receptor markers and EGFP-hDAT; note that hσ1-FLAG receptors 
fluorescence appears predominantly in the cytoplasm whereas EGFP-hDAT appears 
mainly located on the plasma membrane. 
 
3.3.4 Set up of [3H]DA uptake assay 
 
[3H]DA uptake assays were performed in order to check if native HEK-
293 and SH-SY5Y possess a basal uptake activity of the [3H]DA and if, once 
transfected with pcDNA3.1(-)-hDAT, they are able to express a functional 
protein capable to elevate [3H]DA uptake. Thus, uptake abilities of not 
transfected (NT) cells or of cells transfected with pcDNA3.1(-) empty vector 
and of cells transfected with pcDNA3.1(-)-hDAT were compared counting the 
recovered radioactivity after 10 minutes of incubation at 37°C in KRH buffer 
containing the [3H]DA. 
 
A) B) 
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Figure 3.9. DPM values retrieved in three different clones of A) results on HEK-293, data 
are presented as mean ±SEM of two independent experiments (carried out in triplicate); B) 
results on SH-SY5Y, after 10 minutes of incubation at 37°C with [3H]DA in KRH buffer 
data are presented as mean ±SEM of two independent experiments (carried out in 
triplicate). 
 
Since radioactivity recovered in cells transfected with pcDNA3.1(-)-
hDAT is extremely higher compared to controls that did not receive this 
plasmid, experiments showed in figure 3.6 confirm that uptake of extracellular 
[3H]DA depends on hDAT activity. Noteworthy, in transfected HEK-293 
(HEK-293-hDAT) the retrieved radioactivity was higher than in transfected 
SH-SY5Y (SH-SY5Y-hDAT) (15000 DPM vs 2700 DPM) whereas 
background was almost the same in both cell lines (~600 DPM). This 
difference between HEK-293-hDAT and SH-SY5Y-hDAT is mainly to 
ascribe to transfection efficiency, which is known to be pretty much lower in 
SH-SY5Y. Before to start to perform uptake assays to test the interactions 
between σ1 receptors and hDAT, method validation was to examine the 
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responsiveness of this system to DAT substrates, known to alter its activity 
and expression. 
 
 
*** = P<0,001 vs HEK-293-hDAT control (Newman-Keuls’s test post ANOVA)
# # # = P<0,001 vs HEK-293 hσ1 + hDAT control (Newman-Keuls’s test post ANOVA)
$ $ $ = P<0,001 vs HEK-293-hDAT treated with staurosporine 10 µM + PMA 1 µM (Newman-Keuls’s test post ANOVA)
§ § § = P<0,001 vs HEK-293 hσ1 + hDAT treated with staurosporine 10 µM + PMA 1 µM (Newman-Keuls’s test post ANOVA)
 
 
 
*** = P<0,001 vs SH-SY5Y hDAT control (Newman-Keuls’s test post ANOVA)
# # # = P<0,001 vs SH-SY5Y hσ1 + hDAT control (Newman-Keuls’s test post ANOVA)
$ $ $ = P<0,001 vs SH-SY5Y hDAT treated with staurosporine 10 µM + PMA 1 µM (Newman-Keuls’s test post ANOVA)
§ § § = P<0,001 vs SH-SY5Y hσ1 + hDAT treated with staurosporine 10 µM + PMA 1 µM (Newman-Keuls’s test post ANOVA)  
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Figure 3.10. Effect of nomifensine, PMA and staurosporine on [3H]DA uptake in A) results 
on HEK-293, data are presented as mean ±SEM of four independent experiments (carried 
out in triplicate); B) results on SH-SY5Y, data are presented as mean ±SEM of two 
independent experiments (carried out in triplicate). 
 
Nomifensine is a known DA reuptake inhibitor (Meiergerd and Schenk, 
1994); as displayed in figure 3.7 nomifensine at 1 µM completely blocked 
reuptake of extracellular DA in both HEK-293 and SH-SY5Y and retrieved 
radioactivity was reduced to not transfected (NT) level. 
PMA is known to reduce in vitro the Vmax of [3H]DA uptake by 
approximately 40% vs control: an effect blocked by the protein kinase 
inhibitor staurosporine (Pristupa et al., 1998). As it’s shown in Fig.3.7, in cells 
transfected with pcDNA3.1(-)-hDAT, PMA and staurosporine cause the same 
effects described in literature.  
These results demonstrate that the expressed recombinant hDAT is 
actively working and the conditions optimized for these experiments were 
used to assay σ receptors ligand and to study their modulation on hDAT 
activity. Nomifensine, at final concentration of 1 µM, was choosen to estimate 
background radioactivity in uptake experiments. 
 
3.3.5 Effect of vehicle on [3H]DA uptake  
 
Since most of σ ligands are lipophilic, DMSO was choosen as the veihcle 
to solubilize these drugs were primarily solubilized at 10-2 M stock solution. 
Further diluitions were performed in sterile KRH buffer. Thus, when σ 
ligands were employed at final concentrations at 100 µM, 10 µM, 1 µM, 0.1 
µM and 0.01 µM, concentration of DMSO, expressed in % v/v, was 
respectively 1%, 0.1%, 0.01%, 0.001% and 0.0001%. Effect of 1h incubation 
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with these concentration of DMSO on [3H]DA was also checked before 
assaying the σ ligands. 
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Figure 3.11. Effect of different concentrations of DMSO alone on [3H]DA uptake.  
 
In HEK-293 and SH-SY5Y, DMSO interfered with uptake only when 
used at 1% v/v. DMSO toxicity is probably the cause of reduction of [3H]DA 
uptake observed with 1% (v/v) of DMSO alone; in fact, after 1 h of treatment, 
cells that received 1% (v/v) of DMSO were detached from the well, floating, 
then in the medium. 
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3.4 Results 
 
3.4.1 Effect of (+)-pentazocine on [3H]DA uptake 
 
The first σ ligand employed in [3H]DA uptake assays was (+)-
pentazocine, the prototype of σ1 agonists, which possess high affinity for σ1 
binding sites (Ki = 16.7 nM) (Fig.3.8).  
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Figure 3.12. Effect of different concentrations of (+)-pentazocine on [3H]DA uptake in A) 
results on HEK-293, data are presented as mean ±SEM of five independent experiments 
(carried out in triplicate); B) results on SH-SY5Y, data are presented as mean ±SEM of 
two independent experiments (carried out in triplicate). 
 
(+)-pentazocine, concentration-dependently increases the uptake of 
[3H]DA in cells stably overexpressing hσ1, with a maximum increase of about 
40% over the basal values. Interistingly, concentration-response studies 
showed a different trend between HEK-293 and SH-SY5Y cell lines.  
In kidney derived cells, the maximum effect of (+)-pentazocine was 
observed at 0.1 µM. At 0.01 µM (+)-pentazocine was less effective and 
inactive at 1 nM. Considering that Ki of (+)-pentazocine for σ1 receptor falls 
in nM range (Tab 1.1), it’s interesting to note that the more active 
B) SH-SY5Y 
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concentrations of the σ1 agonist (0.1 µM) is higher than expected. To explain 
this, subcellular localization of σ receptors might be taken in account. At 
resting state, σ1 receptors are cytoplasmatic proteins, mainly concentrated in 
ER lipid rafts. Thus ligands have to cross cells plasmalemma either passively 
or transported by membrane carriers in order to reach their target. In addition, 
it has been often reported that high concentrations are required to activate σ1 
receptors (Gudelsky et al., 1995 and 1999; Moison et al., 2003). 
In neuroblastoma derived cells, concentration-response curve of (+)-
pentazocine better fits with its calculated Ki. In fact, in the SH-SY5Y model, 
the maximum effect was reached at (+)-pentazocine was used at final 
concentration of 1 nM. Thus it appears that SH-SY5Y appear to be more 
sensitive to (+)-pentazocine than HEK-293. 
 
3.4.2 Effects of (-)-pentazocine on [3H]DA uptake 
 
Since the (-) isomer of pentazocine possess a 50 time lower affinity for σ1 
receptors (Tab.1.1), in cells cotransfected with hσ1 receptor and hDAT 
concentration-effect curves of (-)-pentazocine were obtained in order to 
confirm the specific involvement of overexpressed hσ1 receptors in the 
reported actions of (+)-pentazocine.  
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Figure 3.13. Comparison between effects of (+)- and (-)-pentazocine on [3H]DA uptake in 
A) results on HEK-293, data are presented as mean ±SEM of four independent 
experiments (carried out in triplicate); B) results on SH-SY5Y, data are presented as mean 
±SEM of two independent experiments (carried out in triplicate). 
 
(-)-pentazocine was not able to increase [3H]DA uptake in HEK-293 and, 
in SH-SY5Y, calculated EC50 for (–)-pentazocine is 322-fold higher than EC50 
calculated for its (+) isomer. These results are in line with the low affinity of 
(-)-pentazocine for σ1 receptors and demonstrate the specific involvement of 
overexpressed hσ1 in modulating hDAT [3H]DA uptake. 
 
3.4.3 Effects of σ1 antagonists 
 
Effects of σ antagonists BD-1047 and NE-100 on [3H]DA uptake were 
also evaluated in presence and in absence of (+)-pentazocine. 
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Figure 3.14. Effects of σ antagonists on [3H]DA uptake; A) results on HEK-293, data are 
presented as mean ±SEM of three independent experiments (carried out in triplicate); B) 
results on SH-SY5Y, data are presented as mean ±SEM of two independent experiments 
(carried out in triplicate). 
 
BD-1047 and NE-100 alone did not affect hDAT activity and it is 
relevant that these classics σ1 antagonists were able to prevent the activation 
of hσ1 by (+)-pentazocine. These results further confirm the specific 
involvement of transfected hσ1 as effector of (+)-pentazocine effects.  
 
3.4.4 Effects of SM-21  
 
To evaluate any interference of endogenous σ2 receptors, the σ2 selective 
agonist SM-21 was also tested.  
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Figure 3.15. Effects of σ2 selective agonist SM-21 at 1 µM on [3H]DA uptake in A) results 
on HEK-293; B) results on SH-SY5Y. 
 
As showed in figure 3.15, pretreatment with SM-21 slightly reduces 
[3H]DA uptake both in HEK-293 and SH-SY5Y native or stably 
overexpressing hσ1 receptors. Since in these experiments σ2 receptors 
A) B) 
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recruitment could induce the opposite effect observed for the 1 subtype of σ 
receptors family, it would be interesting in the future to better characterize 
this feature. However data are not statistically significative and thus, in this 
thesis, SM-21 effects aren’t further discussed. 
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CHAPTER 4, 
 
 
FUNCTIONAL CONSEQUENCES OF 
σ1 -MEDIATED INCREASE OF 
DOPAMINE UPTAKE 
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4.1 Aim of the study 
 
Uptake assays shown in chapter 3 demonstrate that in HEK-293 and in 
SH-SY5Y hσ1 receptors activation by (+)-pentazocine positively modulates 
the hDAT uptake. 
As described in section 2.7.1, DA is likely to be considered a neurotoxic 
molecule. In fact, when as consequence of exposure to toxic agents 
intracellular levels of DA abnormally increase, vescicles can’t sequester the 
DA which is metabolized by MAO (A and B) and COMT with consequent 
overproduction of oxygen reactive species and toxic catabolites (Hastings, 
1995, Hastings et al., 1996). Stress induced by these molecules leads cells to 
death. 
For the second part of this thesis, experiments have been performed in 
order to investigate functional alterations caused by the (+)-pentazocine-
mediated increase of DA uptake; particularly it has been investigated if the 
increase of intracellular [DA] could affect cells viability. 
Basal toxicity of DA was first evaluated in native cells and in cells 
transiently transfected with pcDNA.31-hDAT. Once obtained control values, 
a molecular screening has been performed to elucidate relationship between 
σ1 agonists and antagonists and uptaken DA toxicity. 
Cells viability was estimated using the MTT assay, described in section 
4.2.1. 
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4.2 Methods 
 
Cells culture, transfections conditions and controls are described in 
chapter 3, section 3.2.  
 
4.2.1 MTT viability assay 
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is 
a light sensitive yellow salt, highly soluble in water and in phosphate-buffered 
saline (PBS) which is reduced to unsoluble purple formazan in living cells. 
These reductions take place only when mithocondrial reductase enzymes are 
active; since these enzymes are active only in undamaged cells, this 
conversion is used as a measure of cellular viability. Purple formazan is 
soluble in lipophilic solvents, such as DMSO and isopropyl; the dissolved 
formazan produces a purple solution and absorbance of this colored solution 
can be quantified by measuring it between 500 and 600 nm by a 
spectrophotometer. Thus, when the amount of purple formazan produced by 
treated cells is compared with the amount of formazan produced by untreated 
controls, the effectiveness of the treatment in causing death can be deduced 
through the production of a dose-response curve. 
Viability assays were performed in 24-wells plates (Corning) precoated 
with poly-L-lysine. Five days before viability assays, 70000 cells were seeded 
in each well of the plate. 24h later, each well was transfected with 
pcDNA3.1(-)-hDAT. 48h after transfection, HEK-293 and SH-SY5Y were 
then treated with different concentration of DA and σ ligands, diluted in 
respective cell medium. Cell toxicity was evaluated 24h after treatments with 
the colorimetric MTT viability assay. Optimized conditions used in this 
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research are following reported. Exactly 24h after treatments, cells were 
washed two times with PBS and, in each well, medium was substituted with 
500 µl of a 200 µM solution of MTT in sterile PBS and the plate was 
incubated 1,5h at 37°C. After incubation, plates were centrifuged for 30 
minutes at 2600 g in a Beckman Coulter ™ Allegra 25 R centrifuge, using a 
plate rotor to precipitate formazan. Surnatant was rapidly eliminated and 
formazan was solubilized by adding 500 µl of DMSO in each well. 24-wells 
plates were shaked for 1h on a plate shaker at 250 rpm and absorbance was 
directly measured in a PerkinElmer Victor2 luminometer/spectrophotometr 
(545 nm). 
 
4.2.2 Data analysis  
 
Data were analyzed with GraphPad Prism® software (version 4.0; 
GraphPad Software Inc., San Diego, CA, USA). 
Viability data were normalized by setting absorbance values of controls 
as 100% and of background as 0%. Controls were transfected with 
pcDNA3.1(-)-hDAT and didn’t receive any treatment before being assayed 
for MTT conversion in formazan. Background data were obtained treating 
cells with DA at final concentration of 5 mM. In fact, while using such high 
concentration of DA, spontaneous oxidation of the catecholamine is enough to 
kill all treated cells. 
All data are presented as mean ± standard error of the mean (SEM) for 
the indicated number of experiments. Statistical significance was determined 
by Newman-Keuls test post ANOVA using GraphPad Prism Prism® software 
(version 4.0; GraphPad Software Inc., San Diego, CA, USA). Newman-Keuls 
test post ANOVA was used to compare all data versus controls and among 
multiple groups. P-values < 0.05 were considered to be significant.  
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4.2.3 Set up of viability assays 
 
Viability assays were primarly performed in order to check the toxicity 
of DA at different concentration in native HEK-293 and SH-SY5Y, or in cells 
transiently transfected with pcDNA3.1(-)-hDAT.  
Native cells are not able to uptake extracellular DA and then the 
catecholamine toxicity should be ascribed mainly to autoxidation of the 
molecule. Once transfected with hDAT, cells gain the ability to inwardly 
transport the DA and uptaken DA is metabolized to release toxic species 
directly in the cytoplasmatic lumen.  
A first set of experiments was performed to demonstrate that transfected 
cells are more sensitive to DA toxicity (Fig.5.1) 
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A) HEK-293 
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Figure 4.1. Toxicity of different concentration of DA in three different cell clones after 24h 
of incubation. A) HEK-293 the data are presented as mean ±SEM of four independent 
experiment (carried out in triplicate); B) SH-SY5Y 293 the data are presented as mean 
±SEM of two independent experiments (carried out in triplicate). 
 
As evinced from EC50 values, DA is more toxic in cells transfected with 
hDAT. In addition, SH-SY5Y are more sensitive to DA than HEK-293. This 
is probably due to a different DA metabolism efficiency, wich is higher in the 
neuronal- than in the kidney-derived cell line. 
To confirm the role of DA uptake and metabolism in mediating DA 
toxicity, cells transfected with hDAT were exposed to lethal concentrations of 
DA (1 mM for HEK-293, 500 µM for SH-SY5Y) in presence and in absence 
of nomifensine, a DAT selective inhibitor and of selegiline, a MAO-B 
inhbitor, at the final concentration of 1 µM. 
 
 
B) SH-SY5Y 
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Figure 4.2. Protective effect of nomifensine and selegiline in presence of toxic 
concentration of DA. A) HEK-293 the data are presented as mean ±SEM of two 
independent experiments (carried out in triplicate); B) SH-SY5Y the data are presented as 
mean ±SEM of two independent experiments (carried out in triplicate). 
 
When cells are exposed to DA in the presence of nomifensine, viability is 
increased of about 40% in HEK-293 and of about 60% in SH-SY5Y, in 
comparison to cells exposed to DA alone. Protective activity of nomifensine 
confirms the role of cell uptake in mediating DA toxicity. Moreover, 
selegiline is able to decrease the mortality rate; this last finding indicates that, 
in both the cell lines, oxidative metabolism of DA contribute to the toxicity of 
this catecholamine. 
However, viability never reaches the control values. This is due to the 
autoxidation of DA wich produces toxic species. Thus, the concentrations of 
DA used to estimate σ1 contribution to cell toxicity were choosen in order to 
reduce the DA autoxidation counterpart.  
 
A) HEK-293 B) SH-SY5Y 
Aim of the study, methods and results – Chapter 4 
 - 184 - 
4.2.4 Effect of vehicle on cell viability 
 
As previously reported (see section 3.3.5), most of σ ligands are 
lipophilic, thus DMSO was choosen as veihcle to solubilize drugs at 10-2 M as 
stock solution. Further diluitions were performed in sterile media. When σ 
ligands were employed at 100µM, 10µM, 1µM, 0.1µM and 0.01µM, 
concentration of DMSO, expressed in % v/v, was respectively 1%, 0.1%, 
0.01%, 0.001% and 0.0001%. Effect of 1h incubation with these 
concentration of DMSO alone on cell viability was also checked (Fig.5.3) 
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Figure 4.3. Effect of DMSO on cellular viability; A) HEK-293 the data are presented as 
mean ±SEM of two independent experiments (carried out in triplicate); B) SH-SY5Y the 
data are presented as mean ±SEM of two independent experiments(carried out in 
triplicate). 
 
DMSO is toxic when used at the concentration of 1% v/v in both HEK-
293 and SH-SY5Y 
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4.3 Results 
 
4.3.1 Effects of (+)-pentazocine on DA toxicity 
 
Data acquired to set up viability assays were used to choose the 
concentrations of DA used in first set of experiments, wich are respectively 
500 µM for HEK-293 and 150 µM for SH-SY5Y. These concentrations are 
slightly lower than EC50 and allow to estimate the σ1 contribution to cell 
toxicity avoiding any interference induced by DA autoxidation alone. (+)-
pentazocine was used at 1 µM in both cell lines. 
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# # # = P<0,001 vs HEK-293 hDAT + (+)-pentazocine 1 µM + DA 500 µM (Newman-Keuls’s test post ANOVA)
*** = P<0,001 vs HEK-293 hσ1 + (+)-pentazocine 1 µM + DA 500 µM (Newman-Keuls’s test post ANOVA)
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# # = P<0,01 vs SH-SY5Y hDAT + (+)-pentazocine 1 µM + DA 150 µM (Newman-Keuls’s test post ANOVA)
** = P<0,01 vs SH-SY5Y hσ1 + (+)-pentazocine 1 µM + DA 150 µM (Newman-Keuls’s test post ANOVA)
 
 
Figure 4.4. Effect of (+)-pentazocine at the concentration of 1 µM on DA toxicity; A) 
HEK-293 the data are presented as mean ±SEM of five independent (carried out in 
triplicate); B) SH-SY5Y the data are presented as mean ±SEM of two independent 
experiments (carried out in triplicate). 
 
(+)-pentazocine at 1 µM is able to increase the toxicity of the DA only in 
cells co-expressing both hσ1 receptor and hDAT. The increase of DA cell 
toxicity is to ascribe only to hσ1 receptor activation. 
EC50 curves were also obtained for the σ1 agonist treating the cells with 
different concentrations of (+)-pentazocine, in presence of a fixed 
concentration of DA, respectively 500 µM for HEK-293 and 150 µM for SH-
SY5Y. 
 
 
 
B) SH-SY5Y 
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A) HEK-293 
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Figure 4.5. EC50 curves of (+)-pentazocine obtained in presence of a fixed concentration 
of DA; A) HEK-293, concentration of DA was 500 µM, the data are presented as mean 
B) SH-SY5Y 
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±SEM of four independent experiments (carried out in triplicate); B) SH-SY5Y, 
concentration of DA was 150 µM, the data are presented as mean ±SEM of two 
independent experiments (carried out in triplicate). 
 
In both HEK-293 and SH-SY5Y, EC50 values of cells transfected with 
hDAT alone are almost superimposable to EC50 of cells transfected with hσ1 
alone. In these case the toxicity seems to be mediated exclusively by the 
vehicle (see also Fig. 5.3); therefore these results indicate that (+)-pentazocine 
alone is not toxic in this model. In cells expressing both hσ1 and hDAT, 
toxicity of DA is increased by (+)-pentazocine in a concentration-dependent 
manner. These data strongly support the involvement of hσ1 receptors. 
However, to further confirm the role of the stably overexpressed protein, 
effects of σ1 selective antagonists BD-1047 and NE-100 were also evaluated 
in presence and in absence of (+)-pentazocine. 
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# # # = P<0,001 vs HEK-293 hDAT + hσ1 + NE-100 + (+)-pentazocine 1 µM + DA 500 µM (Newman-Keuls’s test post ANOVA)
*** = P<0,001 vs HEK-293 hDAT + hσ1 + BD-1047 + (+)-pentazocine 1 µM + DA 500 µM (Newman-Keuls’s test post ANOVA)
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Figure 4.6. σ1 selective antagonists BD-1047 and NE-100 block (+)-pentazocine-induced 
increase of DA toxicity; A) HEK-293, the data are presented as mean ±SEM of four 
independent experiments (carried out in triplicate); B) SH-SY5Y, the data are presented as 
mean ±SEM of two independent experiments (carried out in triplicate). 
 
As showed in figure 5.6, both BD-1047 and NE-100 are not toxic when 
used alone at the concentration of 1 µM and they are able to revert the (+)-
pentazocine-induced increase of DA cell toxicity. These data confirm that 
when overexpressed hσ1 receptors, (+)-pentazocine mediates the observed 
alteration of cell susceptibility to DA toxicity. 
In conclusion, it has been shown that (+)-pentazocine increases DA cell 
toxicity in a concentration-dependent manner only in cells co-expressing hσ1 
and hDAT. σ1 selective antagonists are able to block the action of the agonist 
(+)-pentazocine. Since it has been demonstrated in chapter 3 that hσ1 
B) SH-SY5Y 
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receptors activation enhances the hDAT uptake activity, the observed (+)-
pentazocine-mediated increase of DA cell toxicity is likely to be induced by 
raised intracellular DA levels. 
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CONFOCAL MICROSCOPY STUDIES 
 
Aim of the study, methods and results – Chapter 5 
 - 194 - 
5.1 Aim of the study 
 
The described cross-talking between hσ1 receptor and hDAT has been 
further investigated using confocal microscopy. Methods are described in 
section 3.2.10 and results are presented in next section (5.2). 
 
 
5.2 Results 
 
Confocal images were first taken to validate the experimental conditions 
and to verify if HEK-293 cells transfected with pEGFP-C1-hDAT and 
pCMV6 Entry-hSigma-1 plasmids were able to express the proteins under 
investigation. Results of these control experiments are shown in section 3.3.3. 
Following studies were performed in order to describe molecular 
dynamics underlying the σ1-mediated increase of DA uptake. Four 
experimental groups have been then established: 
 
 
 
 
 
 
 
 
Group # EGFP-hDAT 
hσ1-
FLAG 
(+)-pentazocine 1 µM 
(1h pretreatment) 
1) + - - 
2) + - + 
3) + + - 
4) + + + 
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5.2.1 Confocal images of groups 1) and 2) 
 
Uptake studies performed in HEK-293 and detailed in chapter 3 
demonstrate that the modulation of DA uptake activity induced by (+)-
pentazocine is observed only in cells stably expressing the hσ1 receptors. For 
this reason groups 1) and 2) were employed as negative controls, to check if 
(+)-pentazocine is able to modify the distribution of EGFP-hDAT in absence 
of overexpressed hσ1 receptors. Confocal images of these group are reported 
in figure 5.1. 
 
 
 
 
 
 
Group 2) 
Group 1) 
A) 
B) 
A) 
B) 
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Figure 5.1. Confocal images of group 1) and 2); A) separated images of nuclei stained 
with DAPI (blue) and EGFP-hDAT (green); B) merged image of nucleus and hσ1-FLAG 
receptor markers; note that, in both 1) and 2) groups, EGFP-hDAT fluorescence appears 
predominantly in near the cell surface. 
 
In both groups, EGFP-hDAT appears mainly distributed on 
plasmalemma, but a slight green emission is detectable also in the cytoplasm; 
however it is impossible to distinguish if this cytoplasmatic fluorescence is 
due to background, or it is given by intracellular recycled transporters. In 
conclusion, no differences are detectable between group 1) and 2). 
 
5.2.2 Confocal images of groups 3) and 4) 
 
Comparison of images acquired for group 3) and 4) allows to acquire 
more clear data. 
 
 
Group 3) 
A) 
B) 
C) 
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Figure 5.2. Confocal images of group 3); A) separated images of nuclei stained with DAPI 
(blue), hσ1-FLAG receptors labeled with a fluorescent probe (red) and EGFP-hDAT 
(green); B) merged image of nucleus and hσ1-FLAG receptor markers and EGFP-hDAT; 
C) merged image of labeled hσ1-FLAG receptor and EGFP-hDAT, color is due to 
colocalization of the green and the red fluorescence; note that hσ1-FLAG receptors 
fluorescence appears predominantly in the cytoplasm whereas EGFP-hDAT appears 
mainly located on the plasma membrane. However a slight green emission is detectable 
also in the cytoplasm. 
 
 
 
 
Group 4) 
A) 
B) 
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Figure 5.3. Confocal images of group 4); A) and C) separated images of nuclei stained 
with DAPI (blue), hσ1-FLAG receptors labeled with a fluorescent probe (red) and EGFP-
hDAT (green); B) merged image of nucleus and hσ1-FLAG receptor markers and EGFP-
hDAT; D) merged image of nucleus marker and EGFP-hDAT; E) merged image of labeled 
hσ1-FLAG receptor and nucleus; F) merged image of labeled hσ1-FLAG receptor and 
EGFP-hDAT, yellow color is due to colocalization of the green and the red fluorescence; 
note that in the group 4) (exposed to (+)-pentazocine for 1 h) hσ1-FLAG receptors 
fluorescence is more distributed on the plasma membrane, in comparison to the untreated 
group 3). Also EGFP-hDAT green fluorescence appears more concentrated on 
plasmalemma in comparison to group 3). In addition, note that green and red fluorescence 
colocalize at cell surface level. 
 
By comparing group 3) and group 4), redistribution of hσ1 receptor 
(stained in red) is clear. In fact, in non treated cells, hσ1 receptors are mainly 
concentrated in the cytoplasm (see also picture 3.7). Following exposure to 
C) 
D) 
E) 
F) 
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(+)-pentazocine, the red stained protein massively translocates towards the 
plasma membrane. 
As far as it concerns the EGFP-hDAT, if we compare the image of group 
3) with the images of group 4), hDAT seems to be more located at plasma 
membrane level in cells pretreated with (+)-pentazocine. 
In addition, hσ1 and hDAT appear to colocalize both in treated and in 
non-treated cells. Thus, in conclusion, these confocal studies show that 
pretreatment with (+)-pentazocine induce a redistribution of intracellular hσ1 
receptors and suggest that the observed increase of [3H]DA uptake could be 
mediated by a hσ1 redistribution from the cytoplasm to the cell membrane 
where hDAT is localized. 
 
 
 DISCUSSION 
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6.1 Discussion 
 
The concept of sigma (σ) receptors was first introduced in literature by 
Martin and colleagues (Martin et al., 1976), up to now, numerous studies have 
tried to unrevail their role in neuronal transmission. This study reports for the 
first time that in two cells model, HEK-293 and SH-SY5Y cells, hσ1 receptor 
is able to modulate the DA uptake mediated by hDAT. 
Results illustrated in this thesis demonstrate that activation of 
overexpressed hσ1 receptors by (+)-pentazocine, the σ1 agonist prototype, 
determines an increase of 40% of the extracellular [3H]DA uptake, in 
comparison to non-treated controls. The hypothesis that this effect is mediated 
by the hσ1 receptors is confirmed by results obtained in uptake assays, 
hereafter reported: 
 
1) (+)-pentazocine mediates the increase of [3H]DA uptake only in cells 
stably transfected with the vector encoding for the fusion protein hσ1-
FLAG. EC50 value obtained for the σ1 agonist in HEK-293 cell line is 
higher than the EC50 obtained in SH-SY5Y. This difference is mainly 
to ascribe to the different nature of these cells. 
2) (-)-pentazocine, wich has a 42 lower affinity for σ1 than its (+) isomer, 
is not able to increase the [3H]DA uptake in HEK-293. In SH-SY5Y, 
calculated EC50 for (-)-pentazocine is 322 fold higher than EC50 
calculated for the (+)-pentazocine. These results are in line with the 
different affinity of (+)-and (-) isomers of pentazocine for the σ1 
receptors.  
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3) In both the cell lines, the σ1 antagonists BD-1047 and NE-100 prevent 
the positive effect of (+)-pentazocine on DA reuptake; these 
compounds had no effect on uptake if used alone. 
Involvement of σ1 receptors in the modulation of extracellular levels of 
DA has been previously described in vivo (Gudelsky, 1999; Moison et al., 
2003). In these studies, intrastriatal infusion of σ1 receptors agonists, 
particularly (+)-pentazocine, produced a biphasic effect on extracellular DA 
concentration, consisting in a rapid increase, during the first thirty minutes, 
followed by a more prolonged and marked decrease (Fig.1.6 A and B) 
(Gudelsky 1999; Moison et al., 2003). The biphasic effect is mainly evident 
when higher concentrations of the σ1 ligand are administered. At lower doses, 
the σ1 agonists definitely appear to reduce the extracellular [DA] (Gudelsky 
1999; Moison et al., 2003). According to these observations, in the rat 
intravenous administration of σ agonists decreases the firing rate of rats DA 
neurons (Steinfels et al., 1989; Minabe et al., 1999) and this reduction is 
prevented by the σ1 antagonist NE-100. The σ-mediated reduction of 
extracellular [DA] has been related to inhbition of release of this 
catecholamine. However, the hypothesis that σ1 receptors may also increase 
the DA uptake has never been investigated. Results showed in this Ph.D. 
dissertation are partially in line with what has been previously reported by 
Gudelsky and Minabe. In fact, the σ1-mediated increase of [3H]DA uptake 
could represent another mechanism by which (+)-pentazocine regulates the 
extracellular [DA] in vivo. 
In the experimental model adopted in this study, as expected, the major 
activity of σ1 selective antagonists BD-1047 and NE-100 was to block the 
effects of the agonist and, hence, they prevented the (+)-pentazocine-induced 
increase of the [3H]DA uptake. σ1 antagonists have been investigated for the 
treatment of psychostimulant abuse since they are able to block several 
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cocaine and amphetamine mediated effects, like sensitization, relapse, 
iperlocomotion and overdose death (Maurice et al., 2002). These drugs are 
also able to directly bind the σ1 receptors at micromolar concentrations, 
achievable following their in vivo administration (Maurice et al., 2002). As 
widely described in the literature (see section 2.6.2), both cocaine and 
amphetamine act increasing the extracellular DA concentrations, which is 
thought to mediate the rewarding and reinforcing properties of these drugs. 
Thus, it is not easy to fit our results with these axioms, because in our models 
the σ1 agonist actually reduces the extracellular level of DA instead of 
increase it and σ1 antagonists would even prevent this decrease. 
In the attempting to explain these discrepancies, it is necessary not to 
consider the dopaminergic system as the only target of σ1 receptors. In fact, as 
described in chapter 1, activation of σ1 receptors may alter several 
neurotransmitter systems, such as the cholinergic, noradrenergic, GABAergic, 
serotoninergic and glutammatergic systems. This thesis describes a cross 
talking between the hσ1 receptor and the hDAT in two cell models; therefore 
it is not possible to exclude that in vivo σ1 receptors activation by 
psychostimulants may involve multiple neuronal pathways. 
For the second part of this thesis, experiments have been performed in 
order to investigate functional alterations caused by the (+)-pentazocine-
mediated increase of DA uptake; particularly it has been investigated if the 
increase of intracellular [DA] could affect cells viability. In fact, when 
intracellular levels of DA abnormally increase, vescicles can’t sequester the 
DA which is metabolized by MAO (A and B) and COMT with consequent 
overproduction of oxygen reactive species and toxic catabolites (Hastings, 
1995, Hastings et al., 1996). Stress induced by these molecules may leads 
cells to death.  
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As is possible to evince from data showed in chapter 4, DA is more toxic 
in cells that transiently espress the hDAT, underlying the role of cell uptake in 
mediating DA toxicity . SH-SY5Y are more sensitive to DA than the HEK-
293; this difference is probably due to DA metabolism efficiency, wich is 
higher in the neuronal- than in the kidney-derived cell line. 
For what it concerns the role of the transfected hσ1 in modulating the DA 
cell toxicity, this study demonstrates that (+)-pentazocine increases DA cell 
toxicity in a concentration-dependent manner only in cells co-expressing hσ1 
and hDAT. Such effects are evident exclusively when DA is present at a 
concentration slightly lower than EC50 that allow to estimate the σ1 
contribution to cell toxicity avoiding any interference induced by DA 
autoxidation alone (respectively µM for HEK-293 and 150 µM for SH-
SY5Y). EC50 curves of (+)-pentazocine were thus obtained.  
Published studies concerning in vivo DA metabolism modulation by σ1 
receptors demonstrate that some σ1 ligands are able to increase extracellular 
levels of two DA metabolites, dihydroxy phenylacetic acid (DOPAC) and 
homovanillic acid (HVA), in the striatum and medial prefrontal cortex 
(Matsuno et al., 1995; Skuza et al., 1998; Kanzaki et al., 1992). Our results 
are in line with these findings. In fact the increase of DA metabolism could be 
induced through the σ1-mediate raise of intracellular DA levels; moreover, the 
increase of extracellular DA metabolism markers help to explain the σ1-
mediated increase of DA cell toxicity described. 
Relevant is the protective action of σ1 antagonists versus the (+)-
pentazocine-stimulated decrease of viability in presence of DA. In fact, toxic 
effects of psychostimulants are mainly mediated by alterations of extracellular 
DA concentrations (Gluck et al., 2001). In this context, the σ1 antagonists, 
which were proposed as antipsychostimulant therapy, may also have a role in 
protecting neurons from psychostimulant-induced toxicity. 
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A mapping study of σ1 receptors in Parkinson's disease (PD) using the σ 
ligand [11C]SA4503 and positron emission tomography (PET) has been 
performed (Mishina et al., 2005). In PD patients, binding of the radiotracer 
was significantly lower on the more affected than the less affected side of the 
anterior putamen, but there was no significant difference with respect to the 
binding between patients and controls. However, in this study changes of 
basal activity of σ1 have not been described. Further studies are necessary to 
better explore any functional relationship between the disappearance of DA 
and of the σ1 binding sites in the same neurons.  
The data of this thesis support the idea that activation of σ1 receptors, by 
any endogenous or exogenous ligand, may facilitate DA uptake and thus, by 
increasing its cellular concentration, may contribute to cause cell death. It 
could be suggested the σ1 binding sites, located inside the dopaminergic 
neurons, may contribute to the vulnerability of these cells by elevating 
intracellular levels of free DA. Numerous compounds, including several drugs 
of abuse, bind to σ1 receptors and activating them could facilitate the damage 
of dopaminergic neurons exposed to higher intracellular DA levels. If this 
hypothesis will be confirmed by future investigations, it could be appropiated 
to test σ1 receptor antagonists in PD experimental models as adjuvant to 
conventional therapies. 
In the last part of this thesis, functional cross-talking between hσ1 
receptor and hDAT has been further investigated using confocal microscopy. 
From the acquired data it could be suggested that, following exposure to (+)-
pentazocine, the hσ1 receptors massively translocate towards the plasma 
membrane. Translocation of rat σ1 receptors are known to occurr after 1 h of 
exposure to (+)-pentazocine (Hayashi and Su, 2003). However this is the first 
time that a translocation of the human subtype σ1 receptor in HEK-293 is 
described. In addition, colocalization of hDAT and hσ1 appears to occur both 
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in treated and in non-treated cells, suggesting that the observed increase of 
[3H]DA uptake could be mediated by the hσ1 redistribution from the 
cytoplasm to the cell membrane where hDAT is localized. Any physical 
interaction between the two proteins remains to be proved. 
 
 
6.2 Concluding remarks 
 
In this thesis, modulatory effects of hDAT by hσ1 receptors has been 
described in cell models. 
It has been demonstrated that the σ1 receptor agonist (+)-pentazocine 
induces a potentiation of the hDAT [3H]DA uptake activity only in cells 
stably expressing the hσ1 receptor in a concentration-dependent manner. This 
effect is abolished by pretreatment with σ1 antagonists BD-1047 and NE-100, 
which are not able to modify the [3H]DA uptake if tested alone. 
It has been demonstrated that viability of cells is strongly affected by the 
level of the uptaken DA; in viability assays, (+)-pentazocine increases cells 
susceptibility to DA toxicity in a concentration-dependent manner only in 
groups of cells that co-express the hσ1 and the hDAT. This effect is prevented 
by pretreatment with σ1 antagonists BD-1047 and NE-100. The significant 
increase of toxicity induced by (+)-pentazocine could be explained by virtue 
of the raised intracellular [DA], which has been proved in DA uptake assays. 
Confocal microscopy studies showed that hσ1 receptors are able to translocate 
toward the membrane following exposure to (+)-pentazocine; in addition 
colocalization of hDAT and hσ1 appear to occur both in treated and in non-
treated cells. Thus, hσ1 translocation could represent a key step in mediating 
the observed increase of [3H]DA uptake. 
  - 208 - 
References 
 
 
 
 
Gluck MR, Moy LY, Jayatilleke E, Hogan KA, 
Manzino L, Sonsalla PK. Parallel increases in 
lipid and protein oxidative markers in several 
mouse brain regions after methamphetamine 
treatment. J Neurochem 79, 152–160. 2001. 
Gudelsky GA. Biphasic effect of sigma receptor 
ligands on the extracellular concentration of 
dopamine in the striatum of the rat. J Neural 
Transm 106: 849-856, 1999. 
Hastings TG. Enzymatic oxidation of dopamine: 
the role of prostaglandin H synthase. J 
Neurochem. Feb;64(2):919-24. 1995. 
Hastings TG, Lewis DA, Zigmond MJ. Role of 
oxidation in the neurotoxic effects of intrastriatal 
dopamine injections, Proc. Natl. Acad. Sci. U. S. 
A.: 1956–1961. 1996. 
Hayashi T and Su TP. Intracellular dynamics of 
σ1 receptors (σ1 binding sites) in NG108-15 cells. 
J Pharmacol Exp Ther 306: 726-733, 2003a 
Kanzaki A, Okumura K, Ujike H, Tsuchida K, 
Akiyama K and Otsuki S. BMY-14802 reverses 
the reduction of striatal dopamine release induced 
by (+)-3-[3-hydroxyphenyl]-N- (1-
propyl)piperidine. J Neural Transm Gen Sect 90: 
137-144, 1992.  
Martin WR, Eades CG, Thompson JA, 
Huppler RE and Gilbert PE. The effects of 
morphineand nalorphine- like drugs in the 
nondependent and morphine-dependent chronic 
spinal dog. J Pharmacol Exp Ther 197: 517-532, 
1976.  
Matsuno K, Matsunaga KH and Mita S. Acute 
effects of sigma ligands on the extracellular 
DOPAC level in rat frontal cortex and striatum. 
Neurochem Res 20: 233-238, 1995 
Maurice T, Martin-Fardon R, Romieu P and 
Matsumoto RR. Sigma1 (σ1) receptor antagonists 
represent a new strategy against cocaine addiction 
and toxicity. Neurosci Biobehav Rev 26: 499-527, 
2002.  
Minabe Y, Matsuno K and Ashby CR, Jr. 
Acute and chronic administration of the selective 
sigma1 receptor agonist SA4503 significantly 
alters the activity of midbrain dopamine neurons 
in rats: An in vivo electrophysiological study. 
Synapse 33: 129- 140, 1999.  
Mishina M, Ishiwata K, Ishii K, Kitamura S, 
Kimura Y, Kawamura K, Oda K, Sasaki T, 
Sakayori O, Hamamoto M, Kobayashi S, 
Katayama Y. Function of sigma1 receptors in 
Parkinson's disease. Acta Neurol Scand. 
Aug;112(2):103-7. 2005. 
Moison D, De Deurwaerdere P, Cagnotto A, 
Marrazzo A, Prezzavento O, Ronsisvalle G, 
Mennini T and Spampinato U. Intrastriatal 
administration of sigma ligands inhibits basal 
dopamine release in vivo. Neuropharmacology 45: 
945-953, 2003.  
Skuza G, Golembiowska K and Wedzony K. 
Effect of EMD 57445, the selective σ receptor 
ligand, on the turnover and release of dopamine. 
Pol J Pharmacol 50: 61-64, 1998.  
Steinfels GF, Tam SW and Cook L. 
Electrophysiological effects of selective sigma-
receptor agonists, antagonists, and the selective 
phencyclidine receptor agonist MK-801 on 
  - 209 - 
midbrain dopamine neurons. 
Neuropsychopharmacology 2: 201-208, 1989.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  - 210 - 
Acknowledgements 
 
I would like to express my sincere gratitude to: 
 
My mentor, Professor Santi Spampinato, for his support, patience and 
encouragement throughout my graduate studies. His technical and 
editorial advices were essential to the completion of this dissertation. 
 
Professor Giorgio Cantelli Forti for his kind support, avalibility and 
patience. 
 
Professor Christopher Mcurdy, for the guidance, the friendship and all that I 
have learnt from him about life and chemistry throughout the period 
that I spent at OLEMISS in Oxford Mississippi.  
 
Professor Jacques Poupaert who has always inspired my ideas with 
philosophic and scientific conversations.  
 
Professor Giulio Muccioli that brilliantly guided me with kindness and 
patience when I was a young undergraduate student. 
 
Professor Didier M. Lambert that allowed me to work in his laboratory, 
experience that I always remember with affection. 
 
Professor Nadia Calonghi for her kind help with the confocal microscopy. 
 
Professor Susan Amara for her kind avalaibility and for her precious 
contribute to this PhD. investigation. 
  - 211 - 
Giulia, my beloved wife, the main reason of my life. 
 
My parents, whose love have supported me all through these years. Thank 
you to believe in me. 
 
My second mother Ziella that never misses an occasion to show me her love; 
I always felt so lucky to have an angel like you by my side. 
 
Zia Francesca that always guided me through life with love and helped me 
taking the hardest decisions. 
 
Nicoletta and Giuseppe that always take care of me like a son. 
 
Giammi and Antonino, the best collegues you can dream. You can’t 
understand how important is for me your friendship. Thank you for all 
your encouragement and for the wonderful scientific conversations. 
 
Leonardo, Pablo, MariaGrazia and Edie, my italo-american family. I shared 
with you some of the best moments of my life. I’ll never forget a 
second of such precious days toghether. 
 
